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 ABSTRACT 
A GENETIC SCREEN FOR MODULATORS OF THE NOTCH PATHWAY IN 
DROSOPHILA MELANOGASTER IDENTIFIES NOT1 AS A POSITIVE REGULATOR 
OF NOTCH SIGNALING 
 
Eric J. Morreale 
 
Advisor:  Marc A.T. Muskavitch 
 
The Notch pathway is an evolutionarily conserved mechanism of intercellular signaling 
that plays a central role in the development of metazoans.  Here I summarize two genetic 
screens that utilize a rough eye phenotype created by Delta overexpression in the 
Drosophila eye to identify modulators of Notch pathway signaling activity.   Among the 
many “hits” obtained from both screens, I have mapped to the Not1 gene a single 
complementation group that exhibits strong genetic interactions with Notch pathway 
mutants.  NOT1 is a component of the CCR4-NOT complex, a global regulator of gene 
expression that exerts its effects through a variety of mechanisms, including mRNA 
deadenylation and direct transcriptional repression.  I have conducted a series of genetic 
and molecular experiments in an effort to obtain more insight into the relationship 
between the CCR4-NOT complex and the Notch pathway.  Both Not1 EMS mutations 
and RNAi-mediated knockdown of NOT1 expression produce phenotypes that mimic 
those of Notch loss-of-function pathway mutants.  Knockdown of NOT1 in the 
developing bristle organ disrupts Notch-mediated inhibition of neuronal specification, 
resulting in supernumerary neurons and aberrant sheath cell specification.  Knockdown of 
NOT1 within the developing wing margin disrupts expression of the Notch target genes 
Cut and Wingless, as well as the Notch ligand Delta.  Phenotypic rescue experiments 
 imply that Not1 functions downstream of Notch signal activation and acts directly on 
Notch target gene expression.  These results suggest that NOT1 is required for Notch 
signal transmission in certain developmental contexts and implicate the CCR4-NOT 
complex as a positive regulator of the Notch pathway. 
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CHAPTER ONE 
AN OVERVIEW OF THE NOTCH SIGNALING PATHWAY 
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I.  Introduction 
Cell-cell interactions play critical roles in the development of all multicellular organisms.  
Beginning with a single progenitor cell, inductive and inhibitory cues direct the 
development of complex, specialized tissues and organs through precise control of 
cellular organization, cell fate specification, cell proliferation, and cell death.  One 
intensely studied mechanism of localized, juxtacrine intercellular communication is the 
evolutionarily conserved Notch pathway (Artavanis-Tsakonas et al., 1999).  Members of 
this signaling pathway perform multiple functions and are widely expressed in many 
developing multicellular organisms, including humans.  Most notably, this pathway is 
crucial for the development the central and peripheral nervous systems and, not 
surprisingly, alterations in Notch signaling have been implicated in the development of 
various neoplasias (Yavari et al., 1998).   
 
At the molecular level, the core Notch signaling pathway (see Figure 1-1) appears 
deceptively simple.  Binding of the DSL ligands (Delta/Serrate/Lag-2) to the Notch 
receptor on adjacent cells initiates consecutive cleavage events that lead to release of the 
Notch receptor intracellular domain (NICD).  The first cleavage, denoted S2, is initiated 
by the metalloprotease Kuzbanian, which cleaves Notch within its extracellular domain at 
a site just amino-proximal to the transmembrane domain (Pan and Rubin, 1997).  
Following Kuzbanian-mediated S2 cleavage, a constitutive S3 cleavage occurs to release 
the NICD.  This third cleavage is generated by the transmembrane protease Presenilin, 
which cleaves Notch within its transmembrane domain, via a process termed regulated 
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intramembrane proteolysis (RIP) (de Strooper, 1999; Struhl and Greenwald, 1999).  The 
released NICD subsequently translocates to the nucleus (Struhl and Adachi, 1998) and, in 
conjunction with the chromatin-associated protein Suppressor of Hairless [Su(H)],  up-
regulates a series of transcription factors (e.g., members of the Enhancer of split Complex 
[E(spl)-C]) that repress expression of the proneural genes (Jarriault et al., 1995; 
Lecourtois and Schweisguth, 1995; Bailey and Posakony, 1995).  The core members of 
the Notch pathway have been historically classified as "neurogenic" genes (Knust and 
Campos-Ortega, 1999), signifying that impairments in their function lead to breakdowns 
in Notch signaling and development of excess neural tissue. 
 
Despite the apparent simplicity of the core transduction pathway, Notch signaling is 
utilized in a variety of contexts in developing organisms.  This is achieved mainly 
through a complex network of regulation of core pathway member expression and 
activity.  This regulation induces asymmetries in signaling within populations of cells 
that lead to unique cell fate specification events, inhibitory in some contexts and 
inductive in others.  Table 1-1 lists the major proteins that have been identified as 
regulators of the Notch pathway.  These regulators exert their effects through enzymatic 
modification of, or physical association with, core pathway members.  Notch pathway 
regulation can be broken down into three main areas, as described in detail below:  
regulation of DSL ligands, regulation of the Notch receptor, and regulation of the NICD 
transcriptional complexes in the nucleus. 
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II.  Regulation of the Delta ligand 
A.  Delta ubiquitination 
The identification of two E3 ubiquitin ligases as post-translational modifiers of the Delta 
ligand has highlighted the importance of endocytic regulation of Notch signaling activity. 
The neuralized (neur) gene was first identified as one of the original neurogenic genes, as 
loss of function mutations in neur result in hyperplasia of the nervous system 
(Hartenstein et al., 1992).  In-depth study of Neuralized revealed that it possesses a C-
terminal ring-finger domain (RING) that exhibits E3 ubiquitin ligase activity (Lai et al., 
2001; Deblandre et al., 2001).  Neuralized activity induces Delta endocytosis, presumably 
through direct ubiquitination of the ligand, leading to activation of Notch signaling (Lai 
et al., 2001; Deblandre et al., 2001; Pavlopoulos et al., 2001).  Later studies identified 
another RING-finger E3 ubiquitin ligase, Mindbomb1 (Mib1), which also promotes DSL 
ligand internalization to initiate Notch signaling (Lai et al, 2005).  It appears that Neur 
and Mib1 are functionally redundant and differ only in their distribution within the 
developing organism (Lai et al, 2005; Le Borgne et al, 2005).   
 
The mechanism by which DSL ligand endocytosis leads to activation of Notch signaling 
is still not completely understood (Bray, 2006).  One model posits that pulling action of 
the ligand on the Notch receptor induced by ligand internalization exposes the S2 site for 
Kuzbanian-dependent proteolytic cleavage and subsequent NICD release; there is 
evidence that this process, believed to be correlated with Notch extracellular domain 
trans-endocytosis into ligand-expressing cells, occurs in certain developmental contexts 
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(Parks et al., 2000).  Another explanation is that DSL ligands are processed into an active 
state within an endocytic compartment and then returned to the surface as functional 
ligands that can now interact productively with Notch receptors.  It is also possible that 
endocytic trafficking is required to cluster ligands or deliver them to certain regions of 
the plasma membrane in support of receptor activation.  Recent studies also support a 
trafficking requirement for ligand activation, as a functional recycling endosome has been 
shown to be critical for activation of Notch signaling (Emery et al., 2005; Jafar-Nejad et 
al., 2005; Heuss et al., 2008). 
 
Regardless of the method of signal activation, it is clear that ligand endocytosis is a 
critical component of Notch pathway regulation.  A second layer of regulation is also 
imposed by the presence of inhibitors of the Neuralized E3 ligase.  The Bearded family of 
proteins inhibits Neuralized function and includes negative regulators of Notch signaling 
(De Renzis et al., 2006; Bardin and Schweisguth, 2006).  Thus, Bearded family members 
indirectly regulate Delta through their control of Neuralized activity. 
 
B.   Delta proteolytic cleavage     
 Numerous studies have shown that DSL ligands are also subject to proteolytic 
processing.  An early study examining Delta cleavage revealed the presence of multiple 
isoforms of the ligand in vivo (Klueg et al., 1998).  It was later shown that DSL ligands 
can act as substrates for ADAM metalloproteases such as Kuzbanian in both flies and 
mammals (Qi et al., 1999; Dyczynska et al., 2007).  Although experimental evidence 
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strongly supports the existence of DSL ligand cleavage events, it is unclear what role 
these events play in the developing organism.  Delta extracellular domain fragments 
created by proteolytic cleavage events have been shown to inhibit Notch signaling 
(Mishra-Gorur et al., 2002). In addition, studies in mammalian systems indicate that DSL 
ligands can undergo intramembrane cleavage events mediated by gamma-secretase, 
similar to those that result from Presenilin-dependent cleavage of the Notch receptor 
(Ikeuchi and Sisodia, 2003; Six et al., 2003).  Some studies indicate that the released DSL 
ligand intracellular domain can translocate to the nucleus and induce transcription, 
suggesting a mechanism of bi-directional signaling for the Notch pathway (Bland et al., 
2003; LaVoie and Selkoe, 2003).  Given the conflicting reports in the literature regarding 
the true activity of DSL cleavage products, it is clear that more work is needed in this 
area to reveal the true roles of DSL ligand processing in the regulation of Notch 
signaling.  As with most aspects of the Notch pathway, the functional importance of DSL 
cleavage is likely to be dependent on the developmental context being studied.       
 
III.  Regulation of the Notch receptor 
A.  Notch ubiquitination 
As with Delta, E3 ubiquitin ligases have been identified as modulators of Notch signaling 
activity through interactions with the Notch receptor.   Suppressor of deltex [Su(dx)] was 
originally shown to be a negative regulator Notch signaling activity, as loss-of-function 
Su(dx) alleles suppressed Notch loss-of-function phenotypes in the Drosophila wing vein 
(Fostier et al., 1998).  It was later shown that Su(dx) possesses an HECT E3 ubiquitin 
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ligase domain and is a member of the Nedd4 family of ubiquitin ligases (Cornell et al., 
1999).  Later studies revealed that Su(dx) specifically down-regulates Notch pathway 
target gene expression (Mazaleyrat et al., 2003) and the Nedd4 E3 ligases control 
endosomal sorting of the Notch receptor to reduce signaling activity (Wilkins et al., 
2004).  Ultimately, the Nedd4 ligases were shown to interact with and ubiquitinate the 
Notch receptor intracellular domain, supporting a model whereby Notch signaling 
activity is reduced through removal of Notch receptor from the plasma membrane via 
ubiquitin-mediated endocytosis (Sakata et al., 2004; Shaye and Greenwald, 2005).   
 
The RING-finger E3 ubiquitin ligase Deltex (dx) has also been implicated in Notch 
receptor regulation.  Although it is currently unknown if Deltex directly ubiquitinates 
Notch, Deltex does physically interact with the NICD and acts as a positive regulator of 
signaling activity (Matsuno et al., 1995), and mutation of the Deltex RING-finger domain 
disrupts Deltex function (Matsuno et al., 2002).  Furthermore, it has been shown that 
Deltex can induce relocalization of Notch to endosomal vesicles (Hori et al., 2004).  
Thus, it appears that Deltex activates Notch signaling by promoting Notch receptor 
internalization, a direct contrast to the apparent function of Su(dx).  A recent study 
provides evidence that Su(dx) regulates Deltex activity by inducing its degradation via 
direct polyubiquitination (Chastagner et al., 2006). 
 
The extent to which Deltex and the Nedd4 family E3 ligases modulate Notch signaling 
activity is currently unclear.  Deltex itself appears to be required only in certain 
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developmental contexts, as null alleles are not lethal (Fuwa et al., 2006).  In addition, it 
appears that Su(dx)-mediated endocytic regulation of the Notch receptor is only a modest 
contributor to overall regulation of Notch signaling activity since Su(dx) loss-of-function 
alleles produce only very mild phenotypes (Fostier et al., 1998).  In reality, it may be that 
Nedd4 family members possess complementary functions, and the effect of loss of a 
single ligase is muted by the activity of the other family members.  Nonetheless, as with 
the DSL ligands, endocytic regulation of the Notch receptor clearly plays a role in Notch 
signal modulation. 
 
B.  Notch glycosylation 
In addition to ubiquitination by E3 ligases, the Notch receptor is also subject to 
modification by glycosyltransferases.  The importance of glycosylation in Notch 
signaling control was first recognized in studies of the gene fringe.  Early investigations 
of Fringe function revealed that it inhibited Serrate-mediated activation of the Notch 
receptor during wing margin formation by some unknown mechanism (Panin et al., 
1997).  Subsequent work showed that Fringe was actually an 
acetylglucosaminotransferase that directly modifies Notch during Golgi transport through 
addition of N-acetylglucosamine to O-linked fucose residues linked to epidermal growth 
factor-like repeats (ELRs) within the Notch extracellular domain (Moloney et al., 2000; 
Bruckner et al, 2000).  Glycosylation of Notch by Fringe promotes receptor activation by 
Delta, while inhibiting activation by Serrate; Fringe activity is crucial to boundary 
formation in numerous tissues during development (Blair, 2000). 
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Given that Fringe directly modifies O-linked fucose residues present on Notch ELRs, one 
obvious potential source of Notch regulation is through enzymatic addition of these 
fucose residues.  This turns out to be the case, as the enzyme O-fucosyl transferase (O-
Fut) was shown to be required for generation of a functional Notch receptor (Okajima 
and Irvine, 2002; Shi and Stanley, 2003).  Furthermore, O-Fut also functions as a 
chaperone to ensure proper Notch folding (Okajima et al, 2005).  Recently, another 
glycosyltransferase, Rumi, was identified as an essential modifier of the Notch receptor 
required for signaling activation and proper trafficking of the Notch receptor to the 
plasma membrane (Acar et al., 2008).  Given the large number of ELRs present on the 
extracellular domain of Notch, it would not be surprising if additional Notch-modifying 
glycosyltransferases were discovered in the future.   
 
 C.  Physical inhibition of Notch 
Another important regulator of the Notch receptor is the membrane-associated protein 
Numb.  Numb inhibits Notch signaling during lineage decisions, most notably during 
specification of sensory organ precursor (SOP) progeny (Guo et al, 1996).  During 
mitotic division of the presumptive SOP, Numb is preferentially segregated into one of 
two daughter cells along with the E3 ubiquitin ligase Neuralized (Guo et al, 1996; Le 
Borgne and Schweisguth, 2003).  Evidence suggests that Numb may be involved in 
endocytic removal of the Notch receptor because Numb mediates asymmetric segregation 
of alpha-Adaptin, an adaptor that functions in clathrin-mediated endocytosis (Berdnik et 
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al., 2002).  Under this model, Numb, which binds both alpha-Adaptin and the NICD, 
down-regulates Notch signaling by mediating endocytosis of the Notch receptor; 
Neuralized simultaneously activates Notch signaling in the adjacent cell of the lineage by 
stimulating endocytosis of Delta (Berdnik et al., 2002; Le Borgne and Schweisguth, 
2003).  In this way, opposing endocytic mechanisms, one mediating activation and one 
mediating inhibition of Notch signaling, lead to alternative cell fate specification events 
within the same lineage. 
 
An alternative mechanism of Numb-mediated Notch inhibition has also been proposed.  
This model posits that Numb does not act on the Notch receptor directly, but rather 
mediates endocytosis of the Notch-activating transmembrane protein Sanpodo.  Although 
Sanpodo has no known functional domains, it has been shown to be required for proper 
SOP lineage cell fate decisions as a positive regulator of Notch signaling (Skeath and 
Doe, 1998).  Internalization of Sanpodo from the plasma membrane via Numb-mediated 
endocytosis presumably removes a component required for activation of the Notch 
receptor (O’Connor-Giles and Skeath, 2003; Hutterer and Knoblich, 2005).  Regardless 
of the exact functional mechanism, Numb is an important regulator of the Notch receptor 
during lineage decisions in developing Drosophila. 
 
D.   Nuclear regulation of Notch signaling activity 
In addition to modulation of signaling activity through the Notch receptor and DSL 
ligands, a major component of Notch signaling regulation occurs in the nucleus, after 
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translocation of the NICD.  NICD-mediated transcription initiation requires a number of 
co-activators that allow it to access and bind chromosomal promoters.  The basic 
requirements include the CSL [CBF1/Su(H)/LAG-1] proteins, DNA binding proteins that 
act as molecular switches and coordinate transcriptional activation and repression of 
Notch pathway target genes.  In the absence of Notch activation and subsequent NICD 
nuclear translocation, CSL proteins are bound to numerous transcriptional repressors.  In 
Drosophila, the major CSL repressor is Hairless, identified in early studies as an 
antagonist of Notch signaling during SOP specification (Bang and Posakony, 1992; Bang 
et al., 1995).  Hairless recruits the co-repressors CtBP and Groucho to Su(H) to form a 
repression complex (Barolo et al., 2002); this complex binds target gene DNA and 
represses transcription, presumably through histone deacetylation (Kao et al., 1998;   
Subramanian and Chinnadurai, 2003).   
 
Upon Notch signaling activation, NICD translocates to the nucleus and displaces Hairless 
and its associated repressors from Su(H).  The essential transcriptional co-activator 
Mastermind binds the Su(H)-NICD complex and recruits the histone acetylase p300 to 
promote transcription initiation (Wu et al, 2000; Fryer et al, 2002).  Importantly, 
Mastermind has also been shown to recruit cyclin-dependent kinase 8 (CDK8), which 
phosphorylates the NICD (Fryer et al., 2004); the phosphorylated NICD becomes a target 
of the ubiquitin ligase SEL10 and subsequent proteasomal degradation (Oberg et al., 
2001).  Thus, Mastermind not only supports NICD-mediated transcription initiation, but 
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also enables a mechanism by which NICD can be quickly degraded, so that Notch signal 
strength and duration can be tightly controlled. 
 
Clearly, chromatin remodeling is an important focal point of Notch pathway 
transcriptional activation and repression.  Histone acetyltransferase (HAT) and histone 
deacetylase (HDAC) activities appear to be crucial for Notch signal transmission and 
inhibition, respectively.  In addition to the role of p300 described above, the HATs PCAF 
and GCN5 have also been implicated in Notch-mediated transcription initiation (Kurooka 
and Honjo, 2000; Wallberg et al., 2002), while HDAC1 has been shown to repress Notch 
target gene expression (Kao et al., 1998; Cunliffe, 2004).  Histone methylation and 
demethylation have been implicated in the epigenetic regulation of Notch signaling.  
Bre1, an E3 ubiquitin ligase that mediates histone H3 methylation, is required for Notch 
signaling activity (Bray et al., 2005).  In contrast, loss of LSD1, a histone methylase 
known to associate with CtBP, leads to up-regulation of Notch target genes (Wang et al., 
2007).  While epigenetic regulation of Notch signaling has only recently become a focus 
of investigation, it is clear that histone modifications provide a posttranslational 
mechanism through which Notch signaling activity can be regulated precisely. 
 
IV.  The Notch pathway and development 
The regulatory mechanisms described above enable the Notch pathway to manage a 
diverse set of developmental decisions.  Because core Notch pathway members were 
originally identified as neurogenic genes based on loss-of-function phenotypes, Notch 
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signaling is classically thought of in terms of its role in nervous system development.  
Yet, significant research over the past 30 years has revealed that the Notch pathway plays 
a role in the development of almost every major organ system and structure in 
multicellular animals.  In Drosophila, the list of tissues in which Notch signaling exerts 
an impact includes the eyes, wings, legs, gut, epithileum, blood, central and peripheral 
nervous systems, and immune system (Brennan and Moses, 2000; Blair 2007; Mishra et 
al., 2001; Gonzalez-Gaitan and Jackle, 1995; Krzemien et al., 2007; Parks et al., 1997; 
Duvic et al., 2002).  To participate in the development of such a wide array of tissues, the 
Notch pathway mediates several canonical mechanisms to specify cell fate.  These 
mechanisms are lateral inhibition, lineage determination, induction, and boundary 
formation. 
 
A.  Lateral inhibition 
Through a process called "lateral inhibition”, the Notch pathway restricts a cell fate 
specification event to a single cell within an initially homogeneous cell population 
(Beatus and Lendahl, 1998).  During nervous system development in Drosophila, groups 
of equivalent cells are initially organized into “proneural” clusters, within which only one 
cell will be specified as a neural progenitor.  Subtle Notch signaling asymmetries within 
the cluster trigger feedback mechanisms that lead to differential adoption of neural and 
non-neural fates.  One cell within the cluster develops the capacity to send, but appears 
not to receive, the Delta-dependent inhibitory signal and therefore stably expresses 
proneural genes and differentiates into a neuroblast.  In contrast, surrounding cells 
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receive the Delta-dependent signal, resulting in inhibition of proneural gene expression 
and neural development; they adopt an epidermal fate.  Notch-mediated lateral inhibition 
has been particularly well-documented during bristle organ development, in which single 
cells at precise locations across the Drosophila notum adopt an SOP cell fate 
(Schweisguth, 1995).  The presumptive SOP sends an inhibitory Notch signal to 
surrounding cells, leading to NICD-Su(H)-mediated transcription of the E(spl)-C genes, 
which in turn repress transcription of the proneural genes achaete and scute (Nakao and 
Campos-Ortega, 1996).  Simultaneously, the proneural genes are transcribed in the 
presumptive SOP in the absence of Notch inhibitory signals, and serve as inputs into a 
self-stimulatory feedback loop that further promotes SOP cell fate specification (Culi and 
Modolell, 1998).  Ultimately, high levels of proneural gene expression lead to the 
expression of SOP-specific genes such as senseless, which cements the fate of the SOP 
cell as the progenitor of the bristle organ, within a field of epidermal cells (Nolo et al., 
2000).   
 
B.  Lineage decisions 
Notch signaling is also utilized for the specification of very specialized cell types within 
lineages.  For example, upon completion of initial SOP specification via Notch-mediated 
lateral inhibition, the development of the adult bristle requires division and differentiation 
events that convert the progenitor SOP into five distinct cell types: neuron, socket, 
sheath, shaft and glial cells.  To achieve this end, the Notch inhibitory protein Numb is 
sequestered asymmetrically during sequential mitotic divisions of the SOP and its 
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progeny (Rhyu et al., 1994).  Daughter cells that possess Numb cannot receive a Notch 
signal, presumably due to Numb-induced endocytosis of the receptor, and adopt the 
neuronal or socket cell fates (Berdnik et al., 2002).  In contrast, those cells that lack 
Numb receive a Notch signal, leading to inhibition of proneural cell fates and 
development of sheath/shaft cells.   
 
In another lineage event, the Notch pathway affects specification of the R3 and R4 
photoreceptors in the developing eye (Fanto and Mlodzik, 1999; Cooper and Bray, 1999).  
An unknown signal emitted from the equator of the eye imaginal disc activates the 
Frizzled pathway, which in turn induces up-regulation of Delta ligand.  Those cells 
closest to the site of signal generation express Delta more intensely, become signal 
emitters, and develop into R3 photoreceptors; the adjacent cells receive this Notch-
dependent signal from the R3 precursors and differentiate into the R4 photoreceptors.  
Thus, the Notch pathway cannot only restrict cell specification within a large field of 
equivalent cells, but can also control binary cell fate decisions. 
 
C.  Inductive signaling 
The Notch pathway is also known to exhibit inductive effects.  The Drosophila wing 
develops from a monolayer epithelial sheet, called an imaginal disc, that eventually folds 
to produce the dorsal and ventral surfaces to the adult wing.  The site in the imaginal disc 
where this folding occurs, the wing margin, is specified by Notch pathway activity.  This 
specification event is achieved through differential expression of Serrate and its inhibitor 
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Fringe (Irvine and Wieschaus, 1994; Panin et al., 1997).  Near the nascent wing margin 
of the imaginal wing disc, Serrate and Fringe are expressed only in what is to become the 
dorsal region; Delta and Notch have more general expression patterns.  Fringe 
glycosylates Notch prior to its trafficking to the cell membrane; this glycosylation event 
inhibits the ability of Serrate to bind Notch (Moloney et al., 2000; Bruckner et al., 2000).  
Thus, Serrate ligand present on the surface of these cells can only activate Notch-
dependent signal on apposed cells in the ventral region that do not express Fringe; the 
resulting signal up-regulates Delta expression in the ventral cells, enabling them to, in 
turn, activate Notch on adjacent cells in the dorsal region.  The resulting Notch signals 
emanating from the dorsal and ventral regions of the wing disc lead to maximum Notch 
activity at the presumptive dorsal-ventral boundary.  High levels of Notch signaling 
activity within this region produces a pattern of differential gene expression that induces 
specification of wing margin cell types (de Celis et al., 1996). 
 
D.  Boundary formation 
A fourth mechanism through which the Notch pathway exerts its effects during 
development is through generation of cell fate specification boundaries.  The adult 
Drosophila wing possesses four longitudinal veins (L2-L5) that run along its proximo-
distal axis and provide rigidity to the structure (de Celis, 2003).  To generate these 
structures, the prospective wing is first subdivided into provein and intervein regions 
during larval development by the dual action of the Hedgehog (Hh) and Decapentaplegic 
(Dpp) pathways (Zecca et al, 1995; Tanimoto et al., 2000).  The provein region is further 
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refined at the pupal stage into actual vein and non-vein tissue via synergistic action of the 
Notch and Epidermal Growth Factor (EGFR) pathways; Notch blocks vein cell fate 
commitment via a lateral inhibitory mechanism that restricts EGFR pathway activity, an 
activity that promotes the vein cell fate, to a narrow strip of cells (Guichard et al., 1999; 
Yan et al., 2004; Sotillos and de Celis, 2005).   In this process, expression of Delta and 
Serrate is restricted to central provein cells, leading to Notch activation in the lateral 
provein cells flanking this region.  Activation of the pathway results in up-regulation of 
the transcription factor E(spl)mβ, which prevents vein cell development through its 
inhibitory effect on the EGFR pathway (de Celis et al., 1997; Huppert et al., 1997).  
E(spl)mβ represses expression of critical EGFR pathway members, restricting EGFR 
activation to the central provein (de Celis et al., 1997).  In turn, EGFR pathway activation 
up-regulates Delta expression in the central provein, further enhancing Notch signaling 
boundaries.  Thus, through maintenance of Notch signaling boundaries within proveins, 
the width of the longitudinal veins is controlled.  As would be expected, disruptions of 
Notch signaling at this stage of development result in a breakdown of these boundaries, 
leading to expansion of vein width. 
 
V.  The Notch pathway and disease 
Given that the Notch pathway has seemingly ubiquitous involvement in all aspects of 
development, it is not surprising that aberrations in Notch signaling result in several types 
of human disease.  In humans, the core pathway mechanisms for Notch activation are the 
same as those found in lower organisms; the main differences lie in an expansion in the 
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number of ligands and receptors, with humans possessing four distinct Notch receptors 
(Notch 1-4) and five different activating ligands [Delta homologs Delta-like (Dll) 1, 3, 
and 4, and Serrate homologs Jagged 1 and 2].  Diseases that are caused by Notch 
signaling defects are usually the result of ligand or receptor mutations (Louvi and 
Artavanis-Tsakonas, 2007).  Notch pathway defects are responsible for at least three 
major genetically inherited disorders:  CADASIL syndrome, Alagille syndrome, and 
spondylocostal dysostosis (Gridley, 2003). 
 
CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy) is an autosomal-dominant disorder that is the result of mutations in 
cysteine residues within Notch3 receptor ELRs (Joutel et al., 1996).  CADASIL patients 
exhibit vascular lesions that produce symptoms including stroke and dementia.  Evidence 
suggests that the abnormal vascular lesions may be the result of accumulation of Notch3 
on the cell surface of vascular muscle cells, but no functional link has been established to 
defects in Notch signaling (Joutel et al., 2000).  Alagille syndrome is an autosomal-
dominant disorder that is caused by mutations in the Notch1 ligand Jagged1 (Oda et al., 
1997; Li et al., 1997).  Patients afflicted with this developmental disorder exhibit a wide 
range of phenotypes; although the disorder affects most major organs systems, patients 
most frequently exhibit deformities of the liver, cardiovascular system, and vertebrae 
(Kranz et al., 1997).  The disorder appears to be the result of reduced Notch signaling 
caused by Jagged1 mutations (Boyer-Di Ponio et al., 2007).  Spondylocostal dysostosis, a 
third Notch pathway disease, has both autosomal-dominant and recessive forms and 
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causes dwarfism due to rib fusions and deletions (Teli et al., 2004).  The disease has been 
shown to be the result of aberrations in Notch-mediated somite segmentation due to 
mutations in Dll3 (Bulman et al., 2000; Kageyama et al., 2007).   
 
Finally, defects in Notch signaling have been implicated in the development of various 
cancers.  The strongest evidence linking Notch pathway mutations and cancer exists for 
T-cell acute lymphoblastic leukemia (T-ALL; Demarest et al., 2008).  A rare 
chromosomal translocation of Notch1 was originally found to be associated with T-ALL 
(Ellisen et al., 1991); subsequent work revealed that more than 50% of all examined T-
ALL cases exhibit activating mutations in Notch1 (Weng et al., 2004).  Notch1 mutations 
lead to constitutive activation of Notch signaling and produce two distinct cancer-
promoting events.  First, constitutive Notch signaling inhibits the activity of tumor 
suppressor p53, thereby suppressing apoptosis (Beverly et al., 2005).  Second, increased 
Notch signaling activity down-regulates p27 protein levels, inducing cell cycle 
progression (Dohda et al., 2007).   
 
Given the many roles of the Notch pathway in organismal development and the 
devastating impacts breakdowns of Notch function can have on human health, a deeper 
understanding of the functional mechanisms of Notch signaling is of great potential 
benefit. Despite intense investigation over the previous three decades, the mechanisms by 
which the precise spatial and temporal occurrence of Notch signaling is controlled are 
still not understood in many developmental contexts.  For example, the factors that cause 
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initial Notch signaling asymmetries within proneural clusters during CNS development 
are not known, nor is the morphogenetic signal that induces up-regulation of Delta 
expression in the R3 photoreceptor in Drosophila.  These as well as other questions 
suggest even further complexity to Notch pathway regulation and function.  Therefore, 
the central aim of my thesis work was the identification of other potential effectors of the 
Notch pathway and the elucidation of the functional roles they play within the context of 
Notch signaling.  To this end, I describe in the following chapters genetic screens that 
have yielded previously unidentified regulators of Notch signaling activity. 
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Figure 1-1.  Overview of the Notch signaling pathway 
Binding of the Notch receptor to Delta ligand leads to proteolytic cleavage of the Notch 
receptor and release of its intracellular domain, NICD, from the plasma membrane.  
NICD subsequently translocates to the nucleus and binds to its transcriptional co-
activators Suppressor of Hairless [Su(H)] and Mastermind.  The assembled NICD 
complex binds to promoter regions and activates transcription of Notch target genes.  
Despite the simplicity of the core Notch pathway, signaling activation is controlled by a 
complex network of regulators.  See text for detailed discussion. (Figure created by A.L. 
Parks). 
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 Figure 1-1.  Overview of the Notch signaling pathway 
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Table 1-1.  The major regulators of the Notch signaling pathway 
Listed are the major regulators of the Notch pathway.  Included are:  the core pathway 
member upon which they act, their enzymatic activity, and their functional mechanism 
within the Notch pathway, if known.  See text for detailed discussion.  
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Table 1-1.  A list of major regulators of the Notch Pathway 
Regulator Acts on Enzymatic activity 
Effect on Notch 
signaling Mechanism of action 
Kuzbanian Notch Receptor metalloprotease Positive S2 cleavage of Notch receptor; required to release NICD 
Presenilin Notch Receptor gamma-secretase Positive S3 cleavage of Notch receptor; required to release NICD 
Suppressor 
of deltex Notch Receptor RING E3 ubiquitin ligase Negative 
Ubiquitination of Notch intracellular domain to induce 
endocytic removal from plasma membrane 
Deltex Notch Receptor HECT E3 ubiquitin ligase Positive Unknown; may also induce ubiquitin-mediated endocytosis 
of Notch 
Fringe Notch Receptor acetylglucosaminyltransferase Negative 
Glycosylates Notch ELRs to inhibit Serrate-mediated 
signaling activation 
O-fucosyl 
transferase Notch Receptor O-fucosyl transferase Positive Glycosylates Notch ELRs to produce functional receptor 
Rumi Notch Receptor glycosyltransferase Positive Glycosylates Notch ELRs to produce functional receptor 
Numb Notch Receptor None identified Negative 
Mediates endocytic removal of Notch from plasma 
membrane by an unknown mechanism 
Sanpodo Notch Receptor None identified Positive Unknown  
Neuralized DSL ligands RING E3 ubiquitin ligase Positive Involved in ubiquitin-mediated endocytosis of DSL ligands 
Mindbomb1 DSL ligands RING E3 ubiquitin ligase Positive Involved in ubiquitin-mediated endocytosis of DSL ligands 
Kuzbanian DSL ligands metalloprotease Unknown Cleavage of Delta ligand; unknown effect 
Bearded 
proteins 
Neuralized None identified Negative Inhibits Neuralized ability to induce Delta endocytosis 
Suppressor 
of Hairless 
NICD None identified Positive Binds NICD as co-activator of transcription 
Mastermind NICD None identified Positive Binds NICD-Su(H) complex as co-activator of transcription 
p300 NICD histone acetylase Positive 
Recruited by Mastermind to NICD complex to modify 
chromatin in support of transcription 
CDK8 NICD cyclin-dependent kinase Negative 
Recruited by Mastermind to NICD complex to 
phosphorylate NICD and induce proteasomal degradation 
Hairless NICD None identified Negative 
Binds Su(H) as an inhibitor of Notch signaling target gene 
transcription 
CtBP NICD None identified Negative 
Recruited by Hairless to repress Notch target gene 
transcription 
Groucho NICD None identified Negative 
Recruited by Hairless to repress Notch target gene 
transcription 
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AN EMS SCREEN FOR MODIFIERS OF A DELTA OVEREXPRESSION 
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I.  Introduction 
One of the great advantages of using Drosophila melanogaster as a model organism is 
the ability to conduct a variety of large-scale genetic screens to identify genes associated 
with developmental, physiological and behavioral processes (reviewed in St. Johnston, 
2002).  Large brood size, short generation times, inexpensive rearing, simple mutagenesis 
techniques, and the ability to maintain mutations in genetically stable stocks all make the 
fruit fly ideal for conducting genetic screens.  At no point was this utility more evident 
than in the Nobel prize-winning screens conducted almost 30 years ago by Wieschaus 
and Nusslein-Volhard, which identified the embryonic patterning genes (Nusslein-
Volhard, 1980).  By generating homozygous lethal mutant embryos through 
ethylmethane sulfonate (EMS) mutagenesis and examining cuticle patterns, this group 
was able to identify the major genes that define the anteroposterior (A/P) and 
dorsoventral (D/V) axes of Drosophila, some of which have homologs in mammalian 
systems (Pizzuti et al., 1996). 
 
While these screens were very efficient in identifying genes critical to embryonic 
development of the embryo, they were less successful in elucidating, in depth, multiple 
components within distinct signaling pathway networks.  Many signaling pathways genes 
function after the embryonic stage of development in tissue-specific contexts, so they 
went undetected by classic F3 generation lethal screens (St. Johnston, 2002). F1 modifier 
screens were developed in an attempt to saturate the genome for mutations that affect the 
numerous components in specific signaling pathways, such as the receptor tyrosine 
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kinase and Notch pathways.  F1 modifier screens utilize a sensitized genetic background 
to test the effects of loss of one copy of a gene on the phenotype caused by the sensitized 
genetic background in question.  The idea is to create a visible phenotype in a 
nonessential tissue and then examine whether introduction of mutagenized haploid 
genomes causes a modification of the phenotype.  While only one copy of most genes is 
required for normal development of the wild type fly, a mutant fly is often more sensitive 
to changes in gene dosage.  Such modifier screens were first used to great success in 
identifying the signaling molecules involved in R7 photoreceptor specification (reviewed 
in Simon, 1994). 
 
As our goal was to identify additional members or modulators of the Notch signaling 
pathway, which is involved in many postembryonic developmental processes in the eye, 
wing, and other tissues, an F1 modifier screen was our most logical approach.  To 
develop a sensitized background in the fly, we employed the Gal4-UAS system (Perrimon 
and Brand, 1993) to drive tissue-specific expression of a Notch pathway member.  We 
created a transgenic fly strain in which the eye-specific driver GMR-Gal4 (Hay et al., 
1994; Freeman, 1996) and the wild-type Delta responder UAS-DeltaWT (T. L. Jacobsen, 
Ph.D. Thesis, Indiana University) were recombined onto the same chromosome.  The 
resulting GMR-Gal4 UAS-DeltaWT stock (GMR>DlWT) exhibits a flat, “glassy” eye 
phenotype due to Delta overexpression in the eye; and it served as our sensitized 
background and the entrypoint for our screen.  The use of a phenotype produced by Delta 
overexpression in the eye as the screen entrypoint confers two advantages.  First, the 
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Notch pathway plays a significant role in many aspects of eye development, including 
establishment of the eye developmental field, morphogenetic furrow initiation, 
photoreceptor specification (R1-8), cone cell specification, pigment cell specification, 
and interommaditial bristle development.  Due to this extensive involvement in eye 
development, mutations that affect Notch signaling are likely to interfere with some 
aspect of eye development, making this tissue very sensitive to changes in gene dosage of 
Notch pathway interactors.   Second, the eye is not essential for adult fly survival or 
fertility.  Thus, unlike F3 lethal screens, there is little concern about missing potential 
Notch genes due to early-stage lethality. 
 
The workflow of the EMS screen we conducted is outlined in Figure 2-1.  In comparison 
to the transposon screen discussed in Chapter 4, there are significant differences.  Most of 
these differences result from the fact that the transposon screen utilized a collection of 
balanced insertion lines for which genomic locations had been defined (Thibault et al., 
2004).  Thus, there was no need to perform many of the laborious linkage, 
complementation, and mapping studies required for an EMS screen.  In contrast, EMS 
mutagenesis creates point mutations in random positions throughout the genome.  After 
initial mutagenesis and screening, the linkage of isolated modifiers must be determined in 
order to place mutations in stable genetic stocks, over the appropriate balancer. 
Complementation groups are then identified through a series of crosses among all 
modifiers.  At this point, complementation groups can be prioritized based on secondary 
tests that reveal which modifiers are likely to alter genes that function within, or directly 
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affect, the Notch pathway.  Finally, mapping studies are conducted to identify the genes 
within which modifier mutations of interest lie.  Typically, mapping to a single locus 
requires a combination of approaches, including deficiency (Df) and candidate gene 
mapping to define the locations of lethal mutations, and meiotic mapping to identify the 
chromosomal regions within which modifying mutations are located.  
 
The extensive mapping effort required to identify the location of EMS mutations is one of 
the major disadvantages of this screening method.  It is often challenging to definitively 
map a specific mutation to a specific gene in chromosomal regions of high gene density.  
In addition, EMS mutagenesis can often produce multiple mutations on the same 
chromosome, further complicating mapping efforts.  A second problem encountered with 
EMS mutagenesis is mosaicism, a situation in which mutagenized progeny carry the 
mutation of interest only in somatic cells and not in the germ line.  Because somatic 
mutations cannot be maintained in stocks, these modifiers are lost during the screening 
process.       
 
Despite these disadvantages, EMS-based mutagenesis screens do offer one significant 
advantage over transposon-based screens.  An EMS mutagenesis of sufficient scope can 
generate mutations in every gene within the genome involved with a specific pathway, 
yielding a result called "saturation."  This is not the case with a transposon-based 
mutagenesis, due to the insertion preferences of mobilized transposons (Spradling et al., 
1995; Thibault et al., 2004).  Although the basis for insertion preferences is not 
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completely understood, there are regions of the genome where insertion frequencies are 
high (hotspots) and regions where insertion frequencies are low (coldspots) for any given 
transposon.  Thus, transposon mutagenesis methods are skewed toward generating higher 
mutation rates in genes located within hotspots, while failing to generate mutations in 
genes within coldspots.  Because of this preference, transposon mutagenesis is not 
saturating.  This was the case with the Exelixis transposon collection used for screening 
in Chapter 4; only about half of Drosophila genes are affected by insertions in this 
collection. 
 
As will be outlined in the discussion of this chapter, all of the disadvantages of a typical 
EMS screen were encountered in our experiments.  A high level of mosaicism was found 
in our initial screen progeny, and many obstacles were encountered in mapping 
mutations.  Nevertheless, the modifiying mutation that became the focus of my thesis 
work was mapped to the gene Not1, which was not identified in our transposon-based 
screen, suggesting the value in genetic screening with different mutagenesis methods. 
 
II.  Results 
We conducted an F1 modifier screen to identify interactors and effectors of the Notch 
pathway.  The screen made use of a sensitized genetic background in which wild-type 
Delta ligand, under the control of a UAS responder, is overexpressed in the Drosophila 
eye using the GMR-Gal4 driver (GMR>DlWT).  Such overexpression creates a smooth 
and glassy eye phenotype in which the ommatidia appear fused into a single flat sheet.  
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The complete genetic scheme for the screen is outlined in Figure 2-2.  Wild-type 
isogenized males were fed EMS and mated to GMR>DlWT/CyO virgin females.   
Progeny from this cross were then screened for enhancement or suppression of the glassy 
eye phenotype caused by Delta overexpression in the eye.  Examples of enhancement and 
suppression of the GMR>DlWT phenotype are shown in Figure 2-3.  Typically, 
enhancement of the GMR>DlWT phenotype is manifested as a smaller, flatter eye, often 
containing dark discoloration.  Suppression of the phenotype results in a more wild type 
eye – the eye will often appear more rounded and less glassy, and the individual 
ommatidia are more apparent.   
 
A.   A primary screen of 127,200 haploid genomes for GMR>DlWT modification 
identifies 43 complementation groups 
In collaboration with Kris Klueg and Jason Anderson from Indiana University, we 
screened a total of 127,200 haploid genomes for modification of the GMR>DlWT 
phenotype.  A total of 1141 candidate modifiers were identified, of which 195 transmitted 
to subsequent generations.  Linkage of each modifying mutations was determined via 
segregation analysis using marked balancer chromosomes, and balanced stocks were 
generated for each transmitting modifier, as described in Materials and Methods (Chapter 
5).   An overview of screen statistics is presented in Table 2-1. 
 
To prioritize modifiers based on the likelihood of direct interaction with the Notch 
pathway, rather than indirect effects on GMR-Gal4 driver expression, both positive and 
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negative secondary tests were undertaken.  The purpose of the negative secondary test 
was to identify modifiers that have an effect on GMR-Gal4 driver expression and are 
therefore likely to represent false-positive modifiers in the screen.  A GMR-Gal4 driver 
insertion that causes a rough eye phenotype (Freeman 1996; Hay et al., 1994) was used 
for this test; modifiers were crossed into this background and scored for enhancement or 
suppression of this rough eye phenotype (Table 2-2).     
 
Those modifiers that passed negative secondary testing were then subjected to a positive 
secondary test.  The positive secondary test was designed to determine whether the 
GMR>DlWT modification identified in the primary screen reflects detection of mutations 
in genes that affect Notch signaling in multiple contexts, based on the ability to detect 
phenotypic modification in a second Notch pathway mutant genetic background.  For this 
test, the lethal Delta (Dl) allele Dl14 was used (Drosophila Information Service, 1940; 
Alton et al., 1989).  This mutation causes visible thickening of the L2 wing vein, as well 
as ectopic vein formation at the L4/L5 crossvein in heterozygotes (Figure 2-4).  Each 
modifier was crossed into the Dl14 mutant background, to generate flies heterozygous for 
the Dl14 mutation and the modifying mutation, and double heterozygotes scored for 
enhancement or suppression of this wing vein phenotype.  The results of these crosses are 
summarized in Table 2-2.  Almost all modifiers that exhibit a phenotype in the Dl14 
genetic background enhance wing vein thickening and ectopic vein formation.  This 
implies that these modifying mutations reduce net Notch signaling (i.e., result in Notch 
loss-of-function). 
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The combined results of the secondary tests were used to prioritize modifiers of greatest 
interest and aid in selection of those modifiers that would undergo more extensive genetic 
mapping.  Modifiers that failed the negative secondary test (i.e., modified the GMR-Gal4 
rough eye phenotype) were given low priority based on the likelihood that GMR>DlWT 
modification was due to indirect effects on the driver, rather than direct Notch pathway 
interactions.  In addition, modifiers that affected the Dl14-associated phenotype more 
intensely in the positive secondary test were assigned higher priority than those with less 
intense effects.  Of the 195 transmitting modifiers placed into stable stocks, 75 passed the 
negative secondary test.  
 
Those modifiers that passed negative secondary testing were also subjected to inter se 
complementation testing, to identify complementation groups, as described in Materials 
and Methods (Chapter 5).  The results of these tests are summarized in Table 2-3.  The 75 
modifiers that passed negative secondary testing comprise 43 complementation groups 
(including the Star complementation group), as shown in Table 2-4.  Among these 43 
complementation groups, 27 are single-member groups.  As discussed below, the 
percentage of single member groups is higher than expected, while the total number of 
complementation groups is much lower than expected; this is likely due to failure to 
achieve saturation of the genome during this screen. 
 
B.   Low-resolution deficiency mapping of 13 candidate modifiers 
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One of the greatest challenges in any EMS-based screen is mapping transmitting modifier 
mutations down to the resolution of single genes.  Factors such as second site mutations, 
lack of available mapping tools, and high gene density in chromosomal regions of interest 
all complicate the ability to map precisely an EMS-induced mutation.  Because of these 
complications, a relatively large pool of hits from our screen was initially selected for 
low-resolution deficiency mapping.  We theorized that by completing deficiency kit 
mapping with a large group of our top modifier candidates, at least some would be 
correlated with single-site mutations within chromosomal regions that possessed tools to 
enable higher resolution mapping.  
 
Thirteen modifiers that passed both the negative secondary test and also modified either 
the GMR>DlWT and/or the Dl14/+ phenotype were selected for deficiency mapping.  All 
modifiers selected were linked to the second chromosome; mapping was conducted using 
the Bloomington Drosophila Stock Center Deficiency Kit ("BDSC Df Kit") for 
chromosome II, a series of large deficiencies which, at the time of testing, offered 
roughly 90% chromosomal coverage.  Each of the thirteen modifiers was crossed to each 
deficiency kit member in pair-wise complementation tests.  Lethality was scored based 
on the number of heterozygous modifier/deficiency progeny.  The results of deficiency 
kit mapping are summarized in Table 2-5. 
 
C.   High-resolution mapping of modifiers 11A-2, 96B-1, 97-4, and 159-1a  
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 Based on the results of BDSC Df Kit mapping, four modifiers (11A-2, 96B-1, 97-4, and 
159-1a) were selected for more precise mapping experiments using smaller deficiencies, 
as well as candidate gene mutations.  These four were chosen out of the original pool of 
thirteen based on the clarity of low-resolution mapping results and the strength of their 
respective modification phenotypes.  A summary of mapping experiments for each 
modifier is presented below. 
 
D.  Genetic mapping of the modifier 11A-2 
BDSC Df Kit mapping yielded a single deficiency [Df(2L)N22-14] that did not 
complement lethality associated with modifier 11A-2; this deficiency uncovers 
cytogenetic region 29C1;30C9 on the left arm of chromosome 2.  To more precisely map 
this lethality, 11A-2 was crossed to a series of smaller overlapping deficiencies.  
Complementation results reduced the potential location of the 11A-2 lethal mutation to 
the cytogenetic region 29E1;29F1.  A pictorial summary of the mapping results is 
presented in Figure 2-5.   
 
Within this region, there was one small deficiency available [Df(2L)ED632] that 
uncovered the cytogenetic region 29E1;29E4.  This deficiency complemented 11A-2, 
reducing the lethal mutation-bearing region to a 102 kb area containing eight genes.  
Annotations for these genes are presented in Table 2-6.  A single lethal candidate gene 
mutation was available in this region, for the gene raw (raw1); this mutation also 
complemented 11A-2.  
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Overall, lethality associated with the 11A-2 modifier mapped to a set of seven genes: 
Hnf4, CG9314, CG12438, CG9463, CG9465, CG9466, and CG9468.  No other mapping 
stocks currently exist to narrow down, any further, the genetic relationship between 11A-
2 and this set of seven candidate genes. 
 
E.  Genetic mapping of the modifier 96B-1 
BDSC Df Kit mapping yielded three deficiencies, Df(2R)H3E1, Df(2R)stan1, and 
Df(2L)TW50, that failed to complement lethality associated with modifier 96B-1. Test 
crosses to assess the ability of each of these three deficiencies to modify the GMR>DlWT 
phenotype showed that Df(2L)TW50 produced a strong suppression phenotype, 
mimicking that of the 96B-1 modifier, while the other two deficiencies did not produce 
any modification.  Thus, the region uncovered by Df(2L)TW50 was the focus of higher 
resolution mapping experiments. 
 
Df(2L)TW50 spans the cytogenetic region 36E4;38A7.  Additional complementation tests 
for 96B-1-associated lethality using smaller deficiencies narrowed this lethality to the 
region 37B1-6, as outlined in Figure 2-6.  This region includes the following six genes:  
CG33120, CG17321, CG10602, mRpL13, tailup, ssp3.  Annotations for these genes are 
presented in Table 2-6.  Loss-of-function alleles were available for CG10602, mRpL13, 
tailup, and ssp3; and all were tested for complementation of 96B-1-associated lethality.  
Of these four mutations, only tailup1 did not complement 96B-1-associated lethality.  
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Thus, one lethal mutation associated with the second chromosome including the 96B-1 
modifier mutation appears to map to the tailup gene.  Curiously, however, the tailup1 
loss-of-function allele did not modify either the GMR>DlWT or Dl14/+ phenotypes, 
suggesting that either that the tailup mutation on the 96B-1-bearing chromosome is not a 
true loss-of-function allele, or that the actual mutation causing modification of the 
GMR>DlWT phenotype maps to a gene other than tailup. 
 
F.  Genetic mapping of the modifier 97-4 
Two different BDSC Df Kit deficiencies did not complement lethal mutations associated 
with the 97-4 modifying mutation:  Df(2R)BSC29 and Df(2R)BSC11.  Because the 97-4 
modifier mutation is a member of a multi-member complementation group (Table 2-4), 
the location of the mutation of interest could be better assessed by testing the remaining 
97-4 complementation group members against these two deficiencies.  The other three 
97-4 complementation group members complemented Df(2R)BSC11, and failed to 
complement Df(2R)BSC29.  Thus, Df(2R)BSC29 appears to uncover the region of interest 
for further mapping efforts.   
 
Df(2R)BSC29 spans the cytogenetic region 45D3-4;45F2-6 on the right arm of 
chromosome 2.  Complementation testing with smaller deficiencies in this region 
narrowed 97-4-associated lethality to 45F1;45F6, as outlined in Figure 2-7.  This interval 
constitutes a 41.7 kb region including 15 genes:  mir-14, 0r45b, CG1809, Not1, CG1814, 
CG1868, Updo, CG12929, RpL31, CG12928, CG1827, Map60, CG34363, CG30338, 
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and CG1902.  Annotation of these genes is presented in Table 2-6.  More highly resolved 
mapping efforts to identify the gene affected by mutations in the 97-4 complementation 
group are outlined in the following chapter.   
 
G.  Genetic mapping of the modifier 159-1a 
BDSC Df Kit testing revealed four deficiencies that did not complement lethality 
associated with modifier 159-1a:  Df(2R)BSC45, Df(2R)14H10Y-53, Df(2R)Exel7162, 
and Df(2R)BSC19.  Df(2R)BSC45 and Df(2R)14H10Y-53 are overlapping deficiencies 
that uncover cytogenetic region 54D1;54E7.  Similarly, Df(2R)Exel7162 and 
Df(2R)BSC19 are overlapping deficiencies which uncover cytogenetic region 56F12-16.  
Because all of the deficiencies listed also modified the GMR>DlWT phenotype, neither 
region could be ruled out as containing the mutation of interest.  A schematic summary of 
the mapping efforts for modifier 159-1a is shown in Figure 2-8.  Annotation of genes 
present in these two regions is summarized in Table 2-6. 
 
Using smaller overlapping deficiencies available in the first cytogenetic region, 
54D1;54E7, the potential region of interest was narrowed to a 21.1 kb region containing 
five genes:  eIF3-S8, CG30108, CG30109, CG6459, and Sema1b.  Of these genes, only 
eIF3-S8 had a lethal allele available.  This allele (eIF3-S814F06) failed to complement 
159-1a-associated lethality; thus, one lethal mutation present on the 159-1a modifier 
chromosome lies in the eIF3-S8 gene.  The eIF3-S8 loss-of-function allele did not modify 
either the GMR>DlWT or Dl14/+ phenotype. 
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There were no smaller deficiencies available that partitioned the other potential region of 
interest, 56F12-16.  This region is 39.1 kb long and includes the following 10 genes:  
CG11788, CG9143, CG9090, CG16868, CG34199, Cpr56F, CkIIbeta2, CG11200, 
CG8920, CG13868.  A lethal allele was available only for CG11200 (CG11200d02302), 
and this allele complemented 159-1a.  No other mapping tools were available to resolve 
further the position of the 159-1a modifier mutation. 
 
III.  Discussion 
A.  This EMS mutagenesis screen was not saturating for mutations in Notch-interacting 
genes 
It is clear from screen statistics that the mutagenesis did not saturate the genome for 
Notch pathway modifiers.  This is evident from the small number of complementation 
groups identified, as well as the high percentage of single-member complementation 
groups.  Typically, EMS mutagenesis at the standard concentration of 25 mM can be 
expected to produce a mutation rate of 0.03-0.1% (Greenspan, 1997) meaning that one 
mutation per locus should be produced for every 3000 haploid genomes.  Given that over 
127,000 mutagenized haploid genomes were screened, we would expect roughly 40 
mutant alleles of each interacting gene to be generated during the course of the screen.  If 
even a small fraction of these mutations (e.g., 5-10%) would modify a given sensitized 
phenotype, we would expect at least two to four modifying mutations per interacting 
gene.  Yet, among the 42 complementation groups identified, only 15 contained multiple 
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mutations.  The largest of these complementation groups contained 19 members, which 
were alleles of Star, an EGFR pathway member commonly pulled out of eye screens 
(Rebay et al., 2000; Taguchi et al., 2000), based on non-complementation of Star-
associated lethality (data not shown).   
 
Although standard EMS mutagenesis protocols were used, failure to achieve saturation 
could be the result of a number of factors.  One factor is that F1 modifier screens are 
subject to the effects of mosaicism, in which the progeny of mutagenized males possess 
both mutant and wild-type cells.  If mutations are present within only somatic cells of an 
F1 fly and not the germ line, then they cannot be passed on to future generations, and the 
mutation of interest cannot be placed into a genetically stable stock.  Thus, the frequency 
of transmittable mutation in F1 modifier screens may be lower than the initially observed 
frequency of flies with modified phenotypes due to loss of somatic mutants after the first 
generation.  In our screen, although 1141 modifiers of GMR>DlWT were identified 
initially, only 195 modifiers corresponded to germ line mutations that transmitted to the 
next generation.  Given that almost 83% of initial modifiers failed to propagate, it is not 
surprising that the overall yield of modifying mutations and complementation groups was 
lower than expected. 
 
A second factor that could have contributed to the low number of multi-member 
complementation groups defined is the strength of the GMR>DlWT phenotype.  As it 
turns out, the glassy eye phenotype induced by this genotype is not as sensitive to 
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modification as was originally thought, based on validation with deficiencies, including 
some deficiencies deleting members of the Notch pathway (Kris Klueg, unpublished 
data).  Subsequent post-screen studies examining GMR>DlWT modification by point 
mutations in Notch pathway genes identified only a mastermind (mam) loss-of-function 
allele as a modifier of the phenotype (Marisa Osswalt, unpublished data).  In addition, all 
of the EMS modifiers mapped to single gene resolution (tailup, eIF3-S8, and Not1) have 
direct roles in transcription or translation and likely exert their effects on expression of 
members of the pathway.  Similarly, modifiers identified in the GMR>DlWT transposon 
screen (see Chapter 4) are highly enriched in genes that mediate transcription and in 
genes that play basic and crucial roles in eye development and cell maintenance.  These 
results suggest that our screen was skewed toward genes that have very direct and 
significant effects on Notch pathway signaling and eye development.  Mutations in 
subtler modulators and regulators of Notch signaling activity would not have been 
identified due to their inability to alter the GMR>DlWT phenotype.  This would result in 
definition of a lower number of complementation groups than would be expected for a 
more “pushable” phenotype. 
 
Another interesting result is that virtually all of the transmitting modifiers placed into 
stable stocks map to the second chromosome.  Only two (B51A-2 and B56A-1) were 
linked to the third chromosome.  The reasons for this second chromosome preference are 
most likely random.  There is no evidence to suggest that Notch pathway members or 
interactors are more prevalent on the second chromosome (FLYBASE, Release 
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FB2009_02).  The core members of the pathway themselves are distributed among all 
three major chromosomes [e.g., Notch on X, Su(H) on II, Delta on III].  The definition of 
fewer third chromosome modifying complementation groups is probably a random 
occurrence, observed because the mutagenesis did not achieve saturation of the genome 
for Notch pathway members. 
 
B.  Most EMS modifiers isolated are suppressors of the GMR>DlWT phenotype     
The great majority of modifiers identified in our screen were suppressors of the 
GMR>DlWT phenotype.  Of the 75 transmitting modifiers that passed secondary testing, 
only twenty enhanced the phenotype, and nineteen of these were alleles of the Star 
complementation group (Table 2-2).  No definitive statement can be made as to the 
nature of GMR>DlWT suppression by these modifying mutations, based on the 
GMR>DlWT external eye phenotype, as this phenotype is underlain by gain- and loss-of-
function effects on Notch signaling (Shalaby et al., submitted).  Analysis of cone cell and 
photoreceptor development in the developing retinas of GMR>DlWT suppressors 
indicates that this genotype yields Notch signaling impairment during cone cell induction, 
but Notch signaling activation during photoreceptor specification.  This is possible 
because DSL ligands can have cis-inhibitory effects on Notch signaling, in addition to 
their typical effects of activating Notch signaling (Micchelli et al., 1997; de Celis and 
Bray, 1997).  Because the Notch pathway functions in numerous intersecting processes 
during Drosophila eye development, it is difficult to identify all of the underlying causes 
of the gross morphology seen in adult eyes of GMR>DlWT flies.  The phenotype 
 43 
produced by Delta overexpression in the eye is likely the integrated result of gain- and 
loss-of-function effects on Notch signaling activity.  While EMS mutagenesis induces 
primarily point mutations in affected genes and is more prone to produce loss-of-function 
mutations (Sega 1984), including missense and nonsense mutations that reduce or 
obliterate protein function, such mutations may have either stimulatory or inhibitory 
effects on overall Notch signaling levels in the GMR>DlWT background.   
 
C.  The positive secondary test supports a Notch loss-of-function effect for GMR>DlWT 
suppressors 
In contrast to the eye, Notch signaling mechanisms during the development of the wing 
veins are much more clearly defined.  Therefore, the results of our positive secondary 
testing involving wing vein development can support the conclusion of a Notch signaling 
gain- or loss-of-function effect for a given EMS-induced modifying mutation.  As 
discussed earlier, the Dl14 mutation is a lethal loss-of-function Delta allele that causes 
wing vein thickening and ectopic vein formation.  This phenotype is caused by the 
disruption of Notch function during wing vein boundary formation in the course of wing 
development.  Normally, Delta ligand is expressed within central provein region of the 
developing vein, resulting in Notch pathway activation in adjacent lateral provein cells 
(Huppert et al., 1997).  Notch activation leads to up-regulation of the Enhancer of split 
[E(spl)-C] genes, which suppress development as vein cells of lateral provein cells (de 
Celis et al., 1997).  In this way, boundaries defined by E(spl)-C expression are formed 
within the provein, limiting the width of the future adult vein.  Only those cells within the 
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provein that lack E(spl)-C expression adopt the vein cell fate.  In the Dl14/+ mutant, only 
one functional, wild-type copy of Delta is present.  The reduced levels of functional 
Delta expression compromise the formation of the E(spl)-C boundary, leading to mild 
expansions of wing vein tissue. 
 
If those EMS-induced modifying mutations that suppressed the GMR>DlWT 
overexpression phenotype cause reduction in Notch signaling, they would be expected to 
enhance the wing vein thickening phenotype seen in the Dl14/+ mutant.  This was the 
case for the majority of modifiers we isolated from the EMS screen.  Of the 56 non-Star 
modifiers that passed negative secondary testing and suppressed the GMR>DlWT 
phenotype, 40 enhanced the Dl14/+ phenotype.  In addition, there were 14 suppressors of 
GMR>DlWT that did not modify the Dl14/+ phenotype.  These mutations probably affect 
genes specifically involved in eye development, rather than general Notch signaling 
processes.  Finally, only two modifiers (44B-6 and 73A-5) suppressed both the 
GMR>DlWT and Dl14/+ phenotypes.  
 
D.  Mapping data highlight difficulties in mapping EMS mutations 
It is well-known that one of the major drawbacks of genetic screens utilizing EMS 
mutagenesis in Drosophila is the difficulty associated with mapping an EMS point 
mutation to a single gene.  Mapping success is often dependent on the tools that are 
available to conduct complementation testing.  There may be regions along a 
chromosome in which deficiencies are not available.   In addition, it may not be possible 
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to attain sufficient resolution in chromosomal regions of high gene density due to a lack 
of smaller deficiencies and loss-of-function alleles in candidate genes.  While at the time 
of our mapping experiments the Bloomington Drosophila Stock Center Deficiency Kit 
covered almost 90% of chromosome II, this still left 10% of the chromosome within 
which no useful deficiency mapping tools were available.  Furthermore, many of the 
available deficiencies did not have defined breakpoints, making more difficult the 
mapping of any mutations that lie within boundary regions of overlapping deficiencies.   
 
Another challenging issue is the potential of EMS mutagenesis to produce multiple 
mutations within a single mutagen-exposed gametic haploid genome.  Because deficiency 
mapping is predicated on locating lethal mutations on a chromosome, and not necessarily 
the mutation causing the modified phenotype of interest, the presence of two or more 
lethal mutations on a modifier-bearing chromosome complicates the mapping process.  It 
is possible that mapped lethal mutations are not causing modification of the phenotype of 
interest, but are simply accessory lethal hits on the modifier-bearing chromosome.          
 
We ran into all of the challenges framed above, throughout our mapping experiments.  A 
total of 13 modifiers were selected for initial low-resolution deficiency mapping using the 
Bloomington Drosophila Stock Center Deficiency Kit for chromosome II, as outlined in 
Table 2-5.  Four of the 13 modifiers complemented all of the BDSC Df Kit members, 
indicating that the associated mutations lie in regions along the chromosome that are not 
covered by available deficiencies or that one or more of those modifiers is not a lethal 
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mutation.  Without any deficiency tools available to locate these mutations at the time of 
mapping, these modifiers could not be mapped further without resorting to additional 
labor-intensive deficiency generation or meiotic mapping.  In addition, five modifiers 
failed to complement more than one BDSC Df Kit deficiency on chromosome 2.  This 
suggested that there were multiple lethal hits along the chromosomes carrying these 
modifying mutations.  Multi-site mutational hits complicate mapping efforts, particularly 
for single-member complementation groups for which lethal complementation testing 
cannot be used to identify the mutation of interest.  As stated earlier, most of the 
complementation groups identified in this screen were single-member groups. 
 
E.  tailup and eIF3-S8 are identified as lethal mutations associated with two modifiers 
Of the four complementation groups (11A-2, 96B-1, 97-4, and 159-1a) that were selected 
for more extensive mapping experiments, we successfully identified modifier-associated 
lethal mutations for 96B-1, 97-4, and 159-1a.  A lethal mutation in the gene Not1 was 
shown to be allelic to members of the 97-4 complementation group (see Chapter 3).  As 
will be discussed in detail in the next chapter, the modifying mutations of interest also 
map to the Not1 gene. 
 
Higher resolution mapping of the 159-1a complementation group identified a lethal hit in 
the gene eIF3-S8.  Based on sequence similarity, eIF3-S8 is a member of the eukaryotic 
initiation factor family required for initiation of protein synthesis (Lasko, 2000).  
Specifically, eIF3-S8 shares strong protein sequence homology with subunit C of 
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eukaryotic initiation factor 3 (eIF3c) in mammals.  eIF3c is considered a core subunit 
within the eIF3 complex and is required for translation in vivo; eIF3c plays a role in 40S 
ribosome binding, mRNA recruitment and translation start site recognition (Hinnebush, 
2003).   
 
Because deficiency mapping of the modifier 159-1a identified a second-site lethal 
mutation in addition to the lethal mutation in eIF3-S8, it is not clear whether the 
modifying mutation truly lies within eIF3-S8.  The eIF3-S8 lethal allele used to map the 
mutation, eIF3-S814F06 , also did not modify either the GMR>DlWT or Dl14/+ 
phenotypes.  Nevertheless, it is not difficult to envision a scenario under which a 
mutation in eIF3-S8 could affect Notch signaling.  As the Notch signaling pathway exerts 
its effects through alteration of downstream transcriptional activity, particularly of E(spl)-
C expression levels, any mutations in genes required for basic functions of transcription 
and translation could reduce Notch signal strength.  In fact, any mutation that affects core 
cellular functions required for cell maintenance could indirectly impact the efficiency of 
any signaling pathway involving cell surface receptors.  Thus, it is not surprising that a 
growing body of literature implicates the core endocytic machinery, including genes such 
as auxilin, epsin, and clathrin, in Notch signal reception and transmission.  Epsin is an 
endocytic adaptor that activates Notch signaling by targeting DSL ligands for 
internalization after ubiquitination by Neuralized and Mindbomb1 (Wang and Struhl, 
2004; Wang and Struhl, 2005).  Meanwhile, Auxillin, an endocytic protein that 
disassembles clathrin coats from vesicles, has recently also been shown to be required for 
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Notch signaling, through promotion of clathrin-mediated endocytosis of Delta (Eun et al., 
2008; Kandachar et al., 2008). 
 
A single lethal mutation was also associated with the 96B-1 complementation group and 
mapped to the gene tailup.  tailup is the Drosophila homolog of the vertebrate 
transcription factor and LIM-homeodomain protein islet.  Studies in fly and vertebrate 
systems have shown that tailup is required for proper motor neuron system development; 
mutations in the gene lead to aberrant neuronal axon projections, as well as improper 
neurotransmitter expression (Yamada 1992; Pfaff 1994; Thomas 1997).  tailup functions 
as a member of a LIM-homeodomain transcription factor network to control motor 
neuron pathway selection during development (Thomas 1999).   
 
Interestingly, a more recent study supports a role for tailup in sensory organ patterning of 
the Drosophila notum.  Tailup, through its direct interaction with the transcription factor 
Pannier, inhibits sensory organ precursor (SOP) development; loss of tailup causes 
increased expression of Achaete in proneural groups, leading to ectopic SOP formation 
and excessive bristle development (Heitzler 2005).  This research suggests a potential 
genetic interaction between tailup and the Notch pathway, as Notch activity inhibits SOP 
formation in the developing notum through repression of achaete expression.  If tailup 
were to play a similar role in eye and wing development, amorphic mutations in the gene 
should exhibit Notch loss-of-function phenotypes; this is consistent with the phenotype 
observed when the 96B-1 modifier is crossed into the GMR>DlWT and Dl14/+ genetic 
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backgrounds.  Unfortunately, no such phenotypic modification was seen when tailup1, 
which is presumably an amorphic allele of tailup, was also crossed into these 
backgrounds.  And, as with the 159-1a complementation group, multiple lethal mutations 
were identified during deficiency mapping of the 96B-1 modifier.  Thus, no definitive 
statement can be made as to whether the 96B-1 complementation group is comprised of 
mutations in the tailup gene.        
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Figure 2-1.  GMR>DlWT EMS mutagenesis screen workflow 
After isolation of enhancers and suppressors of the GMR>DlWT/+ eye phenotype during 
the primary genetic screen, modifier linkage was determined and modifier stocks were 
generated using the appropriate balancers.  Positive and negative secondary testing were 
then conducted to prioritize modifiers of greatest interest.  Modifiers were placed in 
complementation groups based on inter se complementation testing.  Selected modifiers 
were then localized more exactly based on deficiency, candidate gene, and meiotic 
mapping. 
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Figure 2-1.  GMR>DlWT EMS mutagenesis screen workflow 
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Figure 2-2.  Genetic design of GMR>DlWT EMS mutagenesis screen 
A sensitized genetic background was created through overexpression of Delta using the 
Gal4-UAS system to create a “glassy” eye phenotype.  Isogenized, wild type males were 
mutagenized with ethylmethane sulfonate (EMS) and then crossed into this sensitized 
background (GMR>DlWT).  F1 critical class progeny were screened for enhancement or 
suppression of the GMR>DlWT/+ phenotype. 
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Figure 2-2.  Genetic design of GMR>DlWT EMS mutagenesis screen 
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Figure 2-3.  Representative modifier phenotypes of GMR>DlWT 
The GMR>DlWT/+ phenotype (Panel B) is characterized by a flat, glassy eye in which 
ommatidia appear fused, in comparison to the wild type Drosophila eye.  The 
homozygotes GMR>DlWT/GMR>DlWT exhibit an even more severe eye phenotype, 
characterized by a smaller, blackened rough eye (Panel A).  For the EMS screen, 
mutagenized males were crossed into the GMR>DlWT/+ background, and F1 progeny 
were scored for enhancement or suppression of the eye phenotype depicted in Panel B.  
Panels D and E depict a representative enhancer and suppressor, respectively, of the 
GMR>DlWT/+ phenotype.  Enhancers are typically characterized as a much smaller, 
flatter eye with regions of darkened pigmentation.  In contrast, suppressors exhibit a more 
rounded eye, possessing increased definition of individual ommatidia. 
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Figure 2-3.  Representative modifier phenotypes of GMR>DlWT 
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Figure 2-4.  Representative modifier phenotypes of Dl14/+ 
The Dl14/+ adult wing (Panel B) exhibits slight thickening of the L2 longitudinal vein 
and minor ectopic vein formation near the posterior crossvein in comparison to a wild 
type wing (Panel A).  The positive secondary test consisted of crossing EMS modifiers 
into the Dl14/+ background and scoring critical class progeny for enhancement or 
suppression of the Dl14/+ wing phenotype.  Panels C and D depict a representative 
enhancer (modifier 143A-3) and suppressor (modifier 44B-6), respectively, of the Dl14/+ 
phenotype.  Enhancers exhibit more severe thickening along the L2 longitudinal vein and 
increased ectopic vein formation at the L4/L5 crossvein.  In contrast, suppressors exhibit 
reduced vein thickening and reduced ectopic vein formation. 
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 Figure 2-4.  Representative modifiers phenotypes of Dl14/+  
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Figure 2-5.  Genetic mapping schematic for EMS modifier 11A-2 
Deficiency mapping of modifier 11A-2 using the Bloomington Drosophila Stock Center 
(BDSC) Deficiency Kit on chromosome 2 identified a single deficiency, Df(2L)N22-14 
(29C1;30C9), that failed to complement the modifier.  Subsequent deficiency mapping 
using smaller deficiencies ultimately narrowed the genomic region containing the 11A-2-
associated lethality to 29E4;29F1 on the cytogenetic map.  This represents a 102 kb 
region uncovering the following eight genes:  Hnf4, CG9314, raw, CG12438, CG9464, 
CG9465, CG9466, and CG9468. 
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Figure 2-5.  Genetic mapping schematic for modifier 11A-2 
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Figure 2-6.  Genetic mapping schematic for EMS modifier 96B-1 
Deficiency mapping of modifier 96B-1 using the BDSC Deficiency Kit on chromosome 2 
identified three deficiencies that failed to complement lethality associated with the 
modifier:  Df(2R)H3E1, Df(2R)stan1, and Df(2L)TW50 (not shown).  Only Df(2L)TW50, 
which spans the cytogenetic region 36E4;38A7, modified the GMR>DlWT/+ phenotype 
and therefore further mapping efforts were focused in this region.  Mapping with smaller 
deficiencies narrowed the genomic region containing the 96B-1 lethality to 37B1;37B6 
on the cytogenetic map.  This represents an 84.8 kb region uncovering the following six 
genes:  CG33120, CG17321, CG10602, mRpL13, tailup, and ssp3.  Candidate gene 
mapping with available lethal alleles among these six genes ultimately identified tailup as 
the gene within which a 96B-1-associated lethal mutation lies. 
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Figure 2-6.  Genetic mapping schematic for EMS modifier 96B-1 
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Figure 2-7.  Genetic mapping schematic for EMS modifier 97-4 
Deficiency mapping of modifier 97-4 using the BDSC Deficiency Kit on chromosome 2 
identified two deficiencies that failed to complement the modifier:  Df(2R)BSC29 and 
Df(2R)BSC11.  Only Df(2R)BSC29, which spans the cytogenetic region 45D3-4;45F2-6, 
failed to complement other members of the 97-4 complementation group and therefore 
further mapping efforts were focused on this region.  Mapping with smaller deficiencies 
narrowed the genomic region containing the 97-4 lethality to 45F1;45F6 on the 
cytogenetic map.  This represents a 41.7 kb region uncovering 15 genes.  Further 
mapping efforts within this region are described in the text. 
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Figure 2-7.  Genetic mapping schematic for EMS modifier 97-4 
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Figure 2-8.  Genetic mapping schematic for EMS modifier 159-1a 
Deficiency mapping of modifier 159-1a using the BDSC Deficiency Kit on chromosome 
2 identified four deficiencies that failed to complement the modifier:  Df(2R)BSC45, 
Df(2R)14H10Y-53, Df(2R)Exel7162, and Df(2R)BSC19.  Df(2R)BSC45 and 
Df(2R)14H10Y-53 are overlapping deficiencies that uncover cytogenetic region 
54D1;54E7.  Mapping with smaller deficiencies narrowed the genomic region of lethality 
to 54D4, a 21.1 kb region uncovering the following five genes:  eIF3-S8, CG30108, 
CG30109, CG6459, and Sema1B.  Candidate gene mapping with available lethal alleles 
identified eIF3-S8 as the gene within which one of the 159-1a-associated lethal mutations 
lies.  Df(2R)Exel7162 and Df(2R)BSC19 are also overlapping deficiencies that uncover 
cytogenetic region 56F12;56F16.  This represents a 39.1 kb region including 10 genes; 
smaller deficiencies and candidate gene lethal alleles were not available to further define 
the lethal mutation within this cytogenetic region. 
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Figure 2-8.  Genetic mapping schematic for EMS modifier 159-1a 
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Table 2-1.  EMS screen statistics  
A total of 127,200 EMS-mutagenized haploid genomes were screened for modification of 
the GMR>DlWT/+ rough eye phenotype.  After negative secondary testing, 75 modifiers 
representing 43 complementation groups were identified.  
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Table 2-1.  EMS Screen Statistics 
Haploid Genomes Screened 127,200 
Initial Candidate Modifiers 1141 
Transmitting Modifiers 195 
Lost Modifiers 17 
Failed Negative Secondary Testing 103 
Stocked Transmitting Modifiers 75 
Complementation Groups 43 
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Table 2-2.  Positive secondary testing results for transmitting modifiers isolated 
from the EMS-based GMR>DlWT modifier screen     
EMS modifiers that passed the negative secondary test were then subjected to a positive 
secondary test, to identify those modifiers that possess the strongest interactions with the 
Notch pathway.  Modifiers were tested for enhancement or suppression of the Delta loss-
of-function allele Dl14/+, which exhibits a mild wing vein thickening phenotype.  
Modifier males were crossed to virgin females of genotype Dl14/TM6C, and critical class 
progeny were scored for modification of the Dl14/+ wing vein phenotype.  The primary 
screen phenotype for each modifier in the GMR>DlWT/+ background is also shown.  
(Score Designations:  WS, MS, SS refer to weak suppressor, moderate suppressor, and 
strong suppressor, respectively.  WE, ME, SE refer to weak enhancer, moderate 
enhancer, and strong enhancer, respectively.) 
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Table 2-2.  Positive secondary testing results for transmitting modifiers isolated in the 
EMS-based GMR>DlWT modifier screen 
# Modifier Name Modifier/GMR>DlWT Modifier/Dl14 Modifier/GMR-Gal4 
1 2A-3 W/MS ME Pass 
2 5A-5 WS WE Pass 
3 11A-2 WS M/SE Pass 
4 18-2 WS none Pass 
5 29A-3 W/MS none Pass 
6 30A-1 W/MS ME Pass 
7 35A-7 M/SS none Pass 
8 36A-3 MS WE Pass 
9 44B-6 SS WS Pass 
10 45B-4 MS none Pass 
11 45B-5 W/MS W/ME Pass 
12 51B-5 M/SS WE Pass 
13 53A-4 MS ME Pass 
14 63A-1 W/MS ME Pass 
15 66A-1 WS ME Pass 
16 67A-5 WS WE Pass 
17 67B-4 MS SE Pass 
18 69A-2 WS WE Pass 
19 69A-4 WS WE Pass 
20 70A-1 W/MS WE Pass 
21 72-2 MS WE Pass 
22 73A-5 W/MS WS Pass 
23 75B-1 W/MS WE Pass 
24 76B-1 MS WE Pass 
25 78B-1 MS none Pass 
26 84-1 MS none  Pass 
27 89B-2 W/MS none  Pass 
28 93B-1 WS WE Pass 
29 93B-3 W/MS WE Pass 
30 94-1 M/SS WE Pass 
31 96B-1 SS M/SE Pass 
32 97-4 SS SE Pass 
33 101B-2 WS WE Pass 
34 117-2 WS WE Pass 
35 118A-4 W/MS W/ME Pass 
36 122A-3 W/MS W/ME Pass 
37 126A-2(4) WS W/ME Pass 
38 129A-3 MS M/SE Pass 
39 137A-5 MS ME Pass 
40 138-1 W/MS W/ME Pass 
41 138A-3 WS M/SE Pass 
42 140A-4 SS none Pass 
43 143A-1 WS W/ME Pass 
44 143A-3 W/MS SE Pass 
45 159-1a M/SS W/ME Pass 
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# Modifier Name Modifier/GMR>DlWT Modifier/Dl14 Modifier/GMR-Gal4 
46 161-2 MS none Pass 
47 165-2 WS none Pass 
48 173B-1 WS none Pass 
49 185B-3 WS WE Pass 
50 186B-1 W/MS W/ME Pass 
51 190B-1 M/SS none Pass 
52 209B-2 M/SS SE Pass 
53 211B-2 WS WE Pass 
54 223B-8 MS WE Pass 
55 B51A-2 SE none Pass 
56 B56A-1 MS none Pass 
57-
75 Star (19 alleles) SE none Pass 
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Table 2-3.  Inter se complementation testing results     
All EMS modifiers that passed negative secondary testing were subjected to inter se 
complementation testing to identify complementation groups.  Crosses were conducted in 
a single polarity (i.e., Modifier A/CyO males crossed to Modifier B/CyO virgins or 
Modifier A/CyO virgins crossed to Modifier B/CyO males).  At least 50 progeny were 
scored for each cross; homozygous viability of > 95% was considered reflective of 
complementation. (C - complementation;  FC - failure to complement)   
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Table 2-3.  Inter se complementation testing results 
Modifier 2A-3 5A-5 11A-2 18-2 24A-1 29A-3 30A-1 35A-7 
2A-3   C C C C C C C 
5A-5 C   C C C C C C 
11A-2 C C   C C C C C 
18-2 C C C   C C C C 
24A-1 C C C C   C C C 
29A-3 C C C C C   C C 
30A-1 C C C C C C   C 
35A-7 C C C C C C C   
36A-3 C C C C C C C C 
44B-6 C C C C C C C C 
45B-4 C C C C C C FC C 
45B-5 C C C C C C C C 
51B-5 C C C C C C C C 
53A-4 C C C C C C C C 
63A-1 C C C C C C C C 
66A-1 C C C C C C C C 
67A-5 C C C C C C C C 
67B-4 C C C C C C C C 
69A-2 C C C C C C C C 
69A-4 C C C C C C C C 
70A-1 C C C C C C C C 
72-2 C C C FC C C C C 
73A-5 C C C C C C C C 
75B-1 C C C C C C C C 
76B-1 C C C C C C C C 
78B-1 C C C C C C C C 
84-1 C C C C C C C C 
89B-2 FC C C C C C C C 
93B-1 C C C C C C C C 
93B-3 C C C C C C C C 
94-1 C C C C C C C C 
96B-1 C C C C C C C C 
97-4 C C C C C C C C 
101B-2 C C C C C C C C 
117-2 C C C C C C C C 
118A-4 C C C C C C C C 
122A-3 C C C C C C C C 
126A-2(4) C C C C C C C FC 
129A-3 C C C C C C C C 
138-1 C C C C C C C C 
138A-3 C C C C C C C C 
140A-4 C C C C C C C FC 
143A-1 C C C C C C C C 
143A-3 C C C C C C C C 
159-1a C C C C C C C C 
173B-1 C C C C C C C C 
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Modifier 2A-3 5A-5 11A-2 18-2 24A-1 29A-3 30A-1 35A-7 
185B-3 C C C C C C C C 
186B-1 C C C C C C C C 
190B-1 C C C C C C C FC 
209B-2 C C C C C C C C 
211B-2 C C C C C C C C 
223B-8 C C C C C C C C 
 
 
Modifier 36A-3 44B-6 45B-4 45B-5 51B-5 53A-4 63A-1 66A-1 
2A-3 C  C C C C C C C 
5A-5 C C  C C C C C C 
11A-2 C C C  C C C C C 
18-2 C C C C  C C C C 
24A-1 C C C C C  C C C 
29A-3 C C C C C C  C C 
30A-1 C C FC C C C C  C 
35A-7 C C C C C C C C  
36A-3  C C C C C C C 
44B-6 C  C C C C C C 
45B-4 C C  C C C C C 
45B-5 C C C  C C C C 
51B-5 C C C C  C C C 
53A-4 C C C C C  C C 
63A-1 C C C C C C  C 
66A-1 C C C C C C C  
67A-5 C C C C C C C C 
67B-4 C C C C C C C C 
69A-2 C C C C C C C C 
69A-4 C C C C C C C C 
70A-1 C C C C C C C C 
72-2 C C C C C C C C 
73A-5 C C C C C C C C 
75B-1 C C C FC FC C C C 
76B-1 C C C C C C C C 
78B-1 C C C C C C C C 
84-1 C C C C C C C C 
89B-2 C C C C C C C C 
93B-1 C C C C C C C C 
93B-3 C C C C C C C C 
94-1 C C C C C C C C 
96B-1 C C C C C C C C 
97-4 C C C C C C C C 
101B-2 C C C C C C C C 
117-2 C C C C C C C C 
118A-4 C C C C C C C C 
122A-3 C C C C C C C C 
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Modifier 36A-3 44B-6 45B-4 45B-5 51B-5 53A-4 63A-1 66A-1 
126A-2(4) C C C C C C C C 
129A-3 C C C C C C C C 
138-1 C C C C C C C C 
138A-3 C C C C C C C C 
140A-4 C FC C C C C C C 
143A-1 C C C C C C C C 
143A-3 C C C C C C C C 
159-1a C C C C C C C C 
173B-1 C C C C C C C C 
185B-3 C C C FC FC C C C 
186B-1 C C C C C C C C 
190B-1 C C C C C C C C 
209B-2 C C C C C C C C 
211B-2 C C C C FC C C C 
223B-8 C C C C FC C C C 
 
 
Modifier 67A-5 67B-4 69A-2 69A-4 70A-1 72-2 73A-5 75B-1 
2A-3 C  C C C C C C C 
5A-5 C C  C C C C C C 
11A-2 C C C  C C C C C 
18-2 C C C C  C FC C C 
24A-1 C C C C C  C C C 
29A-3 C C C C C C  C C 
30A-1 C C C C C C C  C 
35A-7 C C C C C C C C  
36A-3 C C C C C C C C 
44B-6 C C C C C C C C 
45B-4 C C C C C C C C 
45B-5 C C C C C C C FC 
51B-5 C C C C C C C FC 
53A-4 C C C C C C C C 
63A-1 C C C C C C C C 
66A-1 C C C C C C C C 
67A-5  C C C C C C C 
67B-4 C  C C C C C C 
69A-2 C C  C C C C C 
69A-4 C C C  C C C C 
70A-1 C C C C  C C C 
72-2 C C C C C  C C 
73A-5 C C C C C C  C 
75B-1 C C C C C C C  
76B-1 C C C C C C C C 
78B-1 C C C C C C C C 
84-1 C C C C C C C C 
89B-2 C C C C FC C C C 
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Modifier 67A-5 67B-4 69A-2 69A-4 70A-1 72-2 73A-5 75B-1 
93B-1 C C C C C C C C 
93B-3 C C C C C C C C 
94-1 C C C C C C C C 
96B-1 C C C C C C C C 
97-4 C C C C C C C C 
101B-2 C C C C C C C C 
117-2 C C C C C C C C 
118A-4 C C C C C C C C 
122A-3 C C C C C C C C 
126A-2(4) C C C C C C C C 
129A-3 C C C C C C C C 
138-1 C C C C C C C C 
138A-3 C C C C C C C C 
140A-4 C C C C C C C C 
143A-1 C C C C C C C C 
143A-3 C C C C C C C C 
159-1a C C C C C C C C 
173B-1 C C C C C C C C 
185B-3 C C C C C C C FC 
186B-1 C C C C C C C C 
190B-1 C C C C C C C C 
209B-2 C C C C C C C C 
211B-2 C C C C C C C C 
223B-8 C C C C C C C C 
 
 
Modifier 76B-1 78B-1 84-1 89B-2 93B-1 93B-3 94-1 96B-1 
2A-3  C C C FC C C C C 
5A-5 C C  C C C C C C 
11A-2 C C C  C C C C C 
18-2 C C C C  C C C C 
24A-1 C C C C C  C C C 
29A-3 C C C C C C  C C 
30A-1 C C C C C C C  C 
35A-7 C C C C C C C C  
36A-3 C C C C C C C C 
44B-6 C C C C C C C C 
45B-4 C C C C C C C C 
45B-5 C C C C C C C C 
51B-5 C C C C C C C C 
53A-4 C C C C C C C C 
63A-1 C C C C C C C C 
66A-1 C C C C C C C C 
67A-5 C C C C C C C C 
67B-4 C C C C C C C C 
69A-2 C C C C C C C C 
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Modifier 76B-1 78B-1 84-1 89B-2 93B-1 93B-3 94-1 96B-1 
69A-4 C C C C C C C C 
70A-1 C C C FC C C C C 
72-2 C C C C C C C C 
73A-5 C C C C C C C C 
75B-1 C C C C C C C C 
76B-1  C C C C C C C 
78B-1 C  C C C C C C 
84-1 C C  C C C C C 
89B-2 C C C  C C FC FC 
93B-1 C C C C  C C C 
93B-3 C C C C C  C C 
94-1 C C C FC C C  C 
96B-1 C C C FC C C C  
97-4 C C C FC C C C C 
101B-2 C C C C C C C C 
117-2 C C C C C C C C 
118A-4 C C C C C C C C 
122A-3 C C C C C C C C 
126A-2(4) C C C C C C C C 
129A-3 C C C C C C C C 
138-1 C C C C C C C C 
138A-3 C C C C C C C C 
140A-4 C C C C C C C C 
143A-1 C C C C C C C C 
143A-3 C C C C C C C C 
159-1a C C C C C C C C 
173B-1 C C C C C C C C 
185B-3 C C C C C C C C 
186B-1 C C C C C C C C 
190B-1 C C C C C C C C 
209B-2 C C C C C C FC C 
211B-2 C C C C C C C C 
223B-8 C C C FC C C C C 
 
 
Modifier 97-4 101B-2 117-2 118A-4 122A-3 
126A-
2(4) 129A-3 138-1 
2A-3  C C C C C C C C 
5A-5 C C  C C C C C C 
11A-2 C C C  C C C C C 
18-2 C C C C  C C C C 
24A-1 C C C C C  C C C 
29A-3 C C C C C C  C C 
30A-1 C C C C C C C  C 
35A-7 C C C C C FC C C  
36A-3 C C C C C C C C 
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Modifier 97-4 101B-2 117-2 118A-4 122A-3 
126A-
2(4) 129A-3 138-1 
44B-6 C C C C C C C C 
45B-4 C C C C C C C C 
45B-5 C C C C C C C C 
51B-5 C C C C C C C C 
53A-4 C C C C C C C C 
63A-1 C C C C C C C C 
66A-1 C C C C C C C C 
67A-5 C C C C C C C C 
67B-4 C C C C C C C C 
69A-2 C C C C C C C C 
69A-4 C C C C C C C C 
70A-1 C C C C C C C C 
72-2 C C C C C C C C 
73A-5 C C C C C C C C 
75B-1 C C C C C C C C 
76B-1 C C C C C C C C 
78B-1 C C C C C C C C 
84-1 C C C C C C C C 
89B-2 FC C C C C C C C 
93B-1 C C C C C C C C 
93B-3 C C C C C C C C 
94-1 C C C C C C C C 
96B-1 C C C C C C C C 
97-4  C C C C C FC C 
101B-2 C  C C C C C C 
117-2 C C  C C C C C 
118A-4 C C C  C C C C 
122A-3 C C C C  C C C 
126A-2(4) C C C C C  C C 
129A-3 FC C C C C C  C 
138-1 C C C C C C C  
138A-3 C C C C C C C FC 
140A-4 C C C C C C C C 
143A-1 C C C C C C C C 
143A-3 FC C C C C C FC C 
159-1a C C C C C C C C 
173B-1 C C C C C C C C 
185B-3 C C C C C C C C 
186B-1 C C C C C C C C 
190B-1 C C C C C C C C 
209B-2 FC C C C C C FC C 
211B-2 C C C C C C C C 
223B-8 C C FC C C C C C 
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Modifier 138A-3 140A-4 143A-1 143A-3 159-1a 173B-1 185B-3 186B-1 
2A-3 C C C C C C C C 
5A-5 C C C C C C C C 
11A-2 C C C C C C C C 
18-2 C C C C C C C C 
24A-1 C C C C C C C C 
29A-3 C C C C C C C C 
30A-1 C C C C C C C C 
35A-7 C FC C C C C C C 
36A-3 C C C C C C C C 
44B-6 C C C C C C C C 
45B-4 C C C C C C C C 
45B-5 C C C C C C FC C 
51B-5 C C C C C C FC C 
53A-4 C C C C C C C C 
63A-1 C C C C C C C C 
66A-1 C C C C C C C C 
67A-5 C C C C C C C C 
67B-4 C C C C C C C C 
69A-2 C C C C C C C C 
69A-4 C C C C C C C C 
70A-1 C C C C C C C C 
72-2 C C C C C C C C 
73A-5 C C C C C C C C 
75B-1 C C C C C C FC C 
76B-1 C C C C C C C C 
78B-1 C C C C C C C C 
84-1 C C C C C C C C 
89B-2 C C C C C C C C 
93B-1 C C C C C C C C 
93B-3 C C C C C C C C 
94-1 C C C C C C C C 
96B-1 C C C C C C C C 
97-4 C C C FC C C C C 
101B-2 C C C C C C C C 
117-2 C C C C C C C C 
118A-4 C C C C C C C C 
122A-3 C C C C C C C C 
126A-2(4) C C C C C C C C 
129A-3 C C C FC C C C C 
138-1 FC C C C C C C C 
138A-3   C C C C C C C 
140A-4 C   C C C C C C 
143A-1 C C   C C C C C 
143A-3 C C C   C C C C 
159-1a C C C C   C C C 
173B-1 C C C C C   C C 
185B-3 C C C C C C   C 
 79 
Modifier 138A-3 140A-4 143A-1 143A-3 159-1a 173B-1 185B-3 186B-1 
186B-1 C C C C C C C   
190B-1 C FC C C C C C C 
209B-2 C C C FC C C C C 
211B-2 C C C C C C C C 
223B-8 C C C C C C C C 
 
 
Modifier 190B-1 209B-2 211B-2 223B-8 
2A-3 C C C C 
5A-5 C C C C 
11A-2 C C C C 
18-2 C C C C 
24A-1 C C C C 
29A-3 C C C C 
30A-1 C C C C 
35A-7 FC C C C 
36A-3 C C C C 
44B-6 C C C C 
45B-4 C C C C 
45B-5 C C C C 
51B-5 C C FC FC 
53A-4 C C C C 
63A-1 C C C C 
66A-1 C C C C 
67A-5 C C C C 
67B-4 C C C C 
69A-2 C C C C 
69A-4 C C C C 
70A-1 C C C C 
72-2 C C C C 
73A-5 C C C C 
75B-1 C C C C 
76B-1 C C C C 
78B-1 C C C C 
84-1 C C C C 
89B-2 C C C FC 
93B-1 C C C C 
93B-3 C C C C 
94-1 C FC C C 
96B-1 C C C C 
97-4 C FC C C 
101B-2 C C C C 
117-2 C C C FC 
118A-4 C C C C 
122A-3 C C C C 
126A-2(4) C C C C 
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Modifier 190B-1 209B-2 211B-2 223B-8 
129A-3 C FC C C 
138-1 C C C C 
138A-3 C C C C 
140A-4 FC C C C 
143A-1 C C C C 
143A-3 C FC C C 
159-1a C C C C 
173B-1 C C C C 
185B-3 C C C C 
186B-1 C C C C 
190B-1   C C C 
209B-2 C   C C 
211B-2 C C   C 
223B-8 C C C   
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Table 2-4.  Complementation groups as determined by inter se complementation 
testing 
Modifiers were placed into complementation groups based on their failure to complement 
each other (see Table 2-3).  A total of 43 complementation groups were identified 
through inter se complementation testing, including the Star complementation group (not 
shown).  
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 Table 2-4.  Complementation groups as determined by inter se complementation testing 
Group # Modifiers 
1 2A-3 89B-2           
2 5A-5             
3 11A-2             
4 18-2 72-2           
5 24A-1             
6 29A-3             
7 30A-1 45B-4           
8 35A-7 126A-2(4) 140A-4 190B-1       
9 36A-3             
10 44B-6 140A-4           
11 45B-5 75B-1 185B-3         
12 51B-5 75B-1 185B-3 211B-2 223B-8     
13 53A-4             
14 63A-1             
15 66A-1             
16 67A-5             
17 67B-4             
18 69A-2             
19 69A-4             
20 70A-1 89B-2           
21 73A-5             
22 76B-1             
23 78B-1             
24 84-1             
25 89B-2 2A-3 70A-1 94-1 96B-1 97-4 223B-8 
26 93B-1             
27 93B-3             
28 96B-1 89B-2           
29 97-4 89B-2 129A-3 143A-3 209B-2     
30 101B-2             
31 117-2 223B-8           
32 118A-4             
33 122A-3             
34 126A-2(4) 35A-7           
35 138-1 138A-3           
36 143A-1             
37 159-1a             
38 173B-1             
39 186B-1             
40 209B-2 94-1 97-4 129A-3 143A-3     
41 B51A-2             
42 B56A-1             
 
 
 83 
Table 2-5.  Complementation testing of EMS modifiers against the Bloomington 
Drosophila Stock Center Deficiency Kit for chromosome 2    
Thirteen EMS modifiers were chosen for low-resolution mapping through 
complementation testing against the Bloomington Drosophila Stock Center Deficiency 
Kit for chromosome 2.  Crosses were conducted in a single polarity for each modifier 
(i.e., Modifier A/CyO males crossed to Df B/Balancer virgins or Modifier A/CyO virgins 
crossed to Df B/Balancer males.) At least 50 progeny were scored for each cross; 
homozygous viability >95% was considered reflective of complementation.  Testing 
results for ten modifiers, completed at Boston College, are shown in the table.  Data not 
shown includes testing of modifiers 44B-6, 56B-1, and 96B-1, conducted by Kris Klueg 
at Indiana University using an earlier version of the Bloomington Drosophila Stock 
Center Deficiency Kit; modifiers 36A-3 and 44B-6 were found to complement all 
Bloomington Drosophila Stock Center Deficiency Kit members, while mapping of 
modifier 96B-1 is described in detail in the text.  (C - complementation; FC - failure to 
complement)        
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Table 2-5.  Complementation testing of EMS modifiers against the Bloomington Stock 
Center Deficiency Kit for chromosome 2 
Deficiency Name Breakpoints 11A-2 29A-3 51B-5 53A-4 67B-4 
Df(2L)BSC4 21B7-C1;21C2-3 C C C C C 
Df(2L)BSC106 21B8;21C4 C C C C C 
Df(2L)BSC16 21C3-4;21C6-8 C C C C C 
Df(2L)ast2 21D1-2;22B2-3 C C C C C 
Df(2L)BSC37 22D2-3;22F1-2 C C C C C 
Df(2L)dpp[d14] 22E4-F2;22F3-23A1 C C C C C 
Df(2L)C144 22F3-4;23C3-5 C C C C C 
Df(2L)JS17 23C1-2;23E1-2 C C C C C 
Df(2L)BSC28 23C5-D1;23E2 C C C C C 
Df(2L)BSC31 23E5;23F4-5 C C C C C 
Df(2L)drm-P2 23F3-4;24A1-2 C C C C C 
Df(2L)ed1 24A2;24D2 C C C C C 
Df(2L)BSC109 25C4;25C8 C C C C FC 
Df(2L)Exel6011 25C8;25D5 C C C C C 
Df(2L)cl-h3 25D2-4;26B2-5 C C FC C C 
Df(2L)BSC5 26B1-2;26D1-2 C C C C C 
Df(2L)BSC6 26D3-E1;26F4-7 C C C C C 
Df(2L)BSC7 26D10-E1;27C1 C C C C C 
Df(2L)spd[j2] 27C1-2;28A C C C C C 
Df(2L)XE-3801 27E2;28D1 C C C C C 
Df(2L)BSC41 28A4-B1;28D3-9 C C C C C 
Df(2L)TE29Aa-11 28E4-7;29B2-C1 C C C C C 
Df(2L)BSC53 29A2-B1;29D2-E1 C FC C C C 
Df(2L)N22-14 29C1-2;30C8-8 FC C C C C 
Df(2L)BSC17 30C3-5;30F1 C C C C C 
Df(2L)BSC50 30F4-5;31B1-4 C C C C C 
Df(2L)BSC32 32A1-2;32C5-D1 C C C C C 
Df(2L)BSC36 32D1;32D4-E1 C C C C C 
Df(2L)FCK-20 32D1;32F1-3 C C C C C 
Df(2L)Prl 32F1-3;33F1-2 C C C C C 
Df(2L)BSC30 34A3;34B7-9 C C C C C 
Df(2L)b87e25 34B12-C1;35B10-C1 C C C C C 
Df(2L)TE35BC-24 35B4-6;35F1-7 C C C C C 
Df(2L)r10 35D1;36A6-7 C C C C C 
Df(2L)cact-255rv64 35F-36A;36D C C C C C 
Df(2L)TW137 36C2-4;37B9-C1 C C C C C 
Df(2L)Exel6049 40A5;40D3 C C C C C 
Df(2L)C' h35;h38L C C C C C 
In(2R)bw[VDe2L]Cy[R] h42-h43;42A-3 C C C C C 
Df(2R)M41A4 41A;41A C C C C C 
Df(2R)nap9 42A1-2;42E6-F1 C C C FC C 
Df(2R)ST1 42B3-5;43E15-18 C C C C C 
Df(2R)H3C1 43F;44D3-8 C C C C C 
Df(2R)H3E1 44D1-4;44F12 C C C C C 
Df(2R)Np5 44F10;45D9-E1 C C C C C 
Df(2R)w45-30n 45A6-7;45E2-3 C C C C C 
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Deficiency Name Breakpoints 11A-2 29A-3 51B-5 53A-4 67B-4 
Df(2R)BSC29 45D3-4;45F2-6 C C C C C 
Df(2R)B5 46A;46C C FC C C C 
Df(2R)X1 46C;47A1 C C C C C 
Df(2R)stan1 46D7-9;47F15-16 C C C C C 
Df(2R)en-A 47D3;48B2 C C C C C 
Df(2R)en30 48A3-4;48C6-8 C C C C C 
Df(2R)BSC39 48C5-D1;48D5-E1 C C C C C 
Df(2R)CB21 48E;49A C C C C C 
Df(2R)BSC40 48E1-2;48E2-10 C C C C C 
Df(2R)BSC3 48E12-F4;49A11-B6 C C C C C 
Df(2R)vg-C 49A4-13;49E7-F1 C C C C C 
Df(2R)CX1 49C1-4;50C23-D2 C C C C FC 
Df(2R)BSC18 50D1;50D2-7 C C C C C 
Df(2R)Exel7131 50D4;50E4 C C C C C 
Df(2R)BSC11 50E6-F1;51E2-4 C C C C C 
Df(2R)Jp1 51D3-8;52F5-9 C FC C C C 
Df(2R)Jp8 52F5-9;52F10-53A1 C C C C C 
Df(2R)BSC49 53D9-E1;54B5-10 C C C C C 
Df(2R)BSC44 54B1-2;54B7-10 C C C C C 
Df(2R)robl-c 54B17-C4;54C1-4 C C C C C 
Df(2R)BSC45 54C8-D1;54E2-7 C C C C C 
Df(2R)14H10Y-53 54D1-2;54E5-7 C C C C C 
Df(2R)14H10W-35 54E5-7;55B5-7 C C C C C 
Df(2R)PC4 55A;55F C C C C C 
Df(2R)P34 55E2-4;56C1-11 C C C C C 
Df(2R)BSC26 56C4;56D6-10 C C C C C 
Df(2R)BSC22 56D7-E3;56F9-12 C C C C C 
Df(2R)AA21 56F9-17;57D11-12 C C C C C 
Df(2R)Exel7162 56F11;56F16 C C C C C 
Df(2R)BSC19 56F12-14;57A4 C C C C C 
Df(2R)Egfr5 57D2-8;58D1 C C C C C 
Df(2R)59AD 59A1-3;59D1-4 C C C C C 
Df(2R)vir130 59B;59D8-E1 C C C C C 
Df(2R)Px2 60C5-6;60D9-10 C C C C C 
Df(2R)ED4071 60C8;60E7 C C C C C 
Df(2R)ES1 60E6-8;60F1-2 C C C C C 
Df(2R)Kr10 60F1;60F5 C C C C C 
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Deficiency Name Breakpoints 76B-1 97-4 137A-5 140A-4 159-1a 
Df(2L)BSC4 21B7-C1;21C2-3 C C C C C 
Df(2L)BSC106 21B8;21C4 C C C C C 
Df(2L)BSC16 21C3-4;21C6-8 C C C C C 
Df(2L)ast2 21D1-2;22B2-3 C C C C C 
Df(2L)BSC37 22D2-3;22F1-2 C C C C C 
Df(2L)dpp[d14] 22E4-F2;22F3-23A1 C C C C C 
Df(2L)C144 22F3-4;23C3-5 C C C C C 
Df(2L)JS17 23C1-2;23E1-2 C C C C C 
Df(2L)BSC28 23C5-D1;23E2 C C C C C 
Df(2L)BSC31 23E5;23F4-5 C C C C C 
Df(2L)drm-P2 23F3-4;24A1-2 C C C C C 
Df(2L)ed1 24A2;24D2 C C C C C 
Df(2L)BSC109 25C4;25C8 C C C C C 
Df(2L)Exel6011 25C8;25D5 C C C C C 
Df(2L)cl-h3 25D2-4;26B2-5 C C C C C 
Df(2L)BSC5 26B1-2;26D1-2 C C C C C 
Df(2L)BSC6 26D3-E1;26F4-7 C C C C C 
Df(2L)BSC7 26D10-E1;27C1 C C C C C 
Df(2L)spd[j2] 27C1-2;28A C C C C C 
Df(2L)XE-3801 27E2;28D1 C C C C C 
Df(2L)BSC41 28A4-B1;28D3-9 C C C C C 
Df(2L)TE29Aa-11 28E4-7;29B2-C1 C C C C C 
Df(2L)BSC53 29A2-B1;29D2-E1 C C C C C 
Df(2L)N22-14 29C1-2;30C8-8 C C C C C 
Df(2L)BSC17 30C3-5;30F1 C C C C C 
Df(2L)BSC50 30F4-5;31B1-4 C C C C C 
Df(2L)BSC32 32A1-2;32C5-D1 C C C C C 
Df(2L)BSC36 32D1;32D4-E1 C C C C C 
Df(2L)FCK-20 32D1;32F1-3 C C C C C 
Df(2L)Prl 32F1-3;33F1-2 C C C C C 
Df(2L)BSC30 34A3;34B7-9 C C C C C 
Df(2L)b87e25 34B12-C1;35B10-C1 C C C C C 
Df(2L)TE35BC-24 35B4-6;35F1-7 C C C C C 
Df(2L)r10 35D1;36A6-7 C C C C C 
Df(2L)cact-255rv64 35F-36A;36D C C C C C 
Df(2L)TW137 36C2-4;37B9-C1 C C C C C 
Df(2L)Exel6049 40A5;40D3 C C C C C 
Df(2L)C' h35;h38L C C C C C 
In(2R)bw[VDe2L]Cy[R] h42-h43;42A-3 C C C C C 
Df(2R)M41A4 41A;41A C C C C C 
Df(2R)nap9 42A1-2;42E6-F1 C C C C C 
Df(2R)ST1 42B3-5;43E15-18 C C C C C 
Df(2R)H3C1 43F;44D3-8 C C C C C 
Df(2R)H3E1 44D1-4;44F12 C C C C C 
Df(2R)Np5 44F10;45D9-E1 C C C C C 
Df(2R)w45-30n 45A6-7;45E2-3 C C C C C 
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Deficiency Name Breakpoints 76B-1 97-4 137A-5 140A-4 159-1a 
Df(2R)BSC29 45D3-4;45F2-6 C FC C C C 
Df(2R)B5 46A;46C C C C C C 
Df(2R)X1 46C;47A1 C C C C C 
Df(2R)stan1 46D7-9;47F15-16 C C C C C 
Df(2R)en-A 47D3;48B2 C C C C C 
Df(2R)en30 48A3-4;48C6-8 C C C C C 
Df(2R)BSC39 48C5-D1;48D5-E1 C C C C C 
Df(2R)CB21 48E;49A C C C C C 
Df(2R)BSC40 48E1-2;48E2-10 C C C C C 
Df(2R)BSC3 48E12-F4;49A11-B6 C C C C C 
Df(2R)vg-C 49A4-13;49E7-F1 C C C C C 
Df(2R)CX1 49C1-4;50C23-D2 C C C C C 
Df(2R)BSC18 50D1;50D2-7 C C C C C 
Df(2R)Exel7131 50D4;50E4 C C C C C 
Df(2R)BSC11 50E6-F1;51E2-4 C FC C C C 
Df(2R)Jp1 51D3-8;52F5-9 C C C C C 
Df(2R)Jp8 52F5-9;52F10-53A1 C C C C C 
Df(2R)BSC49 53D9-E1;54B5-10 C C C C C 
Df(2R)BSC44 54B1-2;54B7-10 C C C C C 
Df(2R)robl-c 54B17-C4;54C1-4 C C C C C 
Df(2R)BSC45 54C8-D1;54E2-7 C C C C FC 
Df(2R)14H10Y-53 54D1-2;54E5-7 C C C C FC 
Df(2R)14H10W-35 54E5-7;55B5-7 C C C C C 
Df(2R)PC4 55A;55F C C C C C 
Df(2R)P34 55E2-4;56C1-11 C C C C C 
Df(2R)BSC26 56C4;56D6-10 C C C C C 
Df(2R)BSC22 56D7-E3;56F9-12 C C C C C 
Df(2R)AA21 56F9-17;57D11-12 C C C C C 
Df(2R)Exel7162 56F11;56F16 C C C C FC 
Df(2R)BSC19 56F12-14;57A4 C C C C FC 
Df(2R)Egfr5 57D2-8;58D1 C C C C C 
Df(2R)59AD 59A1-3;59D1-4 C C C C C 
Df(2R)vir130 59B;59D8-E1 C C C C C 
Df(2R)Px2 60C5-6;60D9-10 C C C C C 
Df(2R)ED4071 60C8;60E7 C C C C C 
Df(2R)ES1 60E6-8;60F1-2 C C C C C 
Df(2R)Kr10 60F1;60F5 C C C C C 
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Table 2-6.  Annotation of EMS modifiers 11A-2, 96B-1, 97-4, and 159-1a  
Genes that lie in mapped regions for modifiers 11A-2, 96B-1, 97-4, and 159-1a (based on 
deficiency mapping; see Figures 2-5 through 2-8) are listed below.  Annotations for 
putative gene function, cytological location, and available lethal alleles were obtained 
from FlyBase Release FB2_2009.  Genes in shaded regions have been ruled out based 
lethal allele complementation of the specified modifier.  Genes in bold lettering indicate 
that a lethal mutation has been mapped to that locus.     
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Table 2-6.  Annotation of EMS modifiers 11A-2, 96B-1, 97-4, and 159-1a 
EMS Modifier 11A-2 
Mapped to region 2L: 29E4; 29F1 (8700124..8801960 = 101836 bp) 
Gene Cytoloc. Function Available lethal stocks 
Hnf4 29E4 Endoderm development None 
CG9314 29E4 Defense response; catalase domain None 
raw 29E4/E6 Malpighian tubule morphogenesis; others Many, including embryonic lethal allele raw1 
CG12438 29E6 Unknown None 
CG9463 29F1 Carbohydrate metabolism None 
CG9465 29F1 Carbohydrate metabolism None 
CG9466 29F1 Carbohydrate metabolism None 
CG9468 29F1 Carbohydrate metabolism None 
 
 
 
 
EMS Modifier 96B-1 
Mapped to region 2L: 37B1; 37B6  
Gene Cytoloc. Function Available stocks 
CG33120 37B1 Unknown None 
CG17321 37B1 Unknown None 
CG10602 37B1 Leukotriene biosynthesis Lethal insertion f04195 (also falls in mRpL13 region) 
mRpL13 37B1 Ribosome component Lethal insertion f04195 (also falls in CG10602) 
tailup 37B1 Transcriptional regulation Many, including embryonic lethal allele tailup1 
ssp3 37B5;B6 Mitotic spindle elongation Lethal insertion f04580 
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EMS Modifier 97-4 
  Mapped to region 2R: 45E2;45F1 (5440757..5482429 = 41672 bp) 
Gene Cytoloc. Function Available stocks 
mir-14 45F1 Apoptosis and lipid metabolism mir-14k10213: complete excision of mir-14 
Or45b 45F1 Odorant receptor None 
CG1809 45F1  Mesoderm development None 
NotI 45F1-F2 Negative regulator of transcription Lethal insertion SH1677 (also falls in CG1814)  
CG1814 45F4 Unknown Lethal insertion SH1677 (also falls in Not1) 
CG1868 45F4-F5 Unknown None 
Updo 45F5 Heme/porphyrin biosynthesis None 
CG12929 45F5 Unknown None 
RpL31 45F5 Ribosome component  Lethal transposon insertion SH0497 
CG12928 45F5 Unknown None 
CG1827 45F5 Asparaginase activity None 
Map60 45F5 Microtubule binding None 
CG34364 45F6 ATP synthase activity None 
CG30338 45F6 Unknown None 
CG1902 45F6 Unknown None 
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EMS Modifier 159-1a 
  Mapped to region 2R: 54D4 (1316980..13190914 = 21085 bp) and 56F12;56F16 (16161991..16201140 = 39149 bp) 
Gene Cytoloc. Function Available stocks 
eIF3-S8 54D4 Translation initiation Lethal transposon insertions (14F06) 
CG30108 54D4 Unknown None 
CG30109 54D4 Unknown None 
CG6459 54D4 Defense response to bacteria None 
Sema-1b 54D4/D5 Axon guidance; putative receptor activity None 
        
CG11788 56F10/F14 Unknown None 
CG9143 56F14/56F15 Nucleotide metabolism None 
CG9090 56F15/F16 Phosphate transporter activity None 
CG16868 56F16 Unknown None 
CG34199 56F16 Unknown None 
Cpr56F 56F16 Structural component of larval cuticle None 
CkIIbeta-2 56F16 Regulatory subunit of casein kinase II None 
CG11200 56F16 Carbonyl reductase activity Lethal transposon insertion d02302 
CG8920 56F16 Nucleic acid binding  None 
CG13868 56F16 Unknown None 
 
 
  
 
 
 
 
 
 
 
CHAPTER THREE 
IDENTIFICATION AND MOLECULAR CHARACTERIZATION OF THE 
NOTCH PATHWAY MODULATOR NOT1 
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I.  Introduction 
The gene Not1 was first annotated as CDC39, based on temperature-sensitive mutants 
identified in genetic studies of cell cycle control in yeast; it was originally thought to play 
a role in regulating G1 progression during the cell cycle (Reed, 1980).  Because cdc39 
mutant cells arrested at the same stage of mitosis at which yeast mating type factors arrest 
cells, it was theorized that CDC39 might also be involved in the yeast pheromone 
response pathway.  This proved to be true, as CDC39 was shown to negatively regulate 
the pheromone response pathway through genetic interactions with pathway components 
such as FUS1, GPA1 and the STE genes (Shuster, 1982; Jenness, 1987; Neiman, 1990; de 
Barros, 1990).    
 
Despite these early studies dissecting the role of CDC39 in yeast mating and cell cycle 
progression, it soon became clear that this gene played a much broader role through 
regulation of global gene expression.  A mutation in CDC39 was isolated in a genetic 
screen for mutations that increase transcription of the HIS3 gene; this mutant was found 
to preferentially increase transcription from the non-canonical, TATA-less Tc promoter 
of HIS3 (Collart and Struhl, 1993).  Because loss-of-function mutations in CDC39 caused 
an increase in transcription from the TATA-less Tc promoter, it was subsequently re-
named NOT1 (negative on TATA-less).   
 
This screen identified were three other complementation groups, named NOT2, NOT3, 
and NOT4, that also encoded functions that preferentially inhibited transcription from the 
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Tc promoter (Collart and Struhl, 1994).  These genes, in addition to NOT1, were grouped 
as part of a NOT functional ensemble for three reasons.  First, all were found to 
negatively regulate the transcription of the same genes, genes that have varied functional 
roles within the cell.  Transcription of HIS4 (histidine biosynthesis), STE4 (pheromone 
response), TBP (TFIID-mediated transcription), and BIK1 (nuclear fusion) were 
increased in not1, not2, not3, and not4 mutant strains.  Transcription of DED1 (RNA 
helicase), TFIIB members, and the small subunit of TFIIA were unaffected in these same 
not mutant strains.  Thus, these initial studies indicated all NOT genes were negative 
regulators of transcription and exerted their effects on the same genes.  Because the genes 
under NOT transcriptional regulation played a wide range of functional roles in the cell, 
this negative regulatory effect appeared to be global, and not confined to cell cycle or 
mating regulation.  In addition, because transcription of some genes was unaffected in 
NOT mutant backgrounds, it was unlikely that NOT members were part of the basic 
transcription machinery.  A second reason behind the grouping of the NOT genes within 
a single ensemble was that several significant genetic interactions between NOT genes 
were observed.  NOT3 was identified as a high-copy number suppressor of a specific not1 
allele, and NOT4 functioned as a high-copy number suppressor of not1 and not2 
mutations.  Finally, biochemical and two-hybrid studies revealed physical interactions 
between members of this ensemble.  Chromatographic fractionation led to co-elution of 
NOT1 and NOT2; and two-hybrid studies confirmed this interaction, while also revealing 
interactions between NOT1 and NOT4 and between NOT3 and NOT4, respectively.  
 
 95 
The hypothesis that a physical complex of NOT proteins functions as a global negative 
regulator of transcription was confirmed, and expanded, in later studies.  
Immunoprecipitation and mass spectrometry experiments revealed that the NOT proteins 
physically associate with another known transcriptional regulatory complex in yeast, the 
CCR4 complex (Liu et al., 1998).  The CCR4 complex was initially identified as a 
positive transcriptional regulator of the yeast alcohol dehydrogenase gene ADH2 (Denis, 
1984), and was subsequently found to play both positive and negative regulatory roles in 
gene expression (Denis and Malvar, 1990; McKenzie et al., 1993; Schilds, 1995, Liu et 
al., 1998).  A fifth NOT ensemble member, NOT5, was also discovered and found to 
exhibit the same negative transcriptional effects as other NOT ensemble members and to 
physically associate with the complex (Oberholzer and Collart, 1998).  The arrangement 
of CCR4 and NOT proteins within the complex was elucidated through an investigation 
of the effect of deletion constructs on complex member association (Bai et al., 1999; 
Maillet et al., 2000).  These studies indicated that CCR4-NOT is a 1.0 MDa complex 
composed of two physically separate subunits; the CCR4 complex member CAF1 
mediates binding of CCR4 to the N-terminal domain of NOT1; while NOT2, NOT4, and 
NOT5 associate with the C-terminal domain of NOT1.  The precise location of NOT3 
within the complex has not been determined.  Two additional proteins, CAF40 and 
CAF130, were also identified as members of the 1.0 MDa complex; CAF40 interacts 
with the N-terminal region of NOT1, away from CAF1-CCR4, while CAF130 exhibits 
interactions with both the N-and C-terminal regions of NOT1 in a NOT 2-5 independent 
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manner (Chen et al., 2001).  A hypothetical schematic of the nine-member CCR4-NOT 
complex is shown in Figure 3-1.   
 
Functional studies of individual components of the CCR4-NOT complex have identified 
three members that possess enzymatic activity and lend insight into the cellular functions 
of the CCR4-NOT complex.  Both the CCR4 and CAF1 proteins possess nuclease 
domains that mediate mRNA deadenylation activities (Tucker et al., 2001; Daugeron et 
al., 2001).  It has been shown that the CCR4-NOT complex physically interacts with a 
number of mRNA binding proteins such as Smaug (Semotok et al., 2005), PUF 
(Goldstrohm et al., 2006) and Bicaudal (Chicoine et al. 2007), that act as transcript-
specific recruiters of the complex to initiate mRNA deadenylation.  CCR4-NOT also 
associates with DHH1, an RNA helicase member of the decapping complex (Maillet et 
al.).  In addition, the deadenylation activities of CCR4-NOT have been implicated in the 
regulation of a growing number of mRNA transcripts in a diverse group of organisms.  
Some identified CCR4-NOT deadenylation targets include CRT1 (Woolestencroft et al., 
2006) and WHI5 (Manukyan et al., 2008) in yeast; hsp70 (Temme et. al, 2004), cyclin A 
(Morris et al., 2005) and nanos (Zaessinger et. al, 2006) in Drosophila; and p27Kip1 in 
humans (Morita et al., 2007).  
 
The complex member NOT4 has also been shown to possess enzymatic activity.  This 
protein includes a RING finger domain that functions as an E3 ubiquitin ligase 
(Hanzawa, 2001; Albert, 2002) that is dependent for activity on interactions with the E2 
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conjugating enzymes Ubc4/5 (Winkler et al, 2004; Mulder et al, 2007).  Currently, the 
only identified target of NOT4 ubiquitin ligase activity is the nascent associated-
polypeptide complex (NAC; Panasenko et al., 2006), a two member protein complex that 
associates with ribosomes and is thought to play a role in the initial folding of translated 
proteins. NOT4 was shown to be required for NAC ubiquitination in vivo, while deletion 
of NOT4 results in mis-localization to endosomal structures of one of the NAC subunits.  
Genetic studies have also shown that NOT4 is required for efficient tri-methylation of 
lysine 4 on histone H3 (H3K4), indicating that the CCR4-NOT complex regulates 
transcriptional activation through chromatin modification (Laribee et al., 2007; Mulder et 
al., 2007).  A role for NOT4 in regulation of the cellular stress response has also been 
identified (Mulder et al. 2007).  Thus, it is likely that there are other targets of NOT4 
ubiquitination not yet identified.   
 
In addition to its functional roles in regulating mRNA and protein stability through 
deadenylation and ubiquitin ligase enzymatic activities, the CCR4-NOT complex has 
been shown to genetically and physically interact with a wide range of cellular proteins. 
Many of these interactions underlie the role of the complex in transcriptional regulation.  
Notably, several CCR4-NOT complex interactions with members of the TFIID general 
transcription factor complex, required for recruitment of RNA polymerase II to promoters 
for transcription initiation (reviewed in Orphanides et al., 1996), have been identified.   
These include genetic and physical interactions with the TATA-box binding protein 
(TBP; Lee, 1998; Badarinarayana et al., 2000), TBP-associated factor 13 (TAF13; 
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Lemaire and Collart, 2000), and TBP-associated factor 1 (TAF1; Deluen et al., 2002). In 
all cases, CCR4-NOT interactions with TFIID complex members have a negative 
regulatory effect on gene transcription, presumably by blocking TFIID access to 
promoter regions such that RNA polymerase II cannot be recruited to initiate 
transcription.   
 
CCR4-NOT complex interactions have also been reported for the SAGA transcriptional 
complex, a transcriptional co-activation complex that regulates transcription for a subset 
of yeast genes, particularly those genes involved in the stress response (reviewed in 
Huisinga et al., 2004).  The SAGA complex mediates chromatin remodeling in support of 
transcription through its histone acetyltransferase subunit, GCN5, and is also involved in 
recruitment of TBP to promoters.  While SAGA and TFIID share some common 
components, most notably TBP, an early study demonstrated that the SAGA-specific 
component ADA2 physically interacts with NOT2 and loss of this interaction leads to 
increased transcription of a reporter gene (Benson et al., 1998).  Later studies confirmed 
genetic interactions between the CCR4-NOT and SAGA complexes and also 
demonstrated that the NOT proteins repress transcription from SAGA-responsive genes 
(Biswas et al. 2006, Cui et al. 2008).   
 
In addition to regulation of transcription through the general transcription complexes 
TFIID and SAGA, the CCR4-NOT complex has been shown to regulate transcription 
factors specifically involved in environmental stress response. CCR4-NOT regulates the 
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general stress response mediated by the yeast transcription factor MSN2, presumably by 
inhibiting activation of MSN2 by the GLC7/BUD14 phosphatase (Lenssen et al., 2002; 
Lenssen et al. 2005).  CCR4-NOT regulation of the yeast oxidative and osmotic stress 
response transcription factor SKN7 has also been demonstrated; increased transcription 
of the SKN7 target gene OCH1 is observed in not4 and not5 null mutants, while SKN7 
physically interacts with NOT5 (Lenssen et al., 2007).  These studies taken together 
imply that CCR4-NOT serves regulatory functions in both general and specific 
environmental stress responses. 
 
Given its core roles as a regulator of transcription and mRNA stability, it is not surprising 
that the CCR4-NOT complex has been implicated in a wide range of cellular processes.  
In addition to the cellular stress response cited above, the CCR4-NOT complex has also 
been implicated as a regulator of embryonic development (Molin et al., 2005; Zaessinger 
et al. 2006), neuronal dendrite formation (Parrish et al., 2006), nuclear hormone receptor 
signaling (Prevot et al., 2001; Winkler et al., 2006; Garapaty et al, 2008), mitotic spindle 
positioning (DeBella et al., 2006), cell cycle progression (Ikematsu et al., 1999; Morel et 
al., 2003; Morita et al., 2007; Manukyan et al., 2008), oogenesis (Morris, et al. 2005, 
Chicoine et al. 2007), spermatogenesis (Berthet et al., 2004; Nakamura et al, 2004), and 
carbon metabolism (Mazzoni et al., 2005).  Considering that a recent microarray study of 
gene expression showed that deletions of CCR4-NOT complex members affected the 
expression of more than 85% of all yeast genes examined (Azzouz et al., 2009), we can 
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expect the known list of cellular processes that the this complex affects, either directly or 
indirectly, to expand. 
 
In the following sections, we report that the 97-4 complementation group, which is 
comprised of one group of modifiers of the GMR>DlWT phenotype, is made up of 
mutations that affect the Not1 gene of Drosophila melanogaster.  Genetic interaction 
studies with EMS-induced Not1 mutations reveal loss-of-function effects on Notch 
signaling.  Molecular studies on the effects of NOT1 knockdown confirm the inhibitory 
impact on Notch signaling of reduced NOT1 function in different developmental 
contexts.  NOT1 knockdown in the developing bristle SOP leads to neurogenic 
phenotypes consistent with reductions in Notch pathway function.  Similarly, NOT1 
knockdown within the developing wing margin results in wing notching and tissue loss in 
the adult flies, additional Notch loss-of-function phenotypes.  We have found that Not1 
RNAi-induced wing margin defects are correlated with disruption of expression of the 
Notch target genes cut and wingless.  We have shown that disruption of Notch target gene 
expression is correlated with loss of Delta expression caused by NOT1 knockdown.  Our 
studies provide evidence that the CCR4-NOT complex is a positive regulator of the 
Notch pathway that can mediate Notch signaling through control of Delta expression 
levels.  We propose that CCR4-NOT complex function is required for the maintenance of 
Notch signaling in multiple developmental contexts in which the Notch pathway 
functions.  
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II.  Results 
A.  The 97-4 complementation group represents the gene Not1 
1.   Single gene mapping of the modifier 97-4 
The potential molecular location of the 97-4 modifier gene was narrowed down to a 41.7 
kb region containing 15 genes, within the interval 45F1-45F6 on the Drosophila 
cytogenetic map using deficiency mapping (see Chapter 2).  In order to better define the 
gene affected by mutations in the 97-4 complementation group, deficiency generation and 
candidate gene mapping were undertaken simultaneously.  Two small deficiencies were 
generated using P-element-mediated excision (see Materials and Methods, Chapter 5; 
Parks et al., 2004).  Df(2R)d00208/f02183 removes part of brp gene and all of CG1888; 
Df(2R)d00208/f04141 removes the same part of the brp gene and CG1888, as well as all 
of mir-14, 0r45b, CG1809, Not1, and a small portion of CG1814 (Figure 3-2).  In crosses 
to members of the 97-4 complementation group, Df(2R)d00208/f02183 complemented all 
members of the group, while Df(2R)d00208/f04141 did not complement any of the 97-4 
complementation group members.  This reduced the potential location of the lethal 
mutation to five candidate genes:  mir-14, 0r45b, CG1809, Not1, and CG1814. 
 
Of the 15 candidate genes originally identified through deficiency mapping, only four 
were represented by lethal alleles that could be used for complementation testing against 
97-4 complementation group members:  mir-14 (mir-14k10213), Not1/CG1814 
[l(2)SH1677SH1677], and RpL31 [l(2)SH0497SH0497].  Only l(2)SH1677SH1677 (hereafter 
referred to as SH1677), a P element transposon insertion in a region of overlap between 
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genes Not1 and CG1814, failed to complement multiple members of the 97-4 
complementation group.  In fact, the SH1677 insertion does not complement modifiers 
97-4, 129A-3, or 143A-3, but does complement modifier 209B-2. 
 
The failure of both Df(2R)d00208/f04141 and transposon insertion SH1677 to 
complement 97-4 complementation group members provides strong evidence that the 
mutation of interest lies within either Not1 or CG1814.  To determine conclusively 
whether Not1 or CG1814 was the gene of interest, the phenotypic effects of RNAi-
induced knockdown (Fire et al., 1998) of each gene was assessed in the GMR>DlWT 
background.  The rationale behind this mapping approach was that, because modifiers in 
the 97-4 complementation group are most likely loss-of-function alleles, RNAi 
knockdown of the "97-4 gene" should approximate loss-of-function effects of the 
modifying mutations.  Therefore, RNAi-mediated reduction of expression of the gene in 
which the modifying mutations lie should produce phenotypes in the GMR>DlWT 
background similar to those associated with members of the 97-4 complementation group 
in that background. 
 
2.   Impacts of RNAi-induced knockdown of Not1 and CG1814 on the GMR>DlWT 
phenotype 
Four independent UAS-Not1 RNAi transgenic lines were obtained from the Vienna 
Drosophila RNAi Center (P{GD4070}v12571, P{GD4070}v13740, P{GD9640}41680, 
and P{GD9640}41681/TM3) and tested for phenotypic modification of the initial 
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GMR>DlWT screen entry point phenotype.  P{GD9640}41680 and 
P{GD9640}41681/TM3 are directed against exon 3 of Not1, whereas P{GD4070}v12571 
and P{GD4070}v13740 are directed against exon 9 of Not1 (Figure 3-3).  The results of 
these tests are presented in Figure 4.  P{GD4070}v12571, P{GD4070}v13740, and 
P{GD9640}41681 were all strong suppressors of the GMR>DlWT phenotype, while 
P{GD9640}41680 was a weak suppressor. 
 
In contrast, a transgenic RNAi line directed against exon 6 of CG1814 
(P{GD8619}v19096) produced no modification of the GMR>DlWT phenotype (Figure 3-
4).  These results suggest Not1 is the gene affected by mutations in the 97-4 
complementation group, because 97-4 complementation group members also suppress the 
GMR>DlWT phenotype, as shown in Figure 3-5.  Because the EMS mutagen is most 
likely to produce loss-of-function mutations (Sega, 1994) and because the EMS-induced 
97-4 complementation group members appear to suppress the GMR>DlWT phenotype, it 
would be expected that knockdown of the gene of interest would produce similar 
phenotypic suppression.  Not1 knockdown using dsRNA directed against two different 
Not1 exons does suppress the GMR>DlWT phenotype, while knockdown of CG1814 
produces no phenotype modification.  These findings strongly imply that the modifying 
mutations in the 97-4 complementation group lie within Not1. 
 
3.  Meiotic mapping of the 97-4 modifying mutation   
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To ascertain whether mutations that induce the phenotypic effects associated with 97-4 
complementation group members map to the predicted location of the Not1 gene, 
conventional meiotic mapping of the 97-4 modifying mutation was undertaken.  As Not1 
lies in the cytogenetic region 45F1-F4, two genetic markers that flank this region, 
cinnabar (cn; 43E16) and curved (c; 52D3-7) were used to determine whether the 97-4 
mutation lies within this region.  A stock containing cn and c markers alone was 
generated and crossed to the 97-4 mutation-bearing chromosome to create recombinant 
chromosomes.  Thirty recombinants from each recombinant class (cn +; + c), as well as 
both non-recombinant classes (cn c; + +) were tested for their ability to modify the 
Dl14/+ wing vein phenotype.  The results are summarized in Figure 3-6.  The results 
indicate that 97-4-mediated modification of Dl14/+ maps to the right of cn, between cn 
and c.  As a rough estimate from the cytogenetic and recombination maps (FlyBase, 
Release FB2009_02), Not1 should lie to the left of engrailed (en; 62 on recombination 
map) at around 60 on the recombination map, only about 3 map units away from cn (57 
on recombination map). This estimate places Not1 at a significantly further distance of 
about 15.5 map units away from c (75.5 on recombination map).  These meiotic mapping 
results are consistent with the results expected for a modifying mutation located on the 
physical map near Not1:  a low frequency of recombination with cn, and a high frequency 
of recombination with c.  These results further support the mapping of the 97-4 
complementation group to Not1, as the Dl14/+ modifying genotype also maps to this 
region. 
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In conclusion, our mapping studies provide strong support for the inference that the 97-4 
complementation group maps to the Not1 locus.  Deficiencies that remove the Not1 gene 
fail to complement 97-4 complementation group members.  A lethal transposon insertion 
in a region of overlap between Not1 and CG1814 also fails to complement most 97-4 
complementation group members.  Multiple UAS-Not1 RNAi transgenic lines are 
suppressors of the GMR>DlWT eye phenotype, with effects similar to those observed for 
members of the 97-4 complementation group.  In contrast, CG1814 RNAi knockdown 
does not modify the GMR>DlWT phenotype.  Finally, meiotic mapping places the 97-4 
mutation in the cytogenetic vicinity of Not1.  Taken as a whole, these results strongly 
support that the conclusion that the 97-4 complementation group is the Not1 gene.  Given 
this result, we sought to further characterize Not1 impacts and function in Notch 
signaling. 
 
4.  NOT1 is a component of a large nine-member transcriptional complex       
As outlined in detail in the chapter introduction, NOT1 is a component of the nine-
member CCR4-NOT complex, which has been shown to regulate global gene expression 
through its functional roles in mRNA deadenylation and transcription initiation (Collart, 
2003).  NOT1, with a molecular weight of 281.1 kDa in Drosophila, is the largest 
member of the complex.  It possesses no known enzymatic activity and is mainly thought 
to function as a scaffold for the entire complex (Collart, 2003).  This view of NOT1 as a 
scaffold is supported by studies that have shown that most complex members make direct 
physical contact with NOT1, and NOT1 is the only complex member that is essential for 
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yeast viability, even though it appears to lack known functional domains (Bai et al., 1999; 
Maillet et al., 2000; Chen et al., 2001).  A pictorial representation of the CCR4-NOT 
complex is shown in Figure 3-1. 
 
5.  The NOT1 protein is highly conserved across species 
A BLAST (Altschul et al., 1990; http://blast.ncbi.nlm.nih.gov/) homology search was 
conducted using the Drosophila melanogaster NOT1 protein sequence (FlyBase, Release 
FB2009_02), as well as the NOT domain, a 382 amino acid conserved region at the C-
terminal end of the protein [Figure 3-7, NCBI Conserved Domains Database, 
www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml] that encompasses an essential portion of 
NOT1 identified in yeast (Maillet et al., 2000).  The top hit from each major organism 
was then selected and pair-wise alignments with each hit and NOT1 were run using the 
alignment program ClustalW (Higgins et al., 1994; http://ebi.ac.uk/Tools/clustalw/).  A 
set of E value scores and identity and similarity scores for these alignments is presented 
in Table 3-1.  The NOT1 amino acid sequence is highly conserved among metazoa 
(Figure 3-7).  Most organisms listed show greater than 44% identity and 60% similarity 
across the entire protein.  Homology is greater when only the NOT domain is considered, 
with identity and similarity exceeding 72% and 85%, respectively, for most organisms.  
NOT1 homology remains significant even in comparisons across different kingdoms.  
The NOT1 homologs from Saccharomyces cerevisiae and Arabadopsis thaliana, 
members of the fungal and plant kingdoms, respectively, are more than 52% similar to 
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the Drosophila sequence.  A complete sequence alignment between yeast, worm, fly, 
mouse, and human NOT1 homologs is shown in Figure 3-7. 
 
The high degree of homology that exists across organisms is not surprising given the 
significant role the CCR4-NOT complex plays in regulation of global gene expression.  
The CCR4-NOT complex includes the major mRNA deadenylase in yeast (Tucker et al., 
2001) and functions in a similar manner in other organisms.  The complex also appears to 
be a direct regulator of the basal transcription machinery, mainly through its inhibition of 
TFIID (Badarinarayana et al., 2000).  Microarray experiments have revealed that CCR4-
NOT impacts the expression of a large number of functional gene classes, including those 
involved in critical cellular functions such as the stress response and DNA damage 
response (Cui et al., 2008).  Given the central role of this complex in regulating core 
cellular processes, a high degree of sequence conservation in its components would be 
expected. 
 
B.  The Not1 EMS mutations behave as Notch loss-of-function mutations 
1.   Not1 EMS  mutations lead to embryonic/L1 larval lethality 
To determine stage of lethality for each of the Not1 EMS mutations, stocks balanced over 
a GFP-expressing balancer were generated (see Materials and Methods, Chapter 5).   
Lethal stage was then determined by tracking embryo development of non-GFP 
expressing embryos, which are homozygous for the Not1 mutation.  Testing was done 
both through targeted selection of homozygous embryos, as well as blind selection of at 
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least 1000 embryos.  For targeted selection, at least 200 non-GFP expressing embryos 
were selected for each Not1 EMS mutation, as well as for the lethal SH1677 transposon 
insertion.  Because there was significant variation in GFP expression levels in embryos, 
usually dependent on embryonic developmental stage, GFP-expressing embryos were 
often erroneously collected.  Thus, a blind selection of 1000 embryos, without regard to 
GFP expression, was also undertaken for each Not1 EMS mutation and SH1677.  The two 
data sets were used together to estimate lethal stage.   The results of lethality testing are 
summarized in Table 3-2. 
 
The calculated hatch rates for targeted GFP selection testing are relatively consistent 
(Table 3-2), ranging from a low of 46.3% for SH1677 to a high of 68% for 209B-2.  
Although these hatch rates are inflated due to the inadvertent collection of some GFP-
expressing embryos, we can conclude that a significant percentage of Not1 homozygous 
mutant embryos reach the first larval instar (L1) stage of development.  The hatch rates 
calculated from blind selection testing are much more variable, ranging from a low of 
21.6% for 97-4 and a high of 61.6% for 129A-3.  Nonetheless, these hatch rates are still 
significant and variability likely arises simply from statistical deviations resulting from 
blind collection.  In all cases, for both blind and GFP selection methods, significant 
numbers of non-GFP expressing L1 larvae were observed; no non-GFP larvae were 
detected beyond this stage of development.  Considering the two data sets together, we 
estimate that roughly 40% of Not1 homozygous mutant embryos reach the L1 larval stage 
of development.  Thus, homozygosity for Not1 loss-of-function mutations appears to 
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result in partial embryonic lethality, and yields complete lethality by the end of the L1 
larval stage. 
  
2.   Not1 RNAi expression does not produce an embryonic neurogenic phenotype 
It has been well-documented that Notch pathway activity is critical to nervous system 
development.  Most of the core pathway members were originally characterized as 
"neurogenic" genes because loss-of-function mutations in any of these genes resulted in 
embryonic lethality and a disorganized central nervous system phenotype (Knust and 
Campos-Ortega, 1989).  This phenotype is the result of a failure of Notch-mediated 
lateral inhibition in the developing embryo that results in net overspecification of the 
neuronal cell type.  Thus, mutations that negatively affect Notch signaling often produce 
an embryonic neurogenic phenotype when homozygous, manifested in a substantial 
increase in the number of embyronic neurons and substantial disorganization of the 
central and peripheral nervous systems. 
 
Because reduction of NOT1 expression mimics Notch loss-of-function mutations in the 
GMR>DlWT genetic background, we investigated the effect of Not1 RNAi knockdown 
on the embryonic development of the nervous system.  UAS-Not1 RNAi transgenic line 
P{GD4070}v12571 was expressed in the developing embryo under control of the 
Actin5C-Gal4 driver (BDSC), which drives expression ubiquitously in all tissues.  
Embryo collections were staged such that all embryos were at least 18 hours old, well 
past the completion of nervous system specification events.  Embryos were stained with 
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the neuronal antibody 22C10 [(Developmental Studies Hybridoma Bank (DSHB)] 
Knockdown of NOT1 expression in the developing embryo did not produce any 
discernible neuronal phenotype; all embryos exhibited an organized central nervous 
system that matched that seen in wild type embryos based on 22C10 staining (data not 
shown).   
 
Therefore, it appears that reduction of NOT1 expression in the developing embryo does 
not produce a neurogenic phenotype, in contrast to what is often seen with other Notch 
pathway loss-of-function mutations.  This result is not surprising, given that roughly 40% 
of Not1 EMS homozygous mutant embryos survived past the embryonic stage of 
development.  Because basic nervous system development occurs relatively early during 
embryonic development (within 10-15 hours after egg laying at 25° C), we would expect 
a severe disruption in this process due to mutation to prohibit developmental progression 
to the larval stages and result in embryonic lethality.  This is not the case with our Not1 
EMS mutants.  It may be that our Not1 loss-of-function mutants do not produce Notch 
loss-of-function embryonic phenotypes because maternal loading of Not1 mRNA yields 
sufficient stored maternal mRNA to support development until the early larval stages, 
when Not1 zygotic gene expression is required.  There is some ancillary support for this 
possibility, as a recent study has shown that the germ plasm of Drosophila embryos is 
enriched for maternal mRNAs of at least two members of the CCR4-NOT complex 
(Yatsu et al., 2008).  Another possibility is that Not1 is not a core component of the 
Notch pathway, and only affects Notch signaling in very specific developmental contexts. 
 111 
 
3.   Not1 EMS mutations enhance vein thickening in Dl14/+ background 
The Not1 mutations we isolated were tested for modification of the phenotype resulting 
from the sensitized Notch pathway background Dl14/+, which includes a loss of function 
Dl mutation that causes thickening of the L2 wing vein and ectopic vein formation at the 
L4/L5 crossvein in heterozygotes. Representative adult female wings for each critical 
class sample are shown in Figure 3-8.  All Not1 modifying mutations strongly enhance 
this vein thickening phenotype.  In this background, all mutations induce severe 
thickening of the L2 and L5 wing veins; most mutations also produce mild thickening or 
delta formation along the distal portions of the L3 and L4 veins.  The Not1 transposon 
insertion SH1677 (Figure 3-8, Panel F) was also tested and did not show any 
modification of the Dl14/+ phenotype. 
 
The strong enhancement of the Dl14/+ wing phenotype by all Not1 EMS modifying 
mutations suggests that these mutations reduce Notch signaling activity, as they 
phenocopy Notch pathway loss-of-function mutations.  Notch pathway activity is 
required to produce a developmental boundary, defined by E(spl)-C expression in regions 
flanking the central provein, to restrict formation of vein tissue (de Celis et al., 1997).  
Erosion of this boundary due to disruption of Notch signaling activity leads to 
specification of increased numbers of vein cells and, ultimately, to expansion of the adult 
wing veins.  Thus, the Not1 EMS mutations modify wing vein phenotypes in a manner 
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consistent with loss-of-function mutations in a gene required for maintenance of Notch 
signaling activity along the central provein/lateral provein developmental boundary.   
 
The fact that SH1677 transposon insertion did not modify the Dl14/+ phenotype indicates 
that it affects Not1 function in a different manner than the Not1 EMS modifying 
mutations.  This is conceivable, given that the CCR4-NOT complex is composed of two 
discrete functional subcomplexes that are physically separated along the proposed NOT1 
scaffold.  The nonessential N-terminal portion of NOT1 serves as a scaffold for mRNA 
deadenylation activities mediated by CCR4 and CAF1, whereas the essential C-terminal 
region serves as a scaffold for direct transcriptional regulation via NOT2-5 (Bai et al., 
1999; Collart et al., 2003).  The SH1677 insertion is located in either a 5'-flanking region 
of the transcription unit (for the predicted Not1-RE protein; FlyBase, Release 
FB2009_02) or in the first intron of the transcription unit (for predicted Not1-RC and 
Not1-RD proteins; FlyBase, Release FB2009_02).  It is possible that SH1677 affects a 
different portion of the Not1 transcription unit, most likely transcriptional regulatory 
sequences, than the Not1 EMS mutations we have isolated, and therefore does not impact 
wing vein boundary formation.  An alternative character for the SH1677 mutation is 
further supported by an unusual result obtained in complementation testing with the 97-4 
complementation group:  SH1677 fails to complement modifiers 97-4, 129A-3, and 143A-
3, but does complement modifier 209B-2.  Again, this may be the result of differing 
nature and locations of the mutations within the Not1 gene, leading to differing effects on 
protein structure and gene expression. 
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4.   Not1 EMS mutations affect cone cell development in the GMR>DlWT background  
The Not1 EMS mutations were originally identified as top candidates from the screen due 
to their strong suppression of the GMR>DlWT phenotype (see Figure 3-5).  To further 
investigate this phenotype at the cellular level, cone cell development was examined for 
each modifying mutation.  We first conducted immunohistochemical stainings for cone 
cells in the developing Drosophila eye, as Notch signaling is required for induction of 
cone cell fate (Tsuda et al., 2002).  During normal development, each ommatidium within 
the ommatidial array possesses four cone cells; disruption of Notch signaling activity in 
the eye is often manifested in the specification of an aberrant number of cone cells.  To 
investigate this possibility, we crossed each Not1 EMS mutation, balanced over a GFP-
marked CyO balancer, to GMR>DlWT homozygotes.  Retinas were dissected from non-
GFP expressing pupae collected 24 hours after puparium formation (APF) and stained for 
the cone cell marker Cut (DSHB).  Representative cone cell stainings for each Not1 EMS 
modifying mutation are presented in Figure 3-9. 
 
Qualitative assessment of the results indicates that the Not1 EMS modifying mutations do 
suppress cone cell disorganization caused by Delta overexpression (Figure 3-9, Panel B).  
In comparison to the wild type control (Figure 3-9, Panel A), which exhibits an ordered 
array of four cone cells per ommatidium, the GMR>DlWT retina displays a severely 
disorganized ommatidial array containing large gaps among ommatidia and ommatidia 
with aberrant cone cell numbers.  In contrast, the presence Not1 EMS mutations in the 
GMR>DlWT background appears to reduce the degree of cone cell disorganization.  This 
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is most apparent with the 209B-2 modifier (Figure 3-9, Panel F), which was the strongest 
suppressor of the GMR>DlWT adult eye phenotype among the Not1 alleles isolated.  
Clearly, there are fewer and smaller gaps in the ommatidial array in comparison to the 
GMR>DlWT/+ retina, with much more regularity to overall organization.  In addition, the 
majority of ommatidia in GMR>DlWT/Not1 retinas possess the wild type number of four 
cone cells per ommatidium.  These results indicate that the Not1 EMS modifying 
mutations are affecting Notch signaling processes in the developing eye, and this 
enhancement of net Notch signaling contributes to their suppression of the GMR>DlWT 
phenotype. 
 
5.   Not1 EMS mutations exhibit loss-of-function effects in other Notch mutant 
backgrounds 
To further investigate Not1 genetic interactions with the Notch pathway, we tested Not1 
EMS mutations for enhancement or suppression of three additional Notch mutant 
genotypes:  DlBX44/+, dx152/Y, and 34B>DeltaΔICD/+.  DlBX44 was derived from an X-ray 
mutagenesis screen for Delta alleles and is amorphic (Shepard et al., 1989).   dx152 is a 
null allele of the Notch pathway modulator deltex, an E3 ubiquitin ligase that positively 
regulates Notch signaling (Fuwa et al., 2006; Takeyama et al., 2003).  Finally, as 
described in Chapter 2, 34B>DeltaΔICD is a transgenic genotype in which a dominant-
negative form of Delta is overexpressed in the wing blade.  All three mutant backgrounds 
exhibit wing vein thickening and ectopic vein formation, classic Notch loss-of-function 
phenotypes.  The four Not1 EMS mutations and SH1677 were introduced into these 
 115 
Notch loss-of-function genetic backgrounds and adult wings were examined for 
enhancement or suppression of wing vein thickening. 
 
Figure 3-10 depicts the modification effects caused by Not1 mutations in the DlBX44/+ 
genetic background.  As with Dl14/+, all of the Not1 EMS mutations strongly enhance 
vein thickening and ectopic vein formation, while SH1677 does not modify the 
phenotype.  In the case of the dx152/Y genetic background, both the Not1 EMS mutations 
and SH1677 moderately enhanced the vein thickening phenotype (Figure 3-11).  In 
addition, dx152/Y;143A-3/+, dx152/Y;209B-2/+, and dx152/Y;SH1677/+ flies all exhibited 
wing notching, another Notch loss-of-function phenotype.  Finally, Not1 mutation and 
SH1677 genetic interactions with the 34B>DeltaΔICD genetic background are shown in 
Figure 3-12.  The Not1 EMS mutations produce weak to mild expansion of the distal 
portion of most wing veins; enhancement may be weaker in this genetic background due 
to the fact that 34B>DeltaΔICD/+ already possess a strong vein thickening phenotype.  
SH1677 produced no modification of this phenotype.   
 
Despite some variation in the strength of modification, the common theme of the genetic 
interaction tests we have conducted in the wing is that the Not1 EMS modifying 
mutations we isolated enhance Notch loss-of-function phenotypes. These results provide 
support to our hypothesis that Not1 positively regulates Notch signaling activity. 
 
6.   Other NOT complex members show interactions with Not1 and the Notch pathway 
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Biochemical studies of NOT1 have shown that it is a member of a large nine-member 
molecular complex and may act as a scaffold for assembly of the other complex 
members.  The NOT1 protein itself has no known enzymatic or functional domains.  
Thus, it is conceivable that the Not1 EMS mutations we have isolated affect overall 
CCR4-NOT complex formation and the ability of complex members other than NOT1 to 
function.  The phenotypic effects caused by Not1 EMS mutations in Notch loss-of-
function genetic backgrounds may be due to an indirect effect on the function of another 
CCR4-NOT complex member. 
 
To investigate potential interactions of other CCR4-NOT complex members with the 
Notch pathway, we obtained available loss-of-function alleles for Drosophila homologs 
of CCR4-NOT complex members.  Table 3-3 lists the Drosophila homologs and 
available lethal stocks; lethal loss-of-function alleles were available for the CCR4-NOT 
complex members CAF1, NOT2, NOT3/5, and CCR4.     
 
The lethal stocks acquired were tested for phenotypic modification in both the 
GMR>DlWT and Dl14/+ genetic backgrounds; they were also tested for complementation 
with the Not1 EMS modifying mutations.  The results of this testing are summarized in 
Table 3-4.  Eye and wing phenotypes observed imply that Not3/5 exhibits the strongest 
interactions, as a mutation in this gene is a moderate suppressor of both the GMR>DlWT 
and Dl14/+ phenotypes.  A mutation in Not2 is a weak suppressor of the GMR>DlWT 
phenotype, while a mutation in Caf1 is a weak enhancer of the Dl14/+ phenotype.  
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Interestingly, the Not3/5 allele we acquired [P{SUPor-P}l(2)NC136KG10496] is an insertion 
in the 5' UTR of the Not3/5 gene [FlyBase Release FB2009_02] shows that this is an 
insertion in the 5' UTR, not in coding sequences], and it did not complement the 209B-2 
modifier mutation, suggesting that the 209B-2 mutation may affect a regulatory sequence 
in Not1 required in the same functional context as the regulatory sequence affected by the 
Not3/5 KG10496 mutation.  The two other CCR4-NOT complex lethal alleles tested, in 
the twin/Ccr4 gene (P{3'SUPor-P}twinKG00877 and P{wHy}twinDG24102), complemented 
the Not1 EMS modifying mutations. 
   
Modification of both the GMR>DlWT and Dl14/+ by P{SUPor-P}l(2)NC136KG10496 
(Table 3-4), as well as its failure to complement EMS modifier mutation 209B-2, provide 
further evidence of a specific genetic interaction between the CCR4-NOT complex and 
the Notch pathway.  Furthermore, the enhancement observed in the wing is similar to that 
seen with the Not1 EMS modifying mutations.  The Not3/5 lethal allele, CAF1 lethal 
allele, and the Not1 EMS modifying mutations enhanced the Dl14/+ phenotype (Table 3-
4), consistent with the hypothesis that these mutations reduce net Notch pathway 
function.  Thus, Not1 and Not3/5, and Pop2 (CAF1) appear to be positive regulators of 
Notch signaling in this context. 
 
It is known that NOT5 binds to the essential C-terminal portion of NOT1, and this region 
of the CCR4-NOT complex functions in transcriptional regulation.  As both Not1 and Not 
3/5 mutations produce similar wing phenotypes in Notch loss-of-function backgrounds, 
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one explanation of their phenotypic effects is that the ability of the C-terminal ensemble 
within the NOT complex to assemble is compromised, disrupting its ability to regulate 
transcription.  
  
7.   Reductions in NOT1 function produce Notch loss-of- function phenotypes  
The UAS-Not1 RNAi transgenic lines used to assign the 97-4 complementation group to 
the Not1 locus also proved useful in examining the effects of Not1 loss-of-function in 
various developmental contexts.  The UAS-Not1 RNAi stock P{GD4070}v12571, which 
was a strong suppressor of the GMR>DlWT phenotype, was tested for phenotypic effects 
in different Drosophila tissues using a broad selection of Gal4 drivers.  Crosses were 
conducted at both 18° C and 25° C, as lower temperatures sometimes enable otherwise 
embryonic- or larval-lethal Gal4-UAS progeny to survive to adulthood, allowing 
examination of adult phenotypes (Brand and Perrimon, 1993).  Unfortunately, this was 
not the case with the crosses that we conducted; crosses that were lethal at 25° C were 
also lethal at 18° C.  A description of each driver and results of crosses are shown in 
Table 3-5. 
 
Eleven of the seventeen driver crosses yielded lethality prior to adulthood in combination 
with P{GD4070}v12571.  One cross, to eyeless-Gal4, was almost completely lethal 
during the pupal stage of development and produced only one escaper with severely 
malformed eyes (Figure 3-13).  Only three drivers produced significant numbers of viable 
adults:  vestigial-Gal4 (vg-Gal4), C96-Gal4, and scabrous-Gal4 (sca-Gal4).  In all three 
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instances, crosses were conducted at least twice and over 100 critical class progeny were 
scored.  vg-Gal4;P{GD4070}v12571 progeny all display shriveled wings and, in severe 
cases, complete loss of wing structures (Figure 3-14).  C96-Gal4;P{GD4070}v12571 
progeny all exhibit moderate to severe wing notching and margin loss (Figure 3-15).  
Finally, all sca-Gal4;P{GD4070}v12571 progeny die shortly after eclosion and exhibit 
loss of notal macrochaetae (Figure 3-16). 
 
To confirm that the phenotypes seen above are truly the result of Not1 RNAi expression, 
and not a random aberration caused by chromosomal insertion of a particular RNAi 
transgene, the remaining UAS-Not1 RNAi stocks (P{GD4070}v13740, P{GD9640}41680, 
and P{GD9640}41681/TM3) were crossed to the C96-Gal4 and sca-Gal4 drivers.  Two 
independent crosses were conducted for each combination, and at least 50 critical class 
progeny from each cross were scored for phenotypic modification.  The 
P{GD4070}v13740 UAS-Not1 RNAi transgenic line produced phenotypes of similar 
penetrance and expressivity as those seen with P{GD4070}v12571; all critical class 
progeny from the C96-Gal4 crosses possessed moderate to severe wing margin notching 
and tissue loss (n=161), while all critical class progeny from the sca-Gal4 crosses were 
missing all dorsocentral and scutellar bristles (n=104).  The P{GD9640}41681/TM3 UAS-
Not1 RNAi  produced more moderate phenotypes, exhibiting weaker penetrance and 
expressivity than either P{GD4070}v12571 or P{GD4070}v13740.  No wing notching 
was observed in critical class progeny (n=106), but more than half exhibited wing margin 
bristle tufting or singing; notal bristle phenotypes were also variable, as critical class 
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progeny usually lacked some, but not all, of the dorsocentral or scutellar bristles.  The 
P{GD9640}41680 transgenic line clearly had the weakest impact on phenotypes, as it did 
not cause wing margin defects when driven with C96-Gal4 (n=241) and only has mild 
effects on bristle patterns, mainly infrequent duplications of single scutellar bristles, 
when driven by sca-Gal4 (n = 100).  In total, these results indicate that the margin and 
bristle loss phenotypes are due to general RNAi-mediated knockdown of NOT1 function 
and are not specific to the dsRNA-encoding transgene insertion in the P{GD4070}v12571 
stock, as other Not1 RNAi stocks exhibited similar phenotypes of varying severity.       
 
C.  Molecular analysis of NOT1 function 
As the roles of the Notch pathway in both wing margin and bristle development have 
been studied extensively (Irvine, 1999; Parks et al., 1997), these tissues constitute useful 
contexts in which to study the Notch pathway at the molecular level.  Disruption of the 
wing margin and loss and/or duplication of the external structures of bristle organs are 
classic Notch loss-of-function mutant phenotypes, and knockdown of NOT1 activity 
within the wing margin (using the C96-Gal4 driver) and within the bristle sense organ 
precursor (SOP; using the sca-Gal4 driver) phenocopies these traits.  Thus, the C96-
Gal4;UAS-Not1 RNAi wing and sca-GAL4;UAS-Not1 RNAi nota present apt contexts in 
which to study the molecular effects of NOT1 on Notch signaling.  
 
1.  The Notch pathway and wing margin formation 
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The adult Drosophila wing is a bilayered epithelial sheet defined by dorsal-ventral (DV), 
anterior-posterior (AP) and distal-proximal (DP) axes (Blair, 2007).  Major structures of 
the adult wing include five longitudinal veins (L1-L5), two short veins (L0 and L6), and 
three crossveins: the anterior crossvein (ACV), which travels from L3 to L4; the posterior 
crossvein (PCV), which travels from L4 to L5; and the humeral crossvein (HCV), which 
travels from the anterior portion of L1 to L0 (Blair, 2007).  Vein L1 forms a boundary 
around the complete adult wing and is commonly know as the wing margin.  The 
Drosophila wing, with the appropriate terminology for the major wing veins, is shown in 
Figure 3-17. 
 
One well-studied function of the Notch pathway during wing development is 
specification of the wing margin (Irvine, 1999).  Notch signaling promotes specification 
of the DV boundary of the wing during the second (L2) and third (L3) larval instar stages 
of development.  Bi-directional activation of the pathway by Delta from the ventral 
compartment of the wing disc and by Serrate from the dorsal compartment leads to up-
regulation within the DV boundary of target genes, such as cut and wingless, that are 
required for specification of margin cell identities.  Figure 3-18 depicts the Notch 
signaling circuitry during wing margin development.  As might be expected, disruption of 
Notch signaling at the DV boundary leads to wing margin defects; thus, a commonly 
observed Notch loss-of-function phenotype is “notching”, loss of wing margin tissue. 
 
2.   Expression of Not1 RNAi causes disruption of Cut expression within the wing margin 
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Overexpression of Not1 RNAi within the wing margin, using the wing margin driver 
C96-Gal4, produced severe notching and margin loss in adult wings (Figure 3-15). 
As cut is known to be directly up-regulated by the Notch signaling pathway within the 
wing margin and is required for margin formation (Micchelli et al., 1997), it is an obvious 
target for analysis of the molecular effects of NOT1 down-regulation. 
 
L3 larval wing discs of genotype C96-Gal4/+;P{GD4070}v12571/+ (C96>Not1 RNAi) 
were stained for Cut expression at the wing margin; all stainings were conducted in 
conjunction with parallel analysis of the +/P{GD4070}v12571 (+/Not1 RNAi) control 
genotype for comparison.  Representative results from this experiment are presented in 
Figure 3-19.  Knockdown of NOT1 expression within the wing margin resulted in clear 
disruption of Cut expression.  This disruption was most typically seen as one or more 
gaps within the domain of Cut expression along the margin.  Some variability in this 
phenotype was observed, with some discs exhibiting weaker disruption than others and a 
rare disc exhibiting no disruption.  Yet, this is not surprising, as the adult wing margin 
phenotype is variable as well; and the wing notching phenotype is typically weaker in 
males, with some male members of the critical class only exhibiting minor notching of 
the margin.  In addition, wandering L3 animals can vary significantly in developmental 
timing and random selection of dissected larvae may contribute to staining variability.  
Overall, multiple independent experiments suggest that Cut disruption is observed in 
greater than 90% of stained discs (n=52).  Furthermore, control discs always showed very 
strong Cut expression along the entire margin. 
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3.   Expression of Not1 RNAi causes disruption of Wingless expression within the wing 
margin 
The wingless gene is also a direct target of Notch within the developing wing margin; 
Notch activity is required for wingless expression at the wing disc DV boundary 
(Neumann and Cohen, 1996).  Thus, any disruption of Notch pathway activity within the 
margin would also be expected to result in disruption of Wingless expression.   
 
To investigate whether reduction of NOT1 function affects Wingless expression within 
the margin, L3 larval wing discs of genotype C96>Not1 RNAi were dissected and stained 
for Wingless; all stainings were conducted in conjunction with parallel analysis of the 
+/Not1 RNAi control genotype for comparison.  Representative results from this 
experiment are presented in Figure 3-20.  Knockdown of NOT1 expression within the 
wing margin resulted in significant disruption in the pattern of Wingless expression at the 
margin.  The phenotype was most typically observed as multiple gaps along the Wingless 
stripe at the DV boundary; this observed phenotype was consistent, with all discs from 
multiple experiments exhibiting significant disruption of Wingless expression along the 
margin (n=34). 
 
4.   Expression of Not1 RNAi leads to reduced Delta expression within the wing margin 
The disruption of Cut and Wingless expression within the wing margin caused by 
reduced NOT1 function raises the question of whether this is a caused by direct 
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transcriptional effects on cut and wingless, or an indirect effect on Notch signaling.  As 
cut and wingless are both targets of Notch signaling, the reduced expression in a Not1 
loss-of-function background may be the indirect result of an impairment of Notch 
signaling.  One potential target for Not1 effects on the Notch pathway is the ligand Delta.  
Notch signaling is initiated at the wing margin through up-regulation of Delta ligand in 
the ventral portion of the developing wing, leading to subsequent expression of Cut and 
Wingless at the DV boundary.  Therefore, disruption of Delta expression could reduce 
Notch pathway activation and reduce expression of Cut and Wingless within the margin. 
 
To determine whether Not1 RNAi down-regulation of Cut and Wingless expression at the 
DV boundary is correlated with an effect on Delta expression, the effect of NOT1 
knockdown on Delta expression within the wing margin was investigated.  L3 larval wing 
discs of genotype C96>Not1 RNAi were dissected and stained for Delta; all stainings 
were completed in parallel with a +/Not1 RNAi control for comparison.  Representative 
results from this experiment are presented in Figure 3-21.  Knockdown of NOT1 
expression within the wing margin resulted in significant disruption of Delta expression 
in this region.  Greater than 95% of all analyzed L3 wing discs (n=44) from multiple 
experiments showed a reduction of Delta expression at the wing margin; the severity of 
the phenotype varied from small gaps in Delta expression along the DV boundary to 
almost complete loss of expression across the entire margin.  Control discs repeatedly 
showed strong and consistent staining of Delta along the wing margin in L3 wing discs. 
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To assess the correlation between loss of Delta expression and disruption of Notch target 
expression, Cut and Delta double stainings in the Not1 RNAi background were 
conducted.  L3 larval wing discs of genotype C96>Not1 RNAi were dissected and stained 
for both Cut and Delta; all stainings were conducted in parallel with the +/Not1 RNAi 
control genotype for comparison.  Representative results from this experiment are shown 
in Figure 3-22.  As shown previously in single target stainings, Not1 RNAi disrupts 
expression of both Cut and Delta within the wing margin.  Importantly, gaps in Cut 
expression are congruent with reduction or loss of Delta expression within the same 
region.  Overall, there are two potential explanations for this result.  First, loss of Cut and 
Wingless could be the indirect result of Not1 RNAi negative regulatory action on Delta, 
rather than direct action of Not1 RNAi on cut itself.  Under this scenario, NOT1 
inhibition of Delta expression impedes the ligand’s ability to activate Notch signaling and 
target gene expression within the wing margin.  A second possibility is that Not1 
knockdown directly inhibits expression of Cut and Wingless, and loss of Delta expression 
is the indirect result of failure of feedback mechanisms that function to maintain Notch 
signaling activity in the developing wing margin.  Wingless is required for maintenance 
of Delta expression in regions flanking the margin through feedback induction (Micchelli 
et al., 1997).  Thus, Not1 RNAi-mediated reduction of Wingless expression could inhibit 
Delta expression in flanking regions through disruption of this feedback mechanism.  
Regardless of its specific mechanism of action, it is clear that Not1 is required for Delta 
expression in the developing wing margin. 
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5.  The Notch pathway and bristle formation 
The adult notum of Drosophila melanogaster is populated by sensory bristles that are 
delineated as either microchaetae or macrochaetae, based on bristle size (Hartenstein and 
Posakony, 1989).  Microchaetae are smaller, fine bristles that are present in larger, 
variable numbers (226/notum on average) and organized in anterior-posterior rows on the 
adult notum.  Macrochaetae number 26/notum and are much larger, coarse bristles that 
are present at precise locations on the notum.  A representative wild type adult notum is 
shown in Figure 3-23, along with the accepted terminology for the specified 
macrochaetae.   
 
All bristles are mechanosensory organs that consist of four cell types:  shaft, sheath, 
socket, and neuron.  Bristle formation begins during the late third instar larval stage with 
the specification of a single cell as the sensory organ precursor (SOP).  The SOP 
undergoes three subsequent divisions during the pupal stage to produce the four 
differentiated cell types of the bristle, as well as a glial cell that is not a component of the 
final bristle organ.  The Notch pathway plays a crucial role throughout this process, as its 
activity is required at each stage of bristle development (Gho et al., 1999)   
 
The initial specification of a single SOP within groups of cells called "proneural clusters" 
is achieved through a process called "lateral inhibition."  The presumptive SOP expresses 
the Notch ligand Delta, leading to Notch pathway activation in surrounding cells and 
subsequent up-regulation of Enhancer of split-Complex [E(spl)-C] genes.  The E(spl)-C 
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encodes proteins that antagonize functions of the bHLH proteins encoded by the 
proneural genes achaete and scute, which are required for SOP specification (Heitzler et 
al., 1996).  Thus, through activation of the Notch pathway in the surrounding cells, the 
SOP inhibits proneural gene function in these cells, leading these cells to adopt an 
epidermal cell fate.   
 
Similarly, during the two-cell stage of bristle development, expression of Delta in the 
pIIb precursor activates the Notch pathway in the neighboring pIIa precursor, preventing 
it from adopting the pIIb cell fate.  The pIIb precursor undergoes an intermediate cell 
division to produce the pIIIb precursor and a glial cell.  The pIIa and pIIIb precursors 
then each undergo a final round of mitosis, during which the Notch pathway is utilized 
once again to specify the final bristle cell fates.  Notch pathway activation in the socket 
cell prevents it from adopting the shaft cell fate, while Notch pathway activation in the 
sheath cell prevents it from adopting the neuronal cell fate.  An overview of bristle organ 
development, highlighting the roles of the Notch pathway, is presented in Figure 3-24.  
 
As previously discussed, overexpression of Not1 RNAi using the SOP driver sca-Gal4 
results in altered macrochaete development, including loss of macrochaete external 
structures, and patches of smooth epidermis on the Drosophila notum.  Bristle “loss” is a 
common Notch loss-of-function phenotype, resulting from a number of failures in bristle 
organ cell fate inhibition and the specification of supernumerary neuronal cells.  To 
determine whether the knockdown of NOT1 expression results in the specification of 
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supernumerary neurons, nota of genotype sca-Gal4/UAS-Not1 RNAi (sca>Not1 RNAi) 
were examined during development using cell-specific markers. 
 
6.  Expression of Not1 RNAi does not alter SOP specification during bristle development 
During the late L3 larval stage, the proneural gene achaete is expressed at its highest 
level within a proneural cluster in the presumptive SOP (Cubas et al., 1991).  An 
inhibitory Notch signal is sent from this SOP to surrounding cells within the cluster, 
resulting in repression of expression of achaete and other proneural genes.  Ultimately, 
through this process of lateral inhibition, achaete expression is restricted to the single 
SOP within the proneural cluster.  Loss of Notch signaling at this stage of bristle 
development would lead to failure of lateral inhibition and the specification of multiple 
SOPs; this would be manifested in an increase in the number of cells within the late-stage 
proneural cluster that exhibit achaete expression. 
 
To determine whether Not1 RNAi expression is impeding lateral inhibition and unitary 
SOP specification, L3 wing discs of genotype sca>Not1 RNAi were dissected and stained 
for Achaete.  Sets of +/Not1 RNAi control L3 wing discs were stained in parallel for 
comparison.  The results indicated that there was no significant difference in Achaete 
staining patterns between experimental and control samples (Figure 3-25).  This result 
was observed for all experimental discs tested (n=19) from multiple experiments.  This 
suggests that Not1 RNAi is not exerting its effects during this early stage of bristle 
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development, when lateral inhibition refines Achaete expression to a single cell within 
each macrochaete and microchaete proneural group. 
 
To confirm this result, the effect of Not1 RNAi expression on a second SOP marker, 
hindsight, was examined.  The hindsight (hnt) gene encodes a zinc finger transcription 
factor that is expressed after selection of the SOP through lateral inhibition (Koelzer and 
Klein, 2003).  Breakdowns in Notch pathway-mediated lateral inhibition would be 
expected to lead to increased expression of hnt in multiple cells within the proneural 
cluster.  To determine if this was the case, L3 wing discs of genotype sca>Not1 RNAi 
were dissected and stained for Hnt.  Sets of +/Not1 RNAi control L3 wing discs were 
stained in parallel for comparison.  The results showed that there were no significant 
differences in Hnt expression between experimental and control samples (Figure 3-26).  
This result was seen for all experimental discs tested (n=33) from multiple experiments.  
As observed for the Achaete expression experiment, this result suggests that Not1 RNAi 
is not exerting its effects on bristle development during initial SOP specification stage. 
 
7.  Expression of Not1 RNAi inhibits pIIa specification, leading to development of 
supernumerary neurons 
As Not1 RNAi expressed under sca-Gal4 control does not appear to be acting during the 
SOP specification stage of bristle development, later stages of bristle development were 
examined next.  As outlined previously in Figure 3-24, the bristle SOP divides to produce 
precursor cells pIIa and pIIb.  Notch pathway activity is required for inhibition of 
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adoption of the default pIIb cell fate.  The pIIb precursor undergoes an intermediate 
mitotic division to produce the pIIIb precursor and a glial cell.  Both pIIa and pIIIb 
precursors undergo a subsequent division to produce the bristle organ terminal cells.  The 
socket and shaft are descendants of the pIIa precursor, whereas the neuron and sheath are 
descendants of the pIIIb precursor.  The Notch pathway affects cell fate specification 
during precursor cell division, as well.  Notch signaling is required to inhibit the default 
shaft cell fate during pIIa division, while it is required to inhibit the default neuron cell 
fate during pIIIb division.   
 
Examining the terminal bristle cell fates in a Not1 RNAi background should elucidate the 
stage(s) of bristle development at which NOT1 is exerting its effects.  For example, if 
Not1 RNAi inhibits Notch signaling following SOP division, inhibition of the pIIb cell 
fate would fail, resulting in two pIIb precursors.  Subsequent divisions of the pIIb 
precursor and failure of Notch signaling could result in the following combinations of 
terminal bristle cell fates:  two sheaths and two neurons, one sheath and three neurons, or 
zero sheaths and four neurons.  The ultimate cell fate combination of the terminal bristle 
components would be dependent upon the extent to which later action of the Notch 
pathway subsequent to SOP specification is also inhibited by NOT1 knockdown.  A 
concept map of potential bristle organ cell fates resulting from Not1 RNAi disruption of 
Notch signaling inhibition of the pIIb cell fate is presented in Figure 3-27. 
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Similarly, if Not1 RNAi inhibited the Notch pathway not during SOP division but rather 
following the precursor cell division stages, a different combination of terminal cell fates 
would be expected.  Under this scenario, both pIIa and pIIb precursor cells would 
develop normally, but during their subsequent division Notch pathway inhibitory activity 
would be disrupted leading to the default cell fates of two shaft cells (from pIIa) and two 
neurons (from pIIIb) per bristle organ.   
 
To determine the effect of NOT1 knockdown on terminal bristle cell fates, nota of 
genotype sca>Not1 RNAi were stained 30 hours after puparium formation (APF) with the 
neuron-staining monoclonal antibody 22C10.  (Conveniently, antibody 22C10 also non-
specifically stains the growing bristle shaft during this late stage of development.)  Sets 
of +/Not1 RNAi 30 hour APF nota were stained in parallel for comparison.  Figure 3-28 
presents a side-by-side comparison of experimental and control nota; the boxed region 
encloses the presumptive scutellar region, where four clearly defined macrochaetae 
develop: the anterior and posterior scutellar bristles (left and right).  As can be seen, there 
are clear differences between the NOT1 knockdown sample and the control sample.  
First, there are no macrochaetae bristle shafts evident in the areas within the notum that 
are subject to NOT1 knockdown, whereas the presence of growing shafts is quite evident 
in the control sample.  This result is not surprising, given that nearly complete loss of 
macrochaete external structures is observed in the sca>Not1 RNAi adults.  Second, the 
NOT1 knockdown sample exhibits excess neuron formation in regions of presumptive 
macrochaetae.  This is most clearly seen in the boxed scutellar region, where control nota 
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have a single large neuron associated with each bristle shaft, while the same region in 
NOT1 knockdown nota exhibit multiple, smaller neurons.  Stainings from multiple 
sca>Not1 RNAi 30hr APF nota samples indicate that either two or four supernumary 
neurons are found at presumptive macrochaete bristle sites.  These results suggest that, in 
some instances, NOT1 knockdown is affecting Notch pathway inhibitory action 
following the SOP cell division stage.  This is because the four-neuron bristle organ can 
only arise from two pIIIb precursors, which develop when Notch inhibition of adoption 
of the pIIb cell fate has failed. 
 
To provide further support for these findings, the state of sheath cell specification in the 
Not1 RNAi background was also examined.  Sets of 30 hour APF nota of genotype 
sca>NOT1 RNAi were stained for Prospero, a homeodomain transcription factor 
expressed in the sheath cell of the pIIIb lineage (Reddy and Rodrigues, 1999).  Sets of 
+/Not1 RNAi nota were stained in parallel for comparison.  Figure 3-29 shows a side-by-
side comparison of experimental and control nota stained for Prospero.  The results 
indicate that aberrant sheath cell specification occurs in the Not1 RNA1 background.  As 
expected, the control notum shows only a single sheath cell within each macrochaete cell 
cluster.  In contrast, the notum subjected to NOT1 knockdown possesses a variable 
number of zero, one, or two sheath cells within each organ cell cluster.  This variation in 
sheath cell specification was observed in multiple sca>Not1 RNAi 30 hr APF samples 
stained for Prospero; in all cases, either zero, one or two sheath cells were observed in a 
single bristle organ. 
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The variation in sheath cell specification caused by NOT1 knockdown is consistent with 
the variation observed in neuronal specification in the same genetic background.  
Complete loss of Notch signaling inhibition at both the SOP division and precursor cell 
division stages would result in a final cell fate combination of four neurons and zero 
sheath cells.  Loss of inhibition only at the SOP division stage would produce two pIIb 
precursors, which could then follow their normal developmental lineage to produce two 
neurons and two sheath cells.  Finally, there is a possibility that only one of the two pIIIb 
precursors is directed into an aberrant lineage due to a reduction of Notch signaling; 
under this scenario, three neurons and a single sheath cell would be produced.  Overall, 
these results indicate that NOT1 knockdown can inhibit Notch signaling during either 
pIIa/pIIb or terminal cell fate specification stages; in some developing bristle organs, 
NOT1 appears to exhibit its effects at both stages of bristle development. 
 
8.   Overexpression of Delta or activated Notch fails to rescue the Not1 RNAi-induced 
phenotypes      
We have shown that knockdown of NOT1 expression produces Notch loss-of-function 
phenotypes in the developing wing and notum.  We have also provided evidence that 
Not1 RNAi disrupts Notch target gene expression and that this disruption may be the 
result of reduced Delta expression caused by loss of NOT1 function.  To elucidate the 
epistatic position of Not1 within the Notch pathway, we conducted rescue experiments 
with a selection of Notch pathway member responders.  We generated the following 
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double responder stocks:  UAS-Delta;UAS-Not1 RNAi, UAS-Serrate;UAS-Not1 RNAi; 
UAS-E(spl)m8;UAS-Not1 RNAi, and UAS-activated Notch;UAS-Not1 RNAi.  Each double 
responder stock was then crossed to both the C96-Gal4 and sca-Gal4 drivers; and critical 
class progeny were examined for wing and bristle phenotypes, respectively.  Rescue of 
the original C96-Gal4/+;UAS-Not1 RNAi/+ and sca-Gal4/UAS-Not1 RNAi phenotypes 
that are observed in the absence of Notch pathway responders would indicate that Not1 
acts upstream of the particular Notch pathway member tested.   
 
Curiously, none of the Notch pathway member responders tested rescued either the C96-
Gal4/+;UAS-Not1 RNAi/+ wing margin scalloping or the sca-Gal4/UAS-Not1 RNAi 
macrochaete loss phenotypes.  Analysis of over 100 critical class progeny collected from 
multiple crosses with each double responder genotype revealed no amelioration of the 
severity of either phenotype.  This result was particularly surprising when UAS-Delta was 
introduced into the C96-Gal4/+;UAS-Not1 RNAi/+ genetic background, as this 
background was previously shown to exhibit reduced Delta expression at the wing 
margin.  This would suggest that loss of Delta expression is not the cause of the observed 
wing margin defects, but is rather a byproduct of this developmental abnormality.  
 
Overall, these results can be explained in a number of ways.  The simplest explanation is 
that the functional impacts of Not1 RNAi-mediated reductions on NOT1 function cannot 
be compensated for by levels of expression mediated by the Notch pathway member 
responders we have employed; and therefore, phenotypic rescue is masked.  Another 
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possibility is that Not1 does not act directly on the Notch pathway, but rather acts 
indirectly through its impact on a secondary pathway that interacts with the Notch 
pathway.  This would not be surprising, given that Notch pathway cross-talk with other 
signaling pathways is a critical component of development in many different contexts 
(Hurlbut et al., 2007).  A final explanation would be that Not1 acts downstream of the 
activated Notch receptor, at the level of transcription initiation of target genes by the 
CSL-NotchICD-Mastermind complex.  Support for this hypothesis can be found in 
studies on CCR4-NOT complex function, as well as the mechanics of Notch target gene 
expression.  It is known that chromatin remodeling plays an important role in Notch 
target gene expression.  For example, Bre1, an E3 ubiquitin ligase that functions to 
induce transcription through its indirect role in methylation of lysine 4 on histone H3 
(H3K4), has been shown to be required for Notch target gene expression (Bray et al., 
2005).  In addition to histone methylation, histone acetylation has also been implicated in 
Notch target gene expression, as the histone acetyltransferase (HAT) GCN5 has been 
shown to interact physically with NotchICD, while HAT inhibitors reduce NotchICD-
mediated target gene expression in cell-based transcriptional reporter assays (Kurooka et 
al., 2000).  Interestingly, the CCR4-NOT complex has been shown to regulate histone 
H2B ubiquitination through recruitment of the Paf1 complex (Mulder et al. 2007).  Also, 
a number of studies revealing genetic interactions between the CCR4-NOT complex and 
GCN5 have been published (Benson et al., 1998; Biswas et al. 2006; Peng et al., 2008).  
Thus, the CCR4-NOT complex may be needed to alter the epigenetic state of developing 
cells, either through histone methylation or acetylation, in order to allow the NotchICD 
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and associated co-factors to access promoter regions to initiate transcription.  Under this 
scenario, overexpression of Notch pathway members would not rescue Not1 RNAi 
knockdown phenotypes, as the Not1 RNAi-induced chromatin state would not be 
amenable to NotchICD-dependent transcription initiation. 
 
III.  Discussion 
We have conducted a genetic screen for modifiers of a rough eye phenotype caused by 
Delta overexpression in the Drosophila eye, and have isolated four mutations that map to 
the Not1 locus.  Not1 is a component of the nine-member CCR4-NOT complex, a global 
regulator of transcription that is highly conserved among species.  We present evidence 
that Not1 is a positive regulator of Notch signaling activity and is required for proper 
development of the Drosophila wing blade and bristle organs.  We propose that the 
CCR4-NOT complex is required for Notch signal transmission in certain developmental 
contexts.     
 
A.  Not1 is a positive regulator of the Notch pathway 
Beginning with an EMS F1 modifier screen that utilized a sensitized genetic background 
created by Delta overexpression in the Drosophila eye, we have identified four new 
mutations that map to the Not1 locus.  These four Not1 alleles fail to complement a small 
deficiency that we have generated [Df(2R)d00208/f04141], which removes most of the 
Not1 coding region; thus, these are probably loss-of-function mutations.  Our Not1 EMS-
induced mutations were isolated as suppressors of the GMR>DlWT eye phenotype, 
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indicating that these loss-of-function mutations are altering effects on Notch signaling 
caused by overexpression of Delta ligand in some contexts.  The hypothesis that Not1 
mutations reduce net Notch signaling is supported by genetic interaction experiments 
focused on Drosophila wing vein development.  Notch signaling activity is required in 
the wing to establish developmental boundaries that define vein and intervein regions.  
Loss of Notch signaling during wing vein development results in an increase in vein cell 
number at the expense of intervein cell number.  When we introduced our Not1 mutations 
into the Notch loss-of-function genetic backgrounds sensitized by the presence of Dl14, 
DlBX44, or dx152 mutations, which yield vein thickening phenotypes, vein thickening was 
strongly enhanced.  Thus, Not1 loss-of-function mutations further exacerbate the 
impairment of Notch signaling, suggesting that Not1 is required to maintain Notch 
signaling integrity during wing vein development in wild type tissue.  These and most 
other genetic interaction studies we have conducted for each of our Not1 mutations 
support the hypothesis that the NOT1 protein exerts a positive regulatory effect on Notch 
signaling. 
 
Our hypothesis that Not1 is a positive regulator of Notch signaling is further supported by 
molecular studies we have conducted examining the effects of RNAi-mediated reduction 
of NOT1 expression levels in known Notch pathway developmental contexts.  One such 
context we investigated was the bristle organ, where Notch signaling activity is required 
during successive stages of development to ensure proper macrochaete cell type 
specification.  Knockdown of NOT1 in the developing notum using the SOP driver sca-
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Gal4 results in disruption of notal macrochaete development.  Similar phenotypes are 
seen in Notch pathway mutants and are typically the result of a failure of inhibitory 
Notch signaling during pIIa/pIIIb specification, leading to a classic neurogenic phenotype 
caused by default specification to the neuronal cell fate.  Immunohistochemical stainings 
of developing nota revealed that reduction of NOT1 expression levels did, in fact, lead to 
the specification of supernumerary neuronal cells.  Thus, NOT1 is required for proper 
cell fate specification during bristle organ development; loss of NOT1 leads to 
impairment of Notch signaling and neurogenic loss-of-function phenotypes. 
 
 
Loss of NOT1 expression produced a similar inhibitory effect on Notch signaling within 
the developing wing margin.  Knockdown of NOT1 in the developing wing using the 
wing margin driver C96-Gal4 results in aberrant margin development, manifested as 
severe wing scalloping and tissue loss in adult flies.  This phenotype mimics that 
commonly seen with Notch loss-of-function alleles, as activation of Notch signaling is 
required within the DV boundary to specify wing margin cell fate.  We investigated the 
molecular effects of Not1 RNAi expression on expression of Cut and Wingless, direct 
transcriptional targets of Notch activity within the margin.  In both cases, knockdown of 
NOT1 led to disruption of Cut and Wingless expression at the DV boundary.  To 
determine whether this NOT1 RNAi-mediated disruption could be the result of a 
reduction in Delta signal emission, we examined the impact of NOT1 knockdown on 
Delta, which emits a Notch-activating signal from the ventral portion of the developing 
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wing disc that upregulates Cut and Wingless expression within the margin boundary.  
NOT1 knockdown did, in fact, reduce Delta expression levels, and regions of reduced 
Delta expression corresponded with regions within which Cut expression is disrupted 
along the DV boundary.   While reduced Delta expression in regions surrounding the DV 
boundary could be due to direct action of Not1 RNAi on Delta gene expression, 
introduction of a UAS-Delta responder into C96>Not1 RNAi genetic background failed to 
rescue the wing scalloping phenotype.  This implies that Not1 RNAi may be exerting its 
effects directly on activation of Cut and Wingless expression, and that loss of Delta 
expression is an indirect effect that may result from disruption of Wingless-mediated 
feedback induction of Delta expression. 
 
Taken together, our studies provide strong support for a positive role for Not1 in Notch 
pathway regulation.  Loss of NOT1 activity consistently resulted in Notch loss-of-
function phenotypes in a variety of developmental contexts.  Furthermore, molecular 
studies have revealed that NOT1 is required for expression of Notch pathway target 
genes, while rescue experiments suggest that NOT1 exerts its effects directly on this 
Notch target gene expression. 
 
B.  Regulatory mechanisms by which CCR4-NOT may affect the Notch pathway 
While it is clear that Not1 is a positive regulator of the Notch pathway, an obvious 
question arises as to how this regulation is achieved.  In examining this question, it is 
important to note that NOT1 does not function alone, but rather is a component of the 
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large nine-member CCR4-NOT complex.  NOT1 itself possesses no known enzymatic 
activity and is thought to act as a scaffold for the components of the CCR4-NOT 
complex.  If NOT1 is simply a scaffold with no enzymatic activity, how does it exert 
such a strong and wide-ranging effect on the integrity of Notch signaling?  We think it 
most probable that mutations in Not1 disrupt the structural integrity of the CCR4-NOT 
complex as a whole, leading to breakdowns in overall complex function.  The CCR4-
NOT complex is known to have at least two core functional domains, physically 
separated along the presumptive NOT1 scaffold.  The CCR4 and CAF1 proteins, both of 
which are mRNA deadenylases that function to reduce stability of mRNA transcripts, 
bind to the N-terminal region of NOT1.  The remaining NOT proteins (NOT2-5) bind to 
the C-terminal region of NOT1.  The major identified function of the NOT domain and 
its associated proteins are as a negative regulators of transcription, which they achieve by 
physically interacting with the TFIID and SAGA transcriptional complexes and 
presumably impeding their access to promoter regions.  Among the NOT proteins, only 
the E3 ubiquitin ligase NOT4 has been shown to possess any enzymatic activity.  Little is 
known regarding NOT4 function and ubiquitination targets, although current evidence 
indicates a role for NOT4 in protein stability and chromatin modification (Panasenko et 
al., 2006; Mulder et al., 2007). 
   
Support for a role for the assembled CCR4-NOT complex in Notch pathway regulation, 
rather than for NOT1 by itself, is supported by two additional types of data.  First, we 
have found that a loss-of-function mutation in the Drosophila homolog of NOT3 and 
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NOT5, NOT3/5, also produced a Notch loss-of-function phenotype in the Dl14/+ genetic 
background, similar to those seen with our Not1 EMS mutations.  Second, a recent 
genetic screen for modifiers of a Drosophila rough eye phenotype caused by 
overexpression of Hairless, a negative regulator of the Notch pathway, identified a NOT2 
EP line as a weak enhancer (Muller et al., 2005).  Curiously, this would suggest that 
NOT2 is a negative regulator of the Notch pathway, contrary to our own conclusions 
regarding NOT1 and the CCR4-NOT complex, although an earlier study of Drosophila 
NOT2 indicated that it can have both positive and negative effects on gene expression 
(Frolov et al., 1998). Nonetheless, these findings do provide additional evidence 
supporting the hypothesis that CCR4-NOT is involved in regulation of Notch pathway 
signaling.  
 
While our results support a positive role for CCR4-NOT in Notch signaling regulation, 
the vast majority of prior studies of CCR4-NOT function over the past two decades have 
suggest negative regulatory functions for the complex (Collart et al., 2003).  As stated 
previously, the core functionalities associated with the CCR4-NOT complex are those of 
an mRNA deadenylase and an inhibitor of TFIID/SAGA-mediated transcription 
initiation.  A small number of previous genetic studies indicate that CCR4-NOT can 
function as a positive regulator of gene expression, as well.  In 2001, Denis and 
colleagues provided evidence that CCR4-NOT is involved in transcriptional elongation, 
as several genetic interactions were identified between CCR4-NOT and transcriptional 
elongation mutants (Denis et al., 2001).  More recently, CCR4-NOT has been implicated 
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in the induction of the ribonucleotide reductase (RNR) enzymatic complex as a cellular 
response to DNA damage; this study identified a requirement for NOT4 in recruiting 
transcription initiation factors to the RNR promoter (Mulder et al., 2005).  NOT4 itself 
has been shown to positively regulate histone methylation in support of gene expression 
(Laribee et al., 2007; Mulder et al., 2007).  Finally, the CCR4-NOT complex has been 
implicated in regulation of histone acetylation, implicating it in another epigenetic 
mechanism by which it may positively impact gene expression (Peng et al., 2008). 
 
We have provided evidence that the CCR4-NOT complex is required for Notch target 
gene expression in the developing wing margin, and this regulation is likely mediated 
through direct control of target gene expression, downstream of Notch signaling 
activation.  Given our current knowledge of CCR4-NOT functions, multiple hypotheses 
can be formulated for the mechanism by which the complex regulates Notch signaling 
activity.  It appears, at minimum, that the core NOT domain of the CCR4-NOT complex 
is involved in Notch pathway regulation, as multiple NOT domain-interacting members 
exhibited genetic interactions with the pathway.  Although unlikely, given the dearth of 
evidence in the literature for CCR4-NOT transcription induction and our finding that 
overexpression of Delta at the wing margin failed to rescue defects caused by NOT1 
knockdown, it is possible that the NOT domain is required for induction of Delta 
transcription.  It would be more likely that the NOT domain contributes indirectly to 
upregulation of Delta expression by inhibiting the transcription of a negative regulator of 
Delta.  This could be achieved either through direct transcriptional inhibition via the 
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NOT domain or de-stabilization of relevant mRNA transcripts through CCR4/CAF1 
deadenylation activity.  This scenario is particularly attractive, as the cross-talk between 
the Notch pathway and several other major signaling pathways during development has 
been well-documented (Doroquez and Rebay, 2006; Hurlbut et al., 2007).    
 
The CCR4-NOT complex could also regulate Delta protein trafficking or stability 
through the innate E3 ubiquitin ligase activity of NOT4.  Ubiquitination plays a critical 
role in Notch signaling.  The E3 ligases Neuralized and Mindbomb1 are important 
regulatory components of the pathway; these enzymes modulate Delta signaling activity 
by ubiquitinating Delta, inducing Delta endocytosis and subsequent proteolytic activation 
of the Notch receptor (Pavloupolos et al., 2001; Itoh et al., 2003).  Thus, it is theoretically 
possible that NOT4 could play a similar role in Delta ubiquitination and Notch signal 
activation.  
 
One final, intriguing possibility is that CCR4-NOT alters the epigenetic state of margin 
cells during wing development, through either histone methylation or acetylation, making 
cells genetically competent for Notch target gene expression.  Prior studies in yeast and 
flies suggest functional links among CCR4-NOT, the Notch pathway, and histone 
methylation.  Studies in yeast have identified a regulatory role for the CCR4-NOT 
complex in methylation of lysine 4 of histone H3 (H3K4), an important event in 
activation of gene expression (Laribee et al., 2007; Mulder et al., 2007).  CCR4-NOT 
regulation of H3K4 methylation appears to be mediated indirectly through control of 
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monoubiquitination of histone H2B by NOT4; NOT4 controls this event through 
recruitment of Paf1, a five-member complex associated with RNA polymerase II that is 
essential for ubiquitination of histone H2B (Mulder et al., 2007).  Separate studies in 
Drosophila have shown previously that methylation of H3K4 is important for Notch 
target gene transcription (Bray et al., 2005), while Paf1 complex member Rtf1 is required 
for normal levels of Notch signaling activity (Tenney et al., 2006).  In fact, it has been 
shown that Rft1 was required for proper wing margin development, as Rft1 knockdown 
produces strong enhancement of a wing margin nicking phenotype caused by a Notch 
hypormorphic genotype (Tenney et al., 2006).  Interestingly, this margin loss phenotype 
was similar to what we find to be caused by NOT1 knockdown within the wing margin.  
Such a hypothesis would posit that CCR4-NOT activity is required to modify chromatin 
in order to enable NotchICD-mediated transcription to occur.  Under this hypothesis, the 
wing margin defects caused by Not1 RNAi expression would be the result of direct 
transcriptional inhibition of Notch targets cut and wingless due to reduction of NOT1 
function.   Loss of Delta expression would be a secondary effect caused by loss of 
Wingless-dependent feedback induction of Delta expression in regions flanking the DV 
boundary (Micchelli et al., 1997).  Further study will be required to determine whether 
CCR4-NOT regulation of Notch signaling is mediated through control of Paf1 
recruitment, and histone ubiquitination and methylation.   
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Figure 3-1.  Schematic of the physical structure of the CCR4-NOT complex 
(adapted from Collart, 2003) 
The CCR4-NOT complex is composed of nine core members.  NOT1 is the largest 
member of the complex and serves as a molecular scaffold for the rest of the complex. 
CAF1 associates with NOT1 near its N-terminus and is essential for CCR4 association 
with the complex.  CAF1 and CCR4 both function as deadenylases and mediate the role 
of the complex in mRNA degradation.  The remaining NOT proteins (NOT2-5) associate 
with the C-terminal region of NOT1 and mediate the role of the complex in 
transcriptional regulation, mainly through inhibition of TFIID and SAGA complexes.  
NOT4, an E3 ubiquitin ligase, has also been shown to cause protein modification.  
CAF40 and CAF130 associate with the N-terminal region of NOT1 and currently have no 
known functions.  
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Figure 3-1.  Schematic of the physical structure of the CCR4-NOT complex (adapted 
from Collart, 2003) 
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Figure 3-2.  Fine mapping of EMS modifier 97-4 
Two deficiencies, Df(2R)d00208/f02183 and Df(2R)d00208/f04141, were generated via 
P-element-mediated excision (Parks et al., 2004) to aid in mapping of the 97-4 lethal 
mutation. Df(2R)d00208/f02183 removes part of the brp gene and all of CG1888; 
Df(2R)d00208/f04141 removes the same part of the brp gene and CG1888, as well as all 
of mir-14, 0r45b, CG1809, Not1, and a small portion of CG1814.  Df(2R)d00208/f02183 
complemented, while Df(2R)d00208/f04141 failed to complement, EMS modifier 97-4, 
reducing the mapped region of interest to mir-14, 0r45b, CG1809, Not1, and CG1814.  A 
lethal allele of mir-14 complemented 97-4, while a lethal transposon insertion in a region 
overlapping Not1 and CG1814 failed to complement 97-4.  Thus, the potential 97-4 lethal 
mutation lies in Not1 or CG1814. 
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Figure 3-2.  Fine mapping of EMS modifier 97-4 
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Figure 3-3.  The regions of the Not1 and CG1814 transcription units targeted by 
UAS-Not1 RNAi and UAS-CG1814 RNAi transgenic lines 
We obtained five different UAS-RNAi lines from the Vienna Drosophila RNAi Center 
(VDRC) to assist in mapping of the 97-4 complementation group mutations.  
P{GD9640}41680 (VDRC41680) and P{GD9640}41681/TM3 (VDRC41681) are directed 
against exon 3 of Not1, whereas P{GD4070}v12571 (VDRC12571) and 
P{GD4070}v13740 (VDRC13740) are directed against exon 9 of Not1.  
P{GD8619}v19096 (VDRC19096) is directed against exon 6 of CG1814. 
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Figure 3-3.  The regions of the Not1 and CG1814 transcription units targeted by UAS-
Not1 RNAi and UAS-CG1814 RNAi transgenic lines 
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Figure 3-4. Suppression of GMR>DlWT/+ phenotype by Not1 RNAi transgenic lines 
Brightfield images of representative adult female eyes are shown.  A) GMR>DlWT/+. B) 
VDRC12571/GMR>DlWT. C) VDRC13740/GMR>DlWT. D) VDRC41680/GMR>DlWT. 
E) VDRC41681/GMR>DlWT. F) VDRC19096/GMR>DlWT.  Not1 RNAi expression with 
transgenic lines VDRC12571, VDRC13740, and VDRC41680 (panels B, C, and D, 
respectively) produces strong suppression of the GMR>DlWT/+ flat, glassy eye 
phenotype (Panel A), manifested as a more rounded eye with increased definition of 
ommatidia.  Another Not1 RNAi line, VDRC41681 (panel E), exhibits weak suppression 
of this phenotype.  In contrast, a CG1814 RNAi transgenic line does not modify the 
GMR>DlWT/+ phenotype. 
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 Figure 3-4.  Suppression of GMR>DlWT/+ phenotype by Not1 RNAi transgenic lines 
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Figure 3-5. Suppression of GMR>DlWT/+ phenotype by Not1 EMS mutations 
Brightfield images of representative adult female eyes are shown.  A) GMR>DlWT/+.  B) 
97-4/GMR>DlWT. C) 129A-3/GMR>DlWT. D) 143A-3/GMR>DlWT.  E) 209B-
2/GMR>DlWT. F) SH1677/GMR>DlWT.  The Not1 EMS mutations 97-4, 129A-3, and 
209B-2 (panels B, C, and E, respectively) produce moderate to strong suppression of the 
GMR>DlWT flat, glassy eye phenotype (Panel A), manifested as a more rounded eye 
with increased definition of ommatidia.  The Not1 mutation 143A-3 (panel D) and the 
transposon insertion SH1677 (an insertion in a 5’ non-coding region of the Not1 gene) 
exhibit only weak suppression of this phenotype. 
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 Figure 3-5.  Suppression of GMR>DlWT/+ phenotype by Not1 EMS mutations 
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Figure 3-6.  Meiotic mapping reveals that the 97-4 modifying mutation lies near the 
Not1 locus 
A)  Recombination map of the Not1 region. Not1 is physically located on the cytogenetic 
map at 45F1-4, between cinnabar (cn) and engrailed (en) and to the left of curved (c).  B)  
For meiotic mapping, 97-4/cn c virgins were crossed to cn c males, and 30 males from 
each recombinant class were then crossed into the Dl14/+ background.  Each recombinant 
was then scored for modification of the Dl14/+ phenotype.  Few of the cn + recombinant 
class modified the Dl14/+, phenotype, indicating that the 97-4 modifying mutation lies 
near cn, close to the known physical location of Not1.  (ME – moderate enhancer; SE – 
strong enhancer) 
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Figure 3-6.  Meiotic mapping reveals that the 97-4 modifying mutation lies near the Not1 
locus 
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Figure 3-7.  NOT1 protein sequence alignment 
Protein sequences for NOT1 homologs in Saccharomyces cerevisiae (NCBI Accession 
ID NP_010017), Drosophila melanogaster (NCBI Accession ID NP_001097242), 
Caenorhabditis elegans (NCBI Accession ID NP_498516), Mus musculus (NCBI 
Accession ID XP_899766) and Homo sapiens (NCBI Accession ID NP_057368) were 
aligned using alignment program ClustalW (http://ebi.ac.uk/Tools/clustalw).  (Red 
lettering – completely conserved amino acid; blue lettering – highly conserved amino 
acid; green lettering – divergent amino acid; gray shading – region of high homology.)  
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Figure 3-7.  NOT1 protein sequence alignment 
 
    yeast     (1) -------------------------------------------------------------------------------- 
      fly     (1) MNVESQLKTPPTHIRNLVKHVNKRNFNESSEQINQFVKEHGLEADRSSLRHLFSVINFS-DLVPSVTVQLQAKLLGIQLE 
     worm     (1) ---MHSTSGLAPVFRVEENHMIRNRENLERPISKKGTITLLSKMPMGFVLNSCSCAYIDNLLAHSSIHRVKPHSFMIQRL 
    mouse     (1) -MNLDSLSLALSQISYLVDNLTKKNYRASQQEIQHIVNRHGPEADRHLLRCLFSHVDFSGDGKSSGKDFHQTQFLIQECA 
    human     (1) -MNLDSLSLALSQISYLVDNLTKKNYRASQQEIQHIVNRHGPEADRHLLRCLFSHVDFSGDGKSSGKDFHQTQFLIQECA 
 
    yeast     (1) -------MLSATYRDLNTASNLETS---------KE---KQAAQIVIAQISLLFTTLNNDNFESVEREIRHILDRSSVDI 
      fly    (80) RQLHSSSFVSNICYAFDQFFASNQKSLKPVAVADLVGQVARLTGINKVCECVFALALTHSSYTELKHSARNNLKGSLSEL 
     worm    (78) VVICGRSSPSLPNHAANIILSAFNFCQIEAPAKKFLEEDAALSLFHTILSYSTVTQINRSG---IEILGAQRLTSALCDL 
    mouse    (80) SLITKPNFISTLSYAIDNPLHYQKS---LKPAPHLFAQLSKVLKLSKVQEVIFGLALLNSSSPDLRGFAAQFIKQKLPDL 
    human    (80) LLITKPNFISTLSYAIDNPLHYQKS---LKPAPHLFAQLSKVLKLSKVQEVIFGLALLNSSSSDLRGFAAQFIKQKLPDL 
 
    yeast    (62) YIKVWERLLTLSSRDILQAGKFLLQENLLHRLLLEFAKDLP-------KK----STDLIELLKERTFNNQEFQKQTGITL 
      fly   (160) IDSYLGNKGTGPADSGLREISFDLLQYLLCCLSEY----V--QPQVEAQFLIKLREEFPRQAVPLVLAPFLYGSTTATIA 
     worm   (155) IYAYTKTMDDMVASKTLTHLCKKLAGLFDPLVVLP----FIS------KL--AKSRRLRHYLQPLFLGHCEYTSDTWGVS 
    mouse   (157) LRSYIDADVSGNQEGGFQDIAIEVLHLLLSHLLFGQKGAFGVGQEQIDAFLKTLRRDFPQERCPVVLAPLLYPEKRDILM 
    human   (157) LRSYIDADVSGNQEGGFQDIAIEVLHLLLSHLLFGQKGAFGVGQEQIDAFLKTLRRDFPQERCPVVLAPLLYPEKRDILM 
 
    yeast   (131) SLFIDLFDKSANKDIIESLDR-----------------------------------------------SSQINDFKTIKM 
      fly   (234) GAGASETDAEAEATTNSNSSSFEADALNEVGIEDIYDHLSEIIFTNQGKNNIMDTSWINLILEIGYEFTSSVEECKNHLC 
     worm   (223) PEGAEIYNQIARGNFTT------QT---------------------------LIEIVQTFLEKEVKEVIISSTTDPIKLV 
    mouse   (237) DRILPDSGGVAKTMMES--------------------------------------SLADFMQEVGYGFCASIEECRNIIM 
    human   (237) DRILPDSGGVAKTMMES--------------------------------------SLADFMQEVGYGFCASIEECRNIIV 
 
    yeast   (164) NHTNYLRNFFLQTTPETLESNLRDLLHSLEG------------------------------------------------- 
      fly   (314) SRERERAELQSKDVAKIVGLMCRRHSSLLDCNVNLPTPANFWPGQGQGGGSNSSGSSQTQITPQQQNPGSSNNNDGSDGN 
     worm   (270) QYLISCSNPDNTEIVQALAFLLYSNTKLLPAG--------------------------------------------SGG- 
    mouse   (279) QFG--VREVTAAQVARVLGMMARTHSGLTDG---IPLQSISAPGSG----------------------IWSDGKDKSEG- 
    human   (279) QFG--VREVTAAQVARVLGMMARTHSGLTDG---IPLQSISAPGSG----------------------IWSDGKDKSDG- 
 
    yeast   (195) --------------E--SLNDLLALLLSEILS-PGSQNLQNDPTRSWLTPPMVLDATNRGNVIARSISSLQAN------- 
      fly   (394) SSSDKKDKKETTEATQTWKPDVFVQALKEVVPQLNWKDVCMELDHPEFVLKDRIGLELLLTILRLATGSNIFPHPECIYR 
     worm   (305) ---------TIDMDVQAADTITTARLGDTKFTQPVKDALLDSGREALLRRMEIYGVSLLSSVENFVTELKQAPIQKKMVT 
    mouse   (331) ------------AQAHTWNVEVLIDVLKELNPSLNFKEVTYELDHPGFQIRDSKGLHNVVYGIQRGLGMEVFP-VDFIYR 
    human   (331) ------------AQAHTWNVEVLIDVLKELNPSLNFKEVTYELDHPGFQIRDSKGLHNVVYGIQRGLGMEVFP-VDLIYR 
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    yeast   (251) QIN-------WNRVFNLMSTKYFLSAPLMPTTASLSCLFAALHDGPVIDEFFSCDWKVIFKLDLAIQLHKWSVQNGCFDL 
      fly   (474) HWANTEGQLSLIATMLKNPDLFSFADFVFSQPALDVLKTAPDADNKEISSWKSLHLVEVLLSIADKGYYTQVHELFKFPA 
     worm   (376) NNSVANAILYMLQYNFDMSRDIENGRQDNSPFWGGSNFVIGITRFVEEQQAAVRDMEGFSDWYPDINWVEVIKEFDSEEF 
    mouse   (398) PWKHAEGQLSFIQHSLINPEVFCFADYPCHTVATDILKAPPEDDNREIATWKSLDLIESLLRLAEVGQYEQVKQLFSFPI 
    human   (398) PWKHAEGQLSFIQHSLINPEIFCFADYPCHTVATDILKAPPEDDNREIATWKSLDLIESLLRLAEVGQYEQVKQLFSFPI 
 
    yeast   (324) LNAEGTRKVSETIPNTKQSLLYLLSIASLNLELFLQREELSDGPMLAYFQECFFEDFNYAPEYLILALVKEMKRFVLLIE 
      fly   (554) QNCPDVLFLALLNTSPPMTPLRQDLFNQLIPTFLGNHPNSNVILASAWSSN--NFQLRSNIMNAMSEWYLRGNEFDQVKL 
     worm   (456) AICRQTIIMFADIFPIMFQPQNFPVSFFLTPWRYYDHQLRLFEFMIEYADTSLSKHMRQHVIYCLTSMHAADSSQLAKIL 
    mouse   (478) KHCPDMLVLALLQINTSWHTLRHELISTLMPIFLGNHPNSAIILHYAWHGQGQSPSIRQLIMHAMAEWYMRGEQYDQAKL 
    human   (478) KHCPDMLVLALLQINTSWHTLRHELISTLMPIFLGNHPNSAIILHYAWHGQGQSPSIRQLIMHAMAEWYMRGEQYDQAKL 
 
    yeast   (404) NRTVIDEILITLLIQVHNKSPSSFKDVISTITDDSKIVDAAKIIINSDDAPIANFLKSLLDTGRLDTVINKLPFNEAFKI 
      fly   (632) SRILDLAQDLKALSALLNARSFLFIIDLACLASRREYLKLEKWLTDKIREHGEPFMQAIIKVLHRRCPQVINAKVPEDQL 
     worm   (536) DVAHDIKPTGLSELLNQAPKHLAFMVDLACLASKRDYLNLEKWIEDKEKAHGEAMTVAVLQFIQKKYQHAQLVAAIAPKT 
    mouse   (558) SRILDVAQDLKALSMLLNGTPFAFVIDLAALASRREYLKLDKWLTDKIREHGEPFIQACMTFLKRRCPSILGGLAPEKDQ 
    human   (558) SRILDVAQDLKALSMLLNGTPFAFVIDLAALASRREYLKLDKWLTDKIREHGEPFIQACMTFLKRRCPSILGGLAPEKDQ 
 
    yeast   (484) LPCARQIGWEGFDTFLKTKVSPSNVDVVLESLEVQTKMTDTNTPFRSLKTFD--------LFAFHSLIEVLNKCPLDVLQ 
      fly   (712) PPKQAQLLPETVTTMINCLQTCINNCMQPEMVEVIMQMTANVAIMANKARAQ-----------QQQQPGLVPPPPPTILR 
     worm   (616) QATTPGAPSEPLQVLIPFVSKRARKPLRQQFPLVFQVMKENSGRSSSVSSGGHVQQSSGSQPQQQQFGGGSGLPPSGVVP 
    mouse   (638) P-KSAQLPAETLATMLACLQACAG-SVSQELSETILTMVANCSNVMNKARQPPPGVMPKGRPPSASSLDAISPVQIDPLA 
    human   (638) P-KSAQLPPETLATMLACLQACAG-SVSQELSETILTMVANCSNVMNKARQPPPGVMPKGRPPSASSLDAISPVQIDPLA 
 
    yeast   (556) LQRFESLEFSLLIAFPRLIN--------------FGFG----------------------------------HD------ 
      fly   (781) GHRGMDLPGGIVPPPPQQ---------PFSGNLNAQMFGPGMDPLTNMSNNLAGLNLSGPNGAFNFGNMLTSPSR----- 
     worm   (696) VQQQPQQPPSLQQQHSQQSLPTPPTTSQQQIHVQQSVPGPIQRPAQFAPQPMFPPQAQAQHQHQHMMGQPPPSSQNAQPG 
    mouse   (716) GMASLSIGGSAAPHTQSM---------QGFPPNLGSAFSTPQSPAKAFPPLSTPNQTTAFSGIGGLSSQLPGG------- 
    human   (716) GMTSLSIGGSAAPHTQSM---------QGFPPNLGSAFSTPQSPAKAFPPLSTPNQTTAFSGIGGLSSQLPVGG------ 
 
    yeast   (582) ---------------EAILANGDIAGINN--------------------------------------------------- 
      fly   (847) -----LMTPGANPYPLNLMQMPQAPPPPNV---------------GNLGRMLPGGPQQQTPTPTPTAPNPNNP------- 
     worm   (776) MNLLMNMSPFASGNNRDLLKVVQPAPPPPSSMSPSTQMMRSLIPPLTQRQNSNSGWHAAPAPQRPSGPPTPQQQMDFRGQ 
    mouse   (780) -----LGTGSLTGIGTGALGLPAVNNDP-----------------FVQRKLGTSGLNQPTFQQSKMKPSDLSQ------- 
    human   (781) -----LGTGSLTGIGTGALGLPAVNNDP-----------------FVQRKLGTSGLNQPTFQQSKMKPSDLSQ------- 
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    yeast   (596) ---------------------------------------------------------------------DIEKEMQNYLQ 
      fly   (900) ----------------------------------------------------------VMADLQIPVSKEVEDEVNSYFQ 
     worm   (856) IQEFAPQGPHQLQRSGSVTGRSMGIVGQKTSSNFSVGAPIPGSAAATAAAAANVQQPMNEDFQSMTFAEDIQEEANSYFE 
    mouse   (831) ----------------------------------------------------------VWPEANQHFSKEIDDEANSYFQ 
    human   (832) ----------------------------------------------------------VWPEANQHFSKEIDDEANSYFQ 
                                                                                         
    yeast   (607) KMYSG----ELAIKDVIELLRRLRDSDLPRDQEVFTCITHAVIAESTFFQDYPLDALATTSVLFGSMILFQLL-RGFVLD 
      fly   (922) RIYNHQPNPTLSIDEVLDILQRFKESSNRREQEVFLCMLRNLFEEYRFFCQYPEKELQITAQLFGGIIDRNLVPTFVALG 
     worm   (936) KIYSVNN--AMSVENLIDLLKRFRVSNDRRERLVLACVVKNLFEEYRFFHEYPERELRTTAAVYGGIIREDII-SNVQFA 
    mouse   (853) RIYNHPPHPTMSVDEVLEMLQRFKDSTIKREREVFNCMLRNLFEEYRFFPQYPDKELHITACLFGGIIEKGLV-TYMALG 
    human   (854) RIYNHPPHPTMSVDEVLEMLQRFKDSTIKREREVFNCMLRNLFEEYRFFPQYPDKELHITACLFGGIIEKGLV-TYMALG 
 
    yeast   (682) VAFRIIMRFAKEPPESKMFKFAVQAIYAFRIRLAEYPQYCKDLLRDVPALKSQAQVYQSIVEAATLANAP---------- 
      fly  (1002) LSLRCVLDALRKPDGSKLYYFGVTALDRFRTRLHTYNKYCEHIRSIPHFSDFPPHLIQYVEYGMHGQEPPPQKLIGLSNT 
     worm  (1013) TAVRKVIESLSADPNTMLWTFGIVALQHCRSKLCAYPKVCQMIVSSENFARFPQLLKDYVIAGVKGELPP---EGGRHTP 
    mouse   (932) LALRYVLEALRKPFGSKMYYFGIAALDRFKNRLKDYPQYCQHLASISHFMQFPHHLQEYIEYGQQSRDPPVKMQGSITTP 
    human   (933) LALRYVLEALRKPFGSKMYYFGIAALDRFKNRLKDYPQYCQHLASISHFMQFPHHLQEYIEYGQQSRDPPVKMQGSITTP                                                                                     
     
    yeast   (752) -------KERSRPVQEMIPLKFFAVDEVSCQINQ------------------EG-------------------------A 
      fly  (1082) IPSAISSGPGTEPIYRNSSMLGNMPAATPGSGPK---------SNAAVSHATRMKSIANATNIDTLLVAN--QEEKVTVP 
     worm  (1090) VGSAQAGSASSTPTPAAAPTNWGAVARAASVDPK------------NSLPANRTGNVLSYTNVDTLVMATNKDGAEIAQP 
    mouse  (1012) GSIALAQAQAQAQVPAKAPLAGQVNTMVTTSTTTTVAKTVTVTKPTGVSFKKDVPPSINTTNIDTLLVATD-QTERIVEP 
    human  (1013) GSIALAQAQAQAQVPAKAPLAGQVSTMVTTSTTTTVAKTVTVTRPTGVSFKKDVPPSINTTNIDTLLVATD-QTERIVEP 
 
    yeast   (782) PKDVVEKVLFVLNNVTLANLNNKVDELKKSLTPN---YFSWFSTYLVTQRAKTEPNYHDLYSKVIVAMGSGLLHQFMVNV 
      fly  (1151) PEPVQDKTAFIFNNLSQLNIPQKCDEIKEIMTKE---YWPWLAQYLVLKRASMEFNFHTLYYNFLDALKNGEINRFVTKE 
     worm  (1158) AEAIVDKISFLFNNLSQSNLIQKKDEVVEMISDHGDAFTLWLAQYIVMKRVSIEQNFQPLYNQFVNAIENP--------- 
    mouse  (1091) PENIQEKIAFIFNNLSQSNMTQKVEELKETVKEE---FMPWVSQYLVMKRVSIEPNFHSLYSNFLDTLKNPEFNKMVLNE 
    human  (1092) PENIQEKIAFIFNNLSQSNMTQKVEELKETVKEE---FMPWVSQYLVMKRVSIEPNFHSLYSNFLDTLKNPEFNKMVLNE 
 
    yeast   (859) TLRQLFVLLS--TKDEQAIDKKHLKNLASWLGCITLALNKPIKHKNIAFREMLIEAYKENR--LEIVVPFVTKILQRASE 
      fly  (1228) TLRNIKVLLRSDKGVINFSDRSLLKNLGHWLGMMTLGRNRPILQLDLDLKSLLAEAYHKGQQELLFVVPFVAKILESSAK 
     worm  (1229) --------------YLDH-DRQLLKNLGSWLGAITIARNKPILLNDLDLKSLLLEAYYKGQAELLYVVPFISKILTACSK 
    mouse  (1168) TYRNIKVLLTSDKAAANFSDRSLLKNLGHWLGMITLAKNKPILHTDLDVKSLLLEAYVKGQQELLYVVPFVAKVLESSIR 
    human  (1169) TYRNIKVLLTSDKAAANFSDRSLLKNLGHWLGMITLAKNKPILHTDLDVKSLLLEAYVKGQQELLYVVPFVAKVLESSIR 
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    yeast   (935) SKIFKPPNPWTVGILKLLIELNEKANWKLSLTFEVEVLLKSFNLTTKSLKPSNFINTPEVIETLSGALGSITLEQQQTEQ 
      fly  (1308) SRIFRSPNPWTMGIMYVLAELHQEPDLKLNLKFEIEVLCKTLNLELAKLRQVIYLKDPNRTHRIEEQMSQPKPKQLEPVA 
     worm  (1294) TSLFTPTCAWIRSILKVLAELHNEPDLKINLKFEIEVLCKELNVDLNQLQMDGILKDTEKLVRVPQQLCDVKLLTRPEAA 
    mouse  (1248) SLVFRPPNPWTMAIMNVLAELHQEHDLKLNLKFEIEVLCKNLALDINELKPGNLLKDKDRLKNLDEQLSAPKKDVKQPEE 
    human  (1249) SVVFRPPNPWTMAIMNVLAELHQEHDLKLNLKFEIEVLCKNLALDINELKPGNLLKDKDRLKNLDEQLSAPKKDVKQPEE 
 
    yeast  (1015) QRQIILMQQHQQQMLIYQ-------------------------------------Q--RQQQQQQRQQQQQHHISANTIA 
      fly  (1388) SAPALPREQQSPAQPPPPPQQQQPPQQQVPPPPSSADVDAQNAAAMMMAAGGANSTPGSVSSPNLPTDSSQVALPPPEPR 
     worm  (1374) SPVQSKIHMSGSAEQLSG-------------------MSPAIPDQVKPATPQPTEAELQSGTGGGGSQGAEAQVVPNVTH 
    mouse  (1328) LPAITT----------------------------------------------------TTTSTTPATSTTCTATVPPQPQ 
    human  (1329) LPPITT----------------------------------------------------TTTSTTPATNTTCTATVPPQPQ 
 
    yeast  (1056) DQQAAFGGEGSISHDNPFNNLLGSTIFVTHPDLKRVFQMALAKSVREILLEVVEKSSGIAVVTTTKIILKDFATEVDESK 
      fly  (1468) YSYVDVNVSNFQLIGQQLVLPPNTPFLHANPGIKHMVVNAVERTITDWLQPIVDRSIRIACATTEQIIRKDFALDADENR 
     worm  (1435) FAYHDINVLTYDGLIPHVKIVSHLPLFQLHPHAKHLVRPAMIHAIKELIGPVTERALKIAMTVTESLVRKDFALDPEEQN 
    mouse  (1356) YSYHDINVYSLAGLAPHITLNPTIPLFQAHPQLKQCVRQAIERAVQELVHPVVDRSIKIAMTTCEQIVRKDFALDSEESR 
    human  (1357) YSYHDINVYSLAGLAPHITLNPTIPLFQAHPQLKQCVRQAIERAVQELVHPVVDRSIKIAMTTCEQIVRKDFALDSEESR 
 
    yeast  (1136) LKTAAIIMVRHLAQSLARATSIEPLKEGIRSTMQSLAPNLMSLSSS-------PAEELDTAINENIGIALVLIEKASMDK 
      fly  (1548) MRTAAHQMVRNLAAGMAMITGKDEIARAISQNLHKALLSGLNGMP----SMAEIQAAAMQLASENVELVCAFIQKTSAEK 
     worm  (1515) LRAASFHMMRAMTAGMAMITCRDPLASSMHSNLANAFSSSLRSTAANPEMKQMIEDAAATITQDNVELSTNFIVKTACEK 
    mouse  (1436) MRIAAHHMMRNLTAGMAMITCREPLLMSISTNLKNSFASALRTASP--QQREMMDQAAAQLAQDNCELACCFIQKTAVEK 
    human  (1437) MRIAAHHMMRNLTAGMAMITCREPLLMSISTNLKNSFASALRTASP--QQREMMDQAAAQLAQDNCELACCFIQKTAVEK 
 
    yeast  (1209) STQDLADQLMQAIAIRRYHKERRADQPFITQNTNPYSLSLPEPLGLKNIGVTPQQFRVYEEFGKNIPNLDVIPFAGLPAH 
      fly  (1624) AAAEIDRRLSTDFETRKIAREE-GNRFVDAQILTYQQERLPEAVRIKVGAAPATLYAVYSEFARSIPGFQQMSDRDIALF 
     worm  (1595) ATQDIEKRLEADYQKRIAAKAE-MSFYRDEIAAAIHAQ-LPKAIATVPGPTDKALMGIYDQFSSRICGFKANSGEDPVSA 
    mouse  (1514) AGPEMDKRLATEFELRKHARQE-GRRYCDPVVLTYQAERMPEQIRLKVGGVDPKQLAVYEEFARNVPGFLPTN--DLSQP 
    human  (1515) AGPEMDKRLATEFELRKHARQE-GRRYCDPVVLTYQAERMPEQIRLKVGGVDPKQLAVYEEFARNVPGFLPTN--DLSQP 
 
    yeast  (1289) APPMTQNVGLTQPQQQQAQMPTQILTSEQIRAQQQQQQLQKSRLNQPSQSAQPPGVNVPNPQGGIAAVQSDLEQNQRVLV 
      fly  (1703) VPKPTDLSQPNVFANDDSMVYGELASKMEAFMNTAIGVPTLQIQASKMHMLLNALIATRR-LRDQESAFNLLTRAVEGLT 
     worm  (1673) EPGSGAITPVQTQSKEMELVCQQLQVIIKEVDQTTQAQPHLSNSAFQTVCLMRELMQNVISTKDANHLMILVTRSTEHLL 
    mouse  (1591) TGFLAQPMKQAWATDDVAQIYDKCITELEQHLHAIPPTLAMNPQAQALRSLLEVVVLSRN-SRDAIAALGLLQKAVEGLL 
    human  (1592) TGFLAQPMKQAWATDDVAQIYDKCITELEQHLHAIPPTLAMNPQAQALRSLLEVVVLSRN-SRDAIAALGLLQKAVEGLL 
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    yeast  (1369) HLMDILVSQIKENATKNNLAELGDQNQIKTIIFQILTFIAKSAQKDQLALKVSQAVVNSLFATSESPLCREVLSLLLEKL 
      fly  (1782) EGLVNMHEN------MEQMKMYQNIHLRILGLLNNSFGAPNTERAVTKCFFDIREEVRYNVEAARALITSHFVNLNQFDG 
     worm  (1753) HAYRLEGTPPKNLLDVEWARRLRDLFIGLMRLLQNYFPLVELSRRITTAIMQIRSDYKWNMEGIEILFKQNLLQSVLWDQ 
    mouse  (1670) DATSGADAD------LLLRYRECHLLVLKALQDGRAYGSPWCNKQITRCLIECRDEYKYNVEAVELLIRNHLVNMQQYDL 
    human  (1671) DATSGADAD------LLLRYRECHLLVLKALQDGRAYGSPWCNKQITRCLIECRDEYKYNVEAVELLIRNHLVNMQQYDL 
 
    yeast  (1449) CSLSLVARKDVVWWLVYALDSRKFNVPVIRSLLEVNLIDATELDNVLVTAMKNKMENSTEFAMKLIQNTVLSDDPILMRM 
      fly  (1856) MLRDCMDNGNNYVAISFGIALLERLIMDDRVINIVSDNEFMATVELLGRLTQHRHRYPECIVNAIDTLWSGNFNSSSDYS 
     worm  (1833) HLAGSMDNGGNMEAVLFAQKFVRSIGGGDMSRIQFLKERFPLTCEQLTKLHQLQSATRTEGMNNAMNNGAGNAAHHHAGL 
    mouse  (1744) HLAQSMENGLNYMAVAFAMQLVKILLVDERSVAHITEADLFHTIETLMRINAHSRGNAPEGLPQLMEVVRSNYEAMIDRA 
    human  (1745) HLAQSMENGLNYMAVAFAMQLVKILLVDERSVAHVTEADLFHTIETLMRINAHSRGNAPEGLPQLMEVVRSNYEAMIDRA 
 
    yeast  (1529) DFIKTLEHLASSEDENVKKFIKEFEDTKIMPVRKGTKTTRTEKLYLVFTEWVKLLQRVENN----DVITTVFIKQLVEKG 
      fly  (1936) PFNGNDRYLSGASHY------IHSGMHHVRSCDTDDPPGLQEKTEFLLKDWVALYTQQNQQSTRDARNFGAFVQKMNTYG 
     worm  (1913) QQQPPVALPMEAAP-------MPQASADAMAQRGYDDQEMTAKVEIIMREWIGLCYSPTGQ-RSPQESLAQMIQLMHEHG 
    mouse  (1824) HGGPNFMMHSGIS----------------QASEYDDPPGLREKAEYLLREWVNLYHSAAAG-RDSTKAFSAFVGQMHQQG 
    human  (1825) HGGPNFMMHSGIS----------------QASEYDDPPGLREKAEYLLREWVNLYHSAAAG-RDSTKAFSAFVGQMHQQG 
 
    yeast  (1605) VISDTDNLLTFVKSSLELSVSSFKESDP---------TDEV----FIAIDALGSLIIKLLILQGFKD--DTRRDYINAIF 
      fly  (2010) ILKTDDLITRFFRQATHICTDVVYRMFAEPSLP----INQAKNKIFQWIDAFVHLIAMLVRHSGEAGNPTTKINLLNKVL 
     worm  (1985) VLATDDKITQFFRLCVENCVDISVRVMKSEQLANGLPTTLIRHRCYYTLDAFVKLMALMIRHSDNGQ-SQNKINLLKKLL 
    mouse  (1887) ILKTDDLITRFFRLCTEMCVEISYRAQAEQQHNPAANPTMIRAKCYHNLDAFVRLIALLVKHSGEATNTVTKINLLNKVL 
    human  (1888) ILKTDDLITRFFRLCTEMCVEISYRAQAEQQHNPAANPTMIRAKCYHNLDAFVRLIALLVKHSGEATNTVTKINLLNKVL 
 
    yeast  (1670) SVIVLVFAKDHSQEGTTFNERPYFRLFSNILYEWATIRTHNFVRISDSSTRQELIEFDSVFYNTFSGYLHALQPFAFPGF 
      fly  (2086) GIVLGTLIKDHEMRGVSFQQVGYHRFFMMLFMELC-------------TADVILESLMHSIVSAFAYTYHLLNPSVAPGF 
     worm  (2064) NIIVGVLHMDHEVRKQDFNAMPYHRILISLFNEITGP-----------DPLKLLEPIAWSILEAFGQTFFALQPRRMPGF 
    mouse  (1967) GIVVGVLLQDHDVRQSEFQQLPYHRIFIMLLLELN-------------APEHVLETINFQTLTAFCNTFHILRPTKAPGF 
    human  (1968) GIVVGVLLQDHDVRQSEFQQLPYHRIFIMLLLELN-------------APEHVLETINFQTLTAFCNTFHILRPTKAPGF 
 
    yeast  (1750) SFAWVTLLSHRMLLPIMLRLPNKIG-------WEKLMLLIIDLFKFLDQYTSKHAVSDAVSVVYKGTLRVILGISNDMPS 
      fly  (2153) CFAWLELISHRVFLGRILVQIPGQK------GWPLYAQLLQDLFKYLAPFLRNTELGKPVQLLYKGTLRVLLVLLHDFPE 
     worm  (2133) AFAWLDIVGHRNVIGRLLANTGIAETVDAVKTAATYTQLIISHLKFLAPFLRNIQLPKSIAILYKGTLRVLLVILHDFPE 
    mouse  (2034) VYAWLELISHRIFIARMLAHTPQQK------GWPMYAQLLIDLFKYLAPFLRNVELTKPMQILYKGTLRVLLVLLHDFPE 
    human  (2035) VYAWLELISHRIFIARMLAHTPQQK------GWPMYAQLLIDLFKYLAPFLRNVELTKPMQILYKGTLRVLLVLLHDFPE 
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    yeast  (1823) FLIENHYELMNNLPPTYFQLKNVILSAIPKNMTVPNPYDVDLNMEDIPACKELP--EVFFDPVIDLHSLKKPVDNYLRIP 
      fly  (2227) FLCDYHFGFCDTIPPNCVQMRNIILSAFPRNMRLPDPFTPNLKVDMLSDSSNAPKVLSSYIMNIQPANFKKDLDSYLKAR 
     worm  (2213) LLCEFHYVICDTIPPNCVQLRNLILSAYPRQMRLPDPFALNFKQVDTIPEMAVEPKSNLNMATIIPDNIRIPLDEYLANR 
    mouse  (2108) FLCDYHYGFCDVIPPNCIQLRNLILSAFPRNMRLPDPFTPNLKVDMLSEINIAPRILTNFTG-VMPPQFKKDLDSYLKTR 
    human  (2109) FLCDYHYGFCDVIPPNCIQLRNLILSAFPRNMRLPDPFTPNLKVDMLSEINIAPRILTNFTG-VMPPQFKKDLDSYLKTR 
 
    yeast  (1901) SNSLLRTILSAIYKDTYDIKKGVGYDFLSVDSKLIRAIVLHVGIEAGIEYKRTSS--NAVFNTKSSYYTLLFNLIQNGSI 
      fly  (2307) APVTFLSELRGHLQVTSEPGT-------RYNMALMNALVMYVGTQAIALIRNKNFVPNTSNIAHSAHMDIFQNLAVDLDT 
     worm  (2293) ISVDFLPNLPTLLQTQNQAGT-------KYNTTVMNALVLYVGIRAIEHLHLRRQRISTLNIAHTSYMDIFQNLAIQLDT 
    mouse  (2187) SPVTFLSDLRSNLQVSNEPGN-------RYNLQLINALVLYVGTQAIAHIHNKGSTPSMSTITHSAHMDIFQNLAVDLDT 
    human  (2188) SPVTFLSDLRSNLQVSNEPGN-------RYNLQLINALVLYVGTQAIAHIHNKGSTPSMSTITHSAHMDIFQNLAVDLDT 
 
    yeast  (1979) EMKYQIILSIVEQLRYPNIHTYWFSFVLMNMFKSDEWNDQKLEVQEIILRNFLKRIIVNKPHTWGVSVFFTQLINNNDIN 
      fly  (2380) EGRYLFLNAIANQLRYPNSHTHYFSCAVLHLFAEANS----EAIQEQITRVLLERLIVNRPHPWGLLITFIELIKNPIYK 
     worm  (2366) EGRYLLFNGIANQLRYPNAHTHYFSCVFLYLFKNSTN----DTIQEQITRILFERLVALRPHPWGLLITFIELIKNPTYN 
    mouse  (2260) EGRYLFLNAIANQLRYPNSHTHYFSCTMLYLFAEANT----EAIQEQITRVLLERLIVNRPHPWGLLITFIELIKNPAFK 
    human  (2261) EGRYLFLNAIANQLRYPNSHTHYFSCTMLYLFAEANT----EAIQEQITRVLLERLIVNRPHPWGLLITFIELIKNPAFK 
 
    yeast  (2059) LLDLPFVQSVPEIKLILQQLVKYSKKYTTSEQDDQSATINRRQTPLQSNA--------- 
      fly  (2456) FWDHDFVHCAPEITKLFESVARSCLAKSNVTQQLNMPVVDGEGQEVATIN--------- 
     worm  (2442) FWRYEFTSCAPEIQRLFQNVANTCVPAQGSQPQAQPDGAPGPLGNNTGAANQQQNPNTN 
    mouse  (2336) FWNHEFVHCAPEIEKLFQSVAQCCMGQKQAQQVMEGTGAS------------------- 
    human  (2337) FWNHEFVHCAPEIEKLFQSVAQCCMGQKQAQQVMEGTGAS------------------- 
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Figure 3-8. Enhancement of Dl14/+ phenotype by Not1 EMS mutations  
Brightfield images of representative adult female wings are shown.  A) Dl14/+.  B) 97-
4/+; Dl14/+.  C) 129A-3/+; Dl14/+.  D) 143A-3/+; Dl14/+.  E) 209B-2/+; Dl14/+.  F) 
SH1677/+; Dl14/+.  Not1 EMS mutations 97-4, 129A-3, 143A-3, and 209B-2 (Panels B, 
C, D, and E, respectively) produce moderate to strong enhancement of the Dl14/+ 
thickened vein phenotype (panel A), manifested as strong thickening of the L2 
longitudinal vein and severe ectopic vein formation at the L4/L5 crossvein.  The 
transposon insertion in the Not1 5’ non-coding region, SH1677 (Panel F), does not 
modify the Dl14/+ phenotype. 
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 Figure 3-8.  Enhancement of Dl14/+ phenotype by Not1 EMS mutations 
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Figure 3-9. Modification of cone cell specification by Not1 EMS mutations 
Individual 24 hr APF pupal retinas were stained for the cone cell marker Cut (green).  
Wild type retinas exhibit an organized lattice of cone cell staining, with each 
ommatidium containing four cone cells (Panel A).  Overexpression of Delta in the 
developing Drosophila eye disrupts Notch-mediated cone cell development.  As shown in 
Panel B, GMR>DlWT/+ retinas display a severely disorganized array of cone cell 
clusters, including large gaps in the ommatidial array (arrows);  in addition, there is 
specification of aberrant numbers of cone cells for some ommatidia.  Not1 EMS 
mutations were crossed into the GMR>DlWT background to examine their impacts on 
cone cell development.  The strongest suppressors of the GMR>DlWT adult eye 
phenotype, 97-4 and 209B-2 (Panels C and F, respectively), also produce a more 
organized cone cell array in the developing retina; it is evident that there are fewer, 
smaller gaps within the cone cell array (arrows, Panel F) and more ommatidia include the 
wild type number of four cone cells.  The Not1 EMS mutations 129A-3 and 143A-3 
(Panels D and E, respectively), exhibit a weaker suppression of GMR>DlWT cone cell 
array disorganization.  
 
 
 
 
 
 
 167 
 Figure 3-9.  Modification of cone cell specification by Not1 EMS mutations 
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Figure 3-10. Enhancement of DlBX44/+ phenotype by Not1 EMS mutations 
Brightfield images of representative adult female wings are shown.  A) DlBX44/+.  B) 97-
4/+;DlBX44/+.  C) 129A-3/+;DlBX44/+.  D) 143A-3/+;DlBX44/+.  E) 209B-2/+;DlBX44/+.  F) 
SH1677/+;DlBX44/+.  Not1 EMS mutations 97-4, 129A-3, 143A-3, and 209B-2 (Panels B, 
C, D, and E, respectively) produce moderate to strong enhancement of the DlBX44/+ 
thickened vein phenotype (Panel A), manifested as strong thickening of the L2 
longitudinal vein, mild thickening of portions of the L3 and L4 longitudinal veins, and 
severe ectopic vein formation at the L4/L5 crossvein.  The transposon insertion in the 
Not1 5’ non-coding region, SH1677 (Panel F), does not modify the DlBX44/+ phenotype. 
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  Figure 3-10.  Enhancement of DlBX44/+ phenotype by Not1 EMS mutations 
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Figure 3-11. Enhancement of dx152/Y phenotype by Not1 EMS mutations  
Brightfield images of representative adult female wings are shown.  A) dx152/Y.  B) 
dx152/Y;97-4/+.  C) dx152/Y;129A-3/+.  D) dx152/Y; 143A-3/+.  E) dx152/Y;209B-2/+.  F) 
dx152/Y;SH1677/+.  Not1 EMS mutations 97-4, 129A-3, 143A-3, and 209B-2 (Panels B, 
C, D, and E, respectively) produce moderate enhancement of the dx152/Y thickened vein 
phenotype (Panel A), manifested as moderate thickening of the distal end of each 
longitudinal vein; in addition, mild notching of the wing margin is observed in some 
instances.  The transposon insertion in the Not1 5’ non-coding region, SH1677 (Panel F), 
is also a weak to moderate enhancer of the dx152/Y phenotype. 
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  Figure 3-11.  Enhancement of dx152/Y phenotype by Not1 EMS mutations 
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Figure 3-12. Enhancement of 34B>DeltaΔICD phenotype by Not1 EMS mutations 
Brightfield images of representative adult female wings are shown.  A) 
34B>DeltaΔICD/+.  B) 97-4/34B>DeltaΔICD.  C) 129A-3/34B>DeltaΔICD.  D) 143A-
3/34B>DeltaΔICD.  E) 209B-2/34B>DeltaΔICD.  F) SH1677/34B>DeltaΔICD.  Not1 
EMS mutations 97-4, 129A-3, 143A-3, and 209B-2 (Panels B, C, D, and E, respectively) 
produce weak enhancement of the 34B>DeltaΔICD/+ thickened vein phenotype (Panel 
A), manifested as mild thickening of the distal end of each longitudinal vein.  The 
transposon insertion in the Not1 5’ non-coding region, SH1677 (Panel F), does not 
modify the 34B>DeltaΔICD/+ phenotype. 
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  Figure 3-12.  Enhancement of 34B>DeltaΔICD phenotype by Not1 EMS mutations 
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Figure 3-13.  Knockdown of NOT1 distorts eye development 
UAS-Not1 RNAi was overexpressed using the eye driver eyeless-Gal4 (ey-Gal4) and 
critical class adults of genotype ey-Gal4/+;UAS-Not1 RNAi/+ were examined for adult 
eye phenotypes.  A) Wild type adult eye.  B-C) The ey-Gal4/+;UAS-Not1 RNAi/+ 
genotype produces small misshapen rough eye phenotype. 
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Figure 3-13.  Knockdown of NOT1 distorts eye development 
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Figure 3-14.  Knockdown of NOT1 inhibits wing blade development 
UAS-Not1 RNAi was overexpressed using the wing blade driver vg-Gal4, and critical 
class adults of genotype vg-Gal4/+;UAS-Not1 RNAi/+ were examined for adult wing 
phenotypes.  A) Wild type adult wing.  B-C) vg-Gal4/+;UAS-Not1 RNAi/+ adult wings 
exhibit complete loss of wing blade structures. 
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Figure 3-14.  Knockdown of NOT1 inhibits wing blade development 
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Figure 3-15.  Knockdown of NOT1 disrupts wing margin formation 
UAS-Not1 RNAi was overexpressed using the wing margin driver C96-Gal4, and critical 
class adults of genotype C96-Gal4/+;UAS-Not1 RNAi/+ were examined for adult wing 
phenotypes.  A) Wild type adult wing.  B) C96-Gal4/+;UAS-Not1 RNAi/+ adult wings 
exhibit severe notching of the wing margin (arrow, Panel B).  C) Magnified view of C96-
Gal4/+;UAS-Not1 RNAi/+ adult wing. 
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Figure 3-15.  Knockdown of NOT1 disrupts wing margin formation 
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Figure 3-16.  Knockdown of NOT1 inhibits macrochaetae formation 
UAS-Not1 RNAi was overexpressed using the SOP driver sca-Gal4, and critical class 
adults of genotype sca-Gal4/UAS-Not1 RNAi were examined for adult notal phenotypes.  
A) Wild type adult notum.  B-C) sca-Gal4/UAS-Not1 RNAi adult nota exhibit loss of 
most macrochaetae. 
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Figure 3-16.  Knockdown of NOT1 inhibits macrochaetae formation 
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Figure 3-17.  Schematic of Drosophila adult wing structures 
The accepted nomenclature of the major veins of the adult wing is in boldface.  L2 
through L5 are the longitudinal veins.  The anterior crossvein (ACV) connects the L3 and 
L4 longitudinal veins, while the posterior crossvein (PCV) connects the L4 and L5 
longitudinal veins.  L1 represents the wing margin.  
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Figure 3-17.  Schematic of Drosophila adult wing structures 
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Figure 3-18.  The role of the Notch pathway in Drosophila wing margin development 
This figure depicts a wild type L3 stage wing disc stained for Cut, one of the downstream 
target genes up-regulated by Notch signaling activity within the wing margin.  To the 
right is a schematic summarizing the patterns of ligand-dependent activation of Notch 
within the developing margin.  Delta ligand from the ventral disc region activates dorsal 
Notch signaling, while Serrate ligand from the dorsal disc region activates ventral Notch 
signaling.  Activation of Notch signaling across the DV boundary of the wing disc leads 
to up-regulation of Cut and Wingless, which help specify margin cell fates. 
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Figure 3-18.  The Notch pathway’s role in Drosophila wing margin development 
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Figure 3-19.  Knockdown of NOT1 expression disrupts Cut expression within the L3 
wing margin 
UAS-Not1 RNAi expression was driven with the wing margin driver C96-Gal4.  L3 wing 
discs of genotype C96-Gal4/+;UAS-Not1 RNAi/+ were then stained with anti-Cut 
antibody (green).  A) +/UAS-Not1 RNAi control; Cut expression is uninterrupted along 
the entire wing margin in the absence of Not1 RNAi.   B-C) C96-Gal4/+;UAS-Not1 
RNAi/+; Not1 RNAi expression down-regulates Cut expression within the wing margin. 
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Figure 3-19.  Knockdown of NOT1 expression disrupts Cut expression within the L3 
wing margin 
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Figure 3-20.  Knockdown of NOT1 expression disrupts Wingless expression within 
the L3 wing margin 
UAS-Not1 RNAi expression was driven with the wing margin driver C96-Gal4.  L3 wing 
discs of genotype C96-Gal4/+;UAS-Not1 RNAi/+ were then stained with anti-Wingless 
antibody (green).  A) +/UAS-Not1 RNAi control; Wingless expression is uninterrupted 
along the entire wing margin in the absence of Not1 RNAi.  B-C)  C96-Gal4/+;UAS-
Not1 RNAi/+; Not1 RNAi expression downregulates Wingless expression within the wing 
margin. 
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Figure 3-20.  Knockdown of NOT1 expression disrupts Wingless expression within the 
L3 wing margin 
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Figure 3-21.  Knockdown of NOT1 expression reduces Delta expression at the L3 
wing margin 
UAS-Not1 RNAi expression was driven with the wing margin driver C96-Gal4.  L3 wing 
discs of genotype C96-Gal4/+;UAS-Not1 RNAi/+ were then stained with anti-Delta 
antibody (green).  A) +/UAS-Not1 RNAi control; Delta expression flanking the DV 
boundary is strong in the absence of Not1 RNAi.  B-C) C96-Gal4/+;UAS-Not1 RNAi/+; 
Not1 RNAi expression down-regulates Delta expression within the wing margin. 
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Figure 3-21.  Knockdown of NOT1 expression reduces Delta expression at the L3 wing    
margin 
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Figure 3-22.  Reduced Delta expression caused by NOT1 knockdown is co-extensive 
with disruption of Cut expression 
UAS-Not1 RNAi expression was driven with the wing margin driver C96-Gal4.  L3 wing 
discs of genotype C96-Gal4/+;UAS-Not1 RNAi/+ were then double-stained with anti-Cut 
antibody (red) and anti-Delta antibody (green).  A, A’, A’’) +/UAS-Not1 RNAi control; 
Cut expression is uninterrupted along the entire DV boundary, and is flanked by strong 
Delta expression in the absence of Not1 RNAi.  B, B’, B’’) C96-Gal4/+;UAS-Not1 
RNAi/+.  Regions of reduced Delta expression coincide with gaps in Cut expression 
within the wing margin (arrows in panel B”).  
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   Figure 3-22.  Reduced Delta expression caused by NOT1 knockdown is co-extensive with the disruption of Cut expression 
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Figure 3-23.  Adult Drosophila bristle patterns   
A) Wild type notum; macrochaete bristles identified include the anterior (aDC) and 
posterior dorsocentral (pDC) macrochaetae and the anterior (aSC) and posterior (pSC) 
macrochaetae.  
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Figure 3-23.  Adult Drosophila bristle patterns 
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Figure 3-24.  Bristle organ developmental circuitry 
Development of the presumptive bristle organ is initiated by Notch-mediated restriction 
of Achaete expression to a single cell, the sensory organ precursor (SOP).  The SOP and 
its progeny undergo three sequential mitotic divisions.  The first division produces the 
precursor cells pIIa and pIIb.  pIIb subsequently divides to produce pIIIb and a glial cell.  
pIIa divides to form the shaft and socket cells; pIIIb divides to form the sheath and 
neuron cells.  Notch inhibitory signals are required during SOP, pIIa, and pIIIb mitotic 
divisions to ensure proper cell fate specification.  (Molecular markers for respective cell 
identities are noted in parentheses.) 
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Figure 3-24.  Bristle organ developmental circuitry 
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Figure 3-25.  Knockdown of NOT1 does not alter Achaete expression in the L3 
notum 
UAS-Not1 RNAi expression was driven with the SOP driver sca-Gal4.  L3 wing discs of 
genotype sca-Gal4/UAS-Not1 RNAi were then stained with anti-Achaete antibody 
(green).  A) +/UAS-Not1 RNAi control.  A’) Higher magnification of boxed region in (A); 
Achaete expression is localized in the region of the presumptive anterior (aDC) and 
posterior (pDC) dorsocentral macrochaetae and anterior (aSC) and posterior (pSC) 
scutellar macrochaetae.  B) sca-Gal4/UAS Not1 RNAi.  B’) Higher magnification of 
boxed region in (B); Not1 RNAi expression does not disrupt Achaete expression in the 
dorsocentral or scutellar bristle regions. 
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  Figure 3-25.  Knockdown of NOT1 does not alter Achaete expression in the L3 notum 
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Figure 3-26.  Knockdown of NOT1 does not alter Hindsight expression in the L3 
notum 
UAS-Not1 RNAi expression was driven with the SOP driver sca-Gal4.  L3 wing discs of 
genotype sca-Gal4/UAS-Not1 RNAi were stained with anti-Hindsight antibody (green).  
A) +/UAS-Not1 RNAi control.  A’) Higher magnification of boxed region in (A); 
Hindsight expression is localized in the region of the presumptive anterior (aDC) and 
posterior (pDC) dorsocentral macrochaetae and anterior (aSC) and posterior (pSC) 
scutellar macrochaetae.  B) sca-Gal4/UAS-Not1 RNAi.  B’) Higher magnification of 
boxed region in (B); Not1 RNAi expression does not disrupt Hindsight expression in the 
dorsocentral or scutellar bristle regions. 
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  Figure 3-26.  Knockdown of NOT1 does not alter Hindsight expression in the L3 notum 
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Figure 3-27.  Not1 RNAi prevents correct pIIa specification, leading to excess 
neurons 
Depicted below are the three bristle organ cell fate scenarios that may result from failure 
of the Notch pathway to inhibit pIIb cell fate specification due to Not1 RNAi activity.  
The two resulting pIIb precursors may develop normally to produce two neurons and two 
sheaths from their pIIIb progeny.  Notch inhibitory signaling may also be impaired during 
the pIIIb mitotic division, resulting in a failure to inhibit neuronal specification.  If Notch 
signal is impaired in only one pIIIb precursor, then three neurons and one sheath cell will 
result.  If Notch signal is impaired in both pIIIb precursors, then four neurons will 
develop. 
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Figure 3-27.  Not1 RNAi prevents correct pIIa specification, leading to excess neurons 
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Figure 3-28.  Knockdown of NOT1 produces excess neurons in the developing 
notum 
UAS-Not1 RNAi expression was driven with the SOP driver sca-Gal4.  Individual 30 hr 
APF nota of genotype sca-Gal4/UAS-Not1 RNAi were then stained with antibody against 
the neuronal marker 22C10 (green).  A) +/UAS-Not1 RNAi control.  A’) Higher 
magnification of boxed region in (A); 22C10 reveals a single neuron and bristle shaft for 
each scutellar macrochaeta.  B) sca-Gal4/UAS-Not1 RNAi.  B’) Higher magnification of 
boxed region in (B); Not1 RNAi expression results in complete loss of macrochaete 
bristle shafts and excess neurons in scutellar regions (arrow).  This suggests a failure in 
Notch-mediated inhibition of neuronal cell fate adoption.  
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  Figure 3-28.  Knockdown of NOT1 produces excess neurons in the developing notum 
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Figure 3-29.  Knockdown of NOT1 alters sheath cell specification 
UAS-Not1 RNAi expression was driven with the SOP driver sca-Gal4.  Individual 30 hr 
APF nota of genotype sca-Gal4/UAS-Not1 RNAi were then stained with the sheath cell 
marker Prospero antibody (green).  A) +/UAS-Not1 RNAi control.  A’) Higher 
magnification of boxed region in (A); a single sheath cell is observed in association with 
each scutellar macrochaeta.  B) sca-Gal4/UAS-Not1 RNAi.  B’) Higher magnification of 
boxed region in (B); Not1 RNAi expression results in an aberrant number of sheath cells 
specified for some macrochaetae.  In the boxed region, the left anterior scutellar (aSC) 
possesses two sheath cells, while the left posterior scutellar (pSC) has no sheath cells 
(arrows); both the right aSC and pSC have the wild type number of one sheath cell.  
These results indicate that failure of Notch-mediated inhibition caused by Not1 RNAi can 
occur during the SOP or pIIIb mitotic divisions during bristle organ development. 
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  Figure 3-29.  Knockdown of NOT1 alters sheath cell specification 
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Table 3-1.  NOT1 protein homology statistics      
A protein homology search was conducted for Drosophila melanogaster NOT1 isoform 
C, as well as its conserved C-terminal NOT domain.  A NCBI BLAST database search 
(www.ncbi.nlm.nih.gov/BLAST) was run against each protein sequence; the top hits for a 
selection of major organisms, along with their respective BLAST statistics, are listed 
below.  Significant homology was observed across a wide range of organisms, with 
sequence similarity exceeding 50% in all cases. 
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Table 3-1.  NOT1 protein homology statistics 
     
Entire Protein NOT Domain            
(a.a. #2114-2495) 
NCBI Accession ID Organism Size (a.a.) BLAST Score E-value Identity Similarity Identity Similarity 
Not1-C 
(NP_001097242.1) 
Drosophila 
melanogaster 
2505 5207           
Not1-E 
(NP_001097244.1) 
Drosophila 
melanogaster 
2220 4623 0 100 100 100 100 
Not1-D 
(NP_001097243.1) 
Drosophila 
melanogaster 
2503 4930 0 99 99 100 100 
XP_001663972.1 Aedes aegypti 2072 2428 0 57 72 76 87 
XP_319808.4 Anopheles gambiae 2198 1892 0 56 70 77 88 
XP_395830.2 Apis mellifera 2381 2357 0 50 66 75 87 
XP_001599430.1 Nasonia vitripennis 2353 1222 0 48 63 75 87 
XP_974867.1 Tribolium castaneum 2347 2245 0 47 64 74 86 
NP_001090658.1 Xenopus tropicalis 2388 2099 0 46 61 73 86 
NP_001073420.1 Danio rerio 2374 2098 0 46 61 73 85 
XP_613555.3 Bos taurus 2376 2084 0 46 61 73 86 
NP_057368.3 Homo sapiens 2376 2082 0 46 61 73 86 
XP_001153220 Pan troglodytes 2375 2079 0 46 61 73 86 
XP_001495291 Equus caballus 2376 2051 0 46 61 73 86 
NP_899766.2 Mus musculus 2375 2048 0 45 61 73 86 
XP_001060702 Rattus norvegicus 2376 2048 0 45 61 73 86 
NP_498516.1 Caenorhabditis 
elegans 
2500 991 0 36 54 53 68 
NP_171710.3 Arabidopsis thaliana 2378 499 7.00E-
139 
38 55 58 71 
XP_001181693 Strongylocentrotus 
purpuratus 
668 451 3.00E-
124 
39 54 None None 
NP_010017.2 Saccharomyces 
cerevisiae 
2108 232 2.00E-58 31 53 32 56 
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Table 3-2.  Lethal stage assessment for the 97-4 complementation group members 
Two methods of lethal stage assessment were conducted to estimate the developmental 
stage(s) during which homozygous mutants perish.  For GFP selection assessment, at 
least 200 non-GFP expressing embryos were collected for each Modifier/GFP-CyO egg 
lay.  For blind assessment, at least 1000 embryos were selected blindly, without regard 
for GFP expression, from each Modifier/GFP-CyO egg lay.  For both assessment 
methodologies, embryo development was tracked at 25° C; dead embryos were scored for 
GFP expression, and the presence of non-GFP larvae was noted.  In all cases, animals 
that do not express GFP die as embryos or L1 larvae. 
 
*"Expected # critical class" is defined as the total number of homozygous mutant 
embryos expected within the embryo sample collection. For embryos samples collected 
based on lack of GFP expression, all collected samples should theoretically be critical 
class; this value is an overestimate due to variations in embryonic GFP expression that 
complicate sample identification.  For blind selection, the “Expected # of critical class” is 
simply calculated from the statistical expectation of critical class embryos in stock 
progeny; this equates to 25% of the 1000 embryos collected, or 250 critical class 
embryos. 
**Hatch rate is calculated by subtracting the observed # of non-GFP expressing dead 
embryos from the expected # of critical class and then dividing this value by the expected 
# of critical class.  For example, in the 97-4 column under GFP selection, the hatch rate 
is:  (206 - 97)/206 = 52.9%. 
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Table 3-2.  Lethal stage assessment for the 97-4 complementation group members 
 GFP Selection Blind Selection 
 97-4 129A-3 143A-3 209B-2 SH1677 97-4 129A-3 143A-3 209B-2 SH1677 
Total embryos collected 206 205 206 219 201 1000 1000 1000 1050 1000 
Dead embryos 120 103 110 88 119 333 245 351 354 285 
Non-GFP dead embryos 97 88 93 70 108 196 96 167 193 138 
Expected # of critical class* 206 205 206 219 201 250 250 250 263 250 
Hatch rate (%)** 52.9 57.1 54.8 68 46.3 21.6 61.6 33.2 26.7 44.8 
Observed non-GFP L1 larvae Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
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Table 3-3.  Drosophila homologs of the yeast CCR4-NOT complex   
Known Drosophila homologs of CCR4-NOT complex components and the lethal alleles 
used for genetic interaction testing with GMR>DlWT/+ and Dl14/+ are listed.  No lethal 
alleles were available for Drosophila Not4 (CG31716) or Caf40 (CG14213); and no 
Drosophila homolog has been identified for Caf130.  As there were numerous lethal Ccr4 
(twin) alleles available, two were acquired for testing.  
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Table 3-3.  Drosophila homologs of the yeast CCR4-NOT complex 
Yeast  Drosophila Lethal Stocks 
NOT2 Regena P{PZ}Rga03834 
NOT3/5 l(2)NC136 P{SUPor-P}l(2)NC136KG10496 
NOT4 CG31716 none 
CAF1 Pop2 P{wHy}DG14804 
CAF40 CG14213 none 
CAF130 none none 
CCR4 twin P{3'SUPor-P}twinKG00877 
    P{wHy}twinDG24102 
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Table 3-4.  Genetic interaction and complementation testing of Drosophila CCR4-
NOT complex homologs          
Lethal alleles of Drosophila CCR4-NOT complex homologs were tested for modification 
of the GMR>DlWT/+ and Dl14/+ phenotypes.  Males carrying an allele for a given 
complex member were crossed to virgin females of genotype GMR>DlWT/CyO or 
Dl14/TM6C, respectively.  Allele/GMR>DlWT and Allele/Dl14 critical class progeny were 
then screened for modification of the associated phenotype.  For complementation 
testing, crosses were conducted in a single polarity.  At least 50 progeny were scored 
from each cross; homozygous viability of >95% was considered reflective of 
complementation.  (Score Designations:  WS - weak suppressor, MS - moderate 
suppressor, WE - weak enhancer, ME - moderate enhancer, no mod. – no modification, 
C- complementation, FC - failure to complement)      
       
 
 
 
 
 
 
 
 
 
 215 
Table 3-4.  Genetic interaction and complementation testing of Drosophila CCR4-NOT complex homologs 
Yeast  Drosophila Lethal Stocks GMR>DlWT Dl14/+ 97-4 129A-3 143A-3 209B-2 SH1677 
NOT2 Regena P{PZ}Rga03834 WS no mod. C C C C C 
NOT3/5 l(2)NC136 P{SUPor-P}l(2)NC136KG10496 MS ME C C C FC C 
CAF1 Pop2 P{wHy}DG14804 no mod. WE C C C C C 
CCR4 twin P{3'SUPor-P}twinKG00877 no mod. no mod. C C C C C 
    P{wHy}twinDG24102 no mod. no mod. C C C C C 
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Table 3-5.  Effects of Not1 RNAi expression in various tissues   
For all crosses, driver males were crossed to P{GD4070}v12571 virgins, and adult 
critical class progeny were scored for phenotypes.  For cases in which a homozygous 
viable driver was used, the stage of lethality was also noted. See Materials and Methods 
(Chapter 5) for origins of Gal4 drivers.       
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Table 3-5.  Effects of Not1 RNAi expression in various tissues 
Driver Driver Expression Result 
34B-Gal4/CyO wing vein lethal 
1348-Gal4 wing lethal (at L3 stage) 
C96-Gal4 wing margin severe notching and loss of wing tissue 
C179-Gal4 embryo/wing lethal (at L1/L2 stage) 
actin5C-Gal4/CyO ubiquitous lethal 
cut-Gal4 wing margin lethal (at L3 stage - larvae are black and shrivelled) 
dpp-Gal4/TM3,Ser wing  no modification 
elav-Gal4 nervous system no modification 
eyeless-Gal4 eye semi-lethal (at pupal stage); only 1 escaper with tiny eyes 
GMR-Gal4/CyO eye lethal 
neur-Gal4/TM3,Sb SOP lethal 
pannier-Gal4/TM3,Ser notum lethal 
patched-Gal4 embryo lethal (at L1 stage - larvae are black and shrivelled) 
scabrous-Gal4 SOP escapers to early adult stage; shortening and/or loss of macrochaetae 
sparkling-Gal4 (A gift from M. Noll) eye no modification 
striped-Gal4 notum lethal 
vestigial-Gal4/TM6b,Tb wing  wings are tiny/shrivelled or in severe cases nonexistent 
wingless-Gal4 wing no modification 
  
 
 
 
 
 
 
 
CHAPTER FOUR 
A SCREEN FOR MODIFERS OF DELTA OVEREXPRESSION IN THE 
DROSOPHILA EYE BASED ON SCREENING OF A PAN-GENOMIC 
TRANSPOSON COLLECTION 
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I.  Introduction 
We have also conducted a second genetic screen for modifiers of Delta overexpression in 
the eye, using a transposon collection to interrupt, overexpress or reduce expression of 
specific genes, in addition to the EMS mutagenesis screen outlined in Chapter 2.  Using 
the same GMR>DlWT/+ genetic background employed for the EMS-based F1 modifier 
screen, we have utilized a transposon insertion collection developed by Exelixis Inc. 
(Thibault et al., 2004) to identify enhancers and suppressors of this Delta overexpression 
eye phenotype. 
     
The Exelixis transposon collection consists of over 15,000 individual insertion lines, 
believed to affect roughly 50% of annotated Drosophila genes.  The collection was 
generated using four distinct types of transposons:  piggyBac (PB), razorBac (RB), and 
wartHog (WH), and XP (a P element) (Figure 4-1).  Different transposons were used to 
create the collection in order to expand the spectrum of transposon insertions, to gain 
more complete coverage of the genome and to provide a range of useful tools for 
researchers using the collection.  Thus, transposons XP, RB, and WH contain FRT sites 
that enable generation of small deficiencies, while XP and WH contain UAS sites that 
allow overexpression or anti-sensing of genes flanking the transposon insertion site. 
 
As discussed previously in Chapter 2, there are numerous advantages to conducting the 
GMR>DlWT modifier screen using the Exelixis collection in comparison to EMS 
mutagenesis.  First and foremost, the insertion site for each line in the collection has been 
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sequence-verified, and thus the genomic position of each insertion is known (Thibault et 
al., 2004).  Because of this, there is a much reduced need for linkage mapping, stock 
generation, complementation testing, or meiotic mapping - each of which is a labor-
intensive component of EMS-based mutagenesis screens.  Second, the problem of second 
site mutagenic events common to EMS mutagenesis is largely bypassed with transposon 
mutagenesis.  Southern Blot analysis of a statistical sampling of transposons within the 
Exelixis collection implies that 97% of the lines contain only a single transposon 
insertion (Thibault et al., 2004).  As a point of contrast, five of 13 (38.4%) of the EMS 
modifiers upon which we conducted low resolution BDSC Df Kit mapping were linked to 
additional lethal mutations.  A third advantage of transposon mutagenesis is that since 
balanced stocks have already been created for each line, there is no danger of losing 
modifiers of interest during screening and retesting processes.  With EMS mutagenesis, 
on the other hand, apparent modifying mutations observed in F1 individuals may not 
transmit because of sterility of F1 individuals, or because the modified phenotype reflects 
a somatic mutation that is not contained within the germ line and therefore cannot be 
preserved through generation of balanced stocks.  With our EMS-based screen, 83% of 
original apparent modifying mutations did not transmit and could not be saved. 
 
Normally, the one disadvantage of transposon-based screens is the inability to achieve 
saturating mutagenesis of the genome due to non-random insertion bias (Spradling et al., 
1995; Thibault et al., 2004).  In fact, the Exelixis collection only offers 53% gene 
coverage (Thibault et al., 2004).  Yet, we have screened the same GMR>DlWT entry 
 221 
point using both EMS-based and transposon-based mutagenesis methods.  By employing 
both methods, we have increased our chances of identifying genes that affect the Notch 
pathway, while gaining the benefits of using pre-mapped insertion lines in the 
transposon-based screen.  In the following section, I describe an F1 modifier screen in the 
GMR>DlWT/+ genetic background utilizing the Exelixis transposon insertion collection.  
We have identified modifying mutations within genes from a wide array of functional 
classes, suggesting that regulation of the Notch pathway involves many distinct, 
important cellular processes.   
 
II.  Results 
A.  A primary screen of 10,447 Exelixis insertion lines for GMR>DlWT modification 
identifies 170 modifying insertions 
In collaboration with Annette Parks and Nevine Shalaby, we have screened a total of 
10,447 Exelixis insertion lines (early access kindly provided by Spyros Artavanis-
Tsakonas, Harvard Medical School) for modification of the GMR>DlWT/+ rough eye 
phenotype (Shalaby et al., submitted).  The primary screen yielded a total of 798 
insertions that modified the GMR>DlWT/+ phenotype.  Of these 798 modifying 
insertions, 284 of the strongest modifiers were selected for further study.  To confirm that 
these 284 insertion lines identified in the primary screen yielded reproducible 
modification, we retested them against the GMR>DlWT/+ genetic background. A total of 
260 of the 284 lines were confirmed as modifiers.  We then tested these modifying lines 
in the same GMR-Gal4 negative secondary test used for the EMS screen (see Chapter 2). 
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The purpose of this test is to ensure that modifying mutations are truly modifying the 
Delta overexpression phenotype, rather than altering expression of the GMR-Gal4 driver 
(Freeman 1996; Hay et al., 1994).  Of the 260 modifying lines tested, 170 passed this 
negative secondary test.  These 170 insertion lines represent the confirmed modifiers of 
GMR>DlWT/+ that were chosen for further study. 
 
This group of 170 modifiers was comprised of 92 suppressors and 62 enhancers of 
GMR>DlWT/+.  Nine modifiers displayed aspects of both enhancement and suppression, 
while seven modifiers were lethal in combination with GMR>DlWT/+.  Given that 
modifiers isolated in the screen might be involved in general eye developmental 
processes or interacting signaling pathways rather than direct effectors of the Notch 
pathway, we conducted two additional genetic interaction tests.  All 170 modifiers were 
tested for modification of phenotypes created by overexpression of a dominant-negative 
form of Delta (DeltaΔICD; Huppert et al., 2007) within the developing wing vein using 
driver 34B-Gal4 (Mlodzik et al., 1990; 34B>DeltaΔICD) and the developing wing 
margin using the C96-Gal4 driver (Gustafson and Boulianne, 1996; C96>DeltaΔICD).  
The 34B>DeltaΔICD flies exhibit wing vein thickening, while C96>DeltaΔICD flies 
exhibit wing notching (Figure 4-2), both Notch loss-of-function phenotypes.  Testing 
revealed that 20 insertion lines enhanced and 11 suppressed the 34B>DeltaΔICD vein 
thickening phenotype; for the C96>DeltaΔICD interaction test, 34 insertion lines 
enhanced and 25 lines suppressed the wing notching phenotype.  Figure 4-2 depicts 
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representative enhancers and suppressors of the 34B>DeltaΔICD and C96>DeltaΔICD 
phenotypes.  Table 4-1 presents all of the testing data for the 170 confirmed modifiers. 
 
B.  Annotation of the 170 confirmed modifying transposons reveals potential effects on 
275 candidate genes 
Because of the intrinsic structures of the transposons used to generate the Exelixis 
collection, there is not a simple one-to-one ratio of modifying insertion lines and 
candidate genes.  This is due to the presence of UAS regulatory sites within the P (XP) 
and wartHog (WH) transposons that can mediate overexpression or anti-sensing of genes 
flanking their insertion sites.  For purposes of annotation, we considered as potentially 
modified any gene within 5 kb downstream of a P (XP) or wartHog (WH) insertion site, 
unless there was an intervening transcription stop site present between the gene and UAS 
site.  The piggyBac (PB) and razorBac (RB) transposons, which do not contain UAS 
regulatory sites, were considered to have disrupted a gene if they inserted within 2 kb of 
the 5’end or 1 kb of the 3’ end of that gene.  Of course, for all transposons, insertions 
within genes were considered disruptive. 
 
Based on our annotation rules, we have identified 275 candidate genes associated with 
152 modifying transposon insertions.  Among these, 16 modifying insertion lines did not 
disrupt any annotated genes, while 2 insertion lines could not be located within the 
genome.  We have organized candidate genes into functional classes based on either 
published reports or FlyBase (Version FB2009_2) gene ontology search results.  These 
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results are summarized in Table 4-2.  Candidate genes represent a wide range of 
functional classes, with the gene regulation class being the most highly represented, 
There were also a large number of candidate genes that have no known function. 
 
III.  Discussion 
A.  Known Notch pathway members were identified in the transposon screen 
Because Exelixis collection insertion sites were defined at molecular resolution within 
the genome, we were able to easily assess the utility of the GMR>DlWT/+ entrypoint by 
examining the list of candidate genes affected by modifying insertion for those that are 
known to play a role in Notch signaling.  Modifying insertions were identified in the 
known Notch pathway members numb and kuzbanian, with three independent hits in the 
numb transcription unit being isolated from the screen.  As discussed in Chapter 1, numb 
and kuzbanian are core regulators of Notch signaling activity.  Kuzbanian mediates S2 
cleavage of the Notch receptor to promote NICD release from the plasma membrane, 
while Numb negatively regulates signaling activity by physically interacting with the 
NICD (Pan and Rubin, 1997; Guo et al., 1996).   
 
Genes known to interact with the Notch pathway in certain developmental contexts were 
also isolated from the screen.  An insertion near scabrous, which encodes a secreted 
glycoprotein of unknown function that can act as an inhibitor of Notch signaling during 
both eye and wing development (Lee et al., 1996; Lee et al., 2000; Li et al., 2003), was 
identified in our screen.  An insertion near wingless, which encodes the activating ligand 
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of the Wingless signaling pathway, was also identified.  Many instances of Notch and 
Wingless pathway cross-talk during development have been documented (Axelrod et al., 
1996; Micchelli et al., 1997; de Celis and Bray, 1997).  Overall, identification of known 
Notch pathway members and interactors from the screen provides internal validation of 
the utility of the GMR>DlWT/+ Delta overexpression phenotype in the eye as a tool for 
the identification of Notch pathway interactors.     
 
B.  The majority of modifying transposons are of the P element (XP) class 
An analysis of the 170 modifying transposons identified in the screen revealed that the 
vast majority are from the P element (XP) transposon class.  Among these 170 modifying 
insertion lines, 152 (89.4%) were XP insertions.  Of the remaining 18 lines, eight were 
wartHog (WH) insertions, four were piggyBac (PB) insertions, and only three were 
razorBac (RB) insertions.  Screen statistics for the 170 confirmed modifying transposons 
are presented in Table 4-3. 
 
The prevalence of XP modifying insertions is likely due to a combination of several 
factors.  First, the XP transposon is the only one of the four transposons used to generate 
the Exelixis collection that possesses two UAS sites, which therefore allow for bi-
directional overexpression or anti-sensing of flanking genes.  This effectively doubles the 
probability that an XP transposon will have an impact on genes surrounding its insertion 
site, in comparison to the other three transposons in the collection.  In contrast, the 
wartHog (WH) transposon contains only one unidirectional UAS regulatory site, while 
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the razorBac (RB) and piggyBac (PB) transposons contain no UAS sites and thus can 
only disrupt gene expression by direct insertion into a transcription unit.  Second, the 
GMR>DlWT/+ genetic background produces a strong rough eye phenotype that is not as 
sensitive to modification as we originally thought.  Strong gain-of-function 
overexpression or loss-of-function anti-sensing effects on flanking gene expression 
mediated by UAS sites would be expected to have a modifying impact on the 
GMR>DlWT/+ phenotype more frequently than recessive loss-of-function insertions.  
Finally, the P-element and piggyBac transposons have different insertion biases.  P-
elements preferentially insert within 5’ regulatory regions of genes (Spradling et al., 
1995; Thibault et al., 2004).  In contrast, piggyBac transposons are more than three times 
more likely to insert within internal exons of genes and fully disrupt gene function 
(Thibault et al., 2004).  Therefore, XP transposons are more likely to insert into 5’ 
flanking regions upstream of transcription start sites, increasing the probability of UAS-
mediated effects on gene expression and function.  Meanwhile, all of the piggyBac 
transposons (WH, RB, PB) are more likely to create loss-of-function alleles due to 
preferential insertion into protein-coding regions.  Because of this overexpression/anti-
sensing bias of XP transposons, it is not surprising that the majority of insertion lines that 
modify the strong GMR>DlWT/+ eye phenotype are of the XP class.        
 
Another interesting result from the transposon screen that supports the idea of a XP 
overexpression/anti-sensing bias is the fact that a significant number of enhancers, as 
well as suppressors, were isolated from the screen.  In total, 62 enhancers of the 
 227 
GMR>DlWT/+ phenotype were identified, representing 93 candidate genes.  In contrast, 
only 20 enhancers were identified from the EMS screen, 19 of which represent alleles of 
the EGFR pathway member Star (which was also one of the potential enhancing 
modifiers identified in the transposon screen).  These results suggest that the transposon 
screen was much more efficient in identifying enhancers of the GMR>DlWT/+ 
phenotype than the EMS screen.  Again, this is likely due to the nature of the 
mutagenesis, with the GMR>DlWT/+ phenotype being more sensitive to modification by 
XP-mediated overexpression or anti-sensing than EMS-induced loss-of-function point 
mutations.  Overall, it is clear that the combined use of EMS and transposon-based 
mutagenesis has been beneficial, as we have identified potential some Notch pathway 
interactors that would have not been discovered through the use of either mutagenesis 
method alone.    
 
C.  Transposon screen hits suggest strong interactions between the Notch pathway and 
epigenetic regulators 
Annotation of candidate genes identified in the transposon screen indicated that members 
of the largest functional group play roles in the regulation of gene expression.  One such 
hit is also one of the strongest modifiers isolated from the transposon screen - an insertion 
in pipsqueak.  This insertion line, c04320, was one of only four piggyBac (PB) confirmed 
modifiers of the GMR>DlWT/+ phenotype and is located within an intronic region at the 
center of the pipsqueak transcription unit.  Because the piggyBac (PB) transposon does 
not contain UAS sites, this insertion is almost certainly a loss-of-function mutation of 
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pipsqueak.  Furthermore, insertion line c04320 was also one of the small number of 
screen hits that modified both the 34B>DeltaΔICD and C96>DeltaΔICD genetic 
interaction tests; in both tests, c04320 enhanced the Notch loss-of-function phenotypes.  
Overall, c04320 can be considered one of the top hits identified in the screen, as the 
effects of its insertion are not complicated by potential UAS-mediated expression of 
flanking genes, while it modified multiple Notch interaction tests. 
 
Pipsqueak was originally identified as a nuclear protein required for oogenesis, as well as 
determination of R3/R4 photoreceptor cell fate (Siegel et al., 1993; Horowitz and Berg, 
1996; Weber et al., 1995).  Later studies eventually revealed that Pipsqueak is an 
important regulator of the Polycomb Group complex (PcG) and mediates sequence-
specific DNA binding of the complex (Huang et al., 2002; Schwendemann and Lehmann, 
2002).  Polycomb Group proteins, best known for their specific roles in regulating 
homeotic gene expression during Drosophila embryonic patterning, are global silencers 
of gene expression (reviewed in Schwarz and Pirrotta, 2007).  PcG complexes function in 
an antagonistic relationship with the transcriptional activator complexes of the Trithorax 
Group (TrxG) to alter chromatin states and regulate gene expression (Papp and Muller, 
2006).  Although the precise mechanism through which PcG complexes induce 
transcriptional silencing is unknown, there is evidence to suggest that silencing effects 
are related to PcG methyltransferase activity and the resulting trimethylation of lysine 27 
of histone H3 (Papp and Muller, 2006; Kahn et al., 2006).   
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Another potential link between Notch signaling and Pipsqueak-mediated epigenetic 
silencing has been revealed in a recent study.  Ferres-Marco and colleagues conducted a 
similar Delta overexpression screen in the Drosophila eye using the ey-GAL4 driver, 
which produces a large-eye phenotype (Ferres-Marco et al., 2006).  Screening for 
modification of this phenotype with overexpression lines, they identified pipsqueak and 
longitudinals lacking (lola) as severe enhancers of the phenotype, causing eye 
tumorigenesis.  They provide evidence that combined action of Notch signaling and 
Pipsqueak/Lola silencing down-regulates expression of the Drosophila Retinoblastoma 
family homolog Rbf, leading to uncontrolled cell cycle progression and tumorigenesis.  
These results suggest that there is significant cross-talk between the Notch pathway and 
PcG-mediated epigenetic regulation during development.   
 
Interestingly, lola was also identified as a candidate modifier in our Delta overexpression 
eye screen.  The insertion line d04250 contains an XP insertion within the first intron at 
the 5’ end of the lola transcription unit; although d04250 was a moderate suppressor of 
the GMR>DlWT/+ phenotype, and this particular insertion did not modify either the 
34B>DeltaΔICD or C96>DeltaΔICD phenotypes.  Nonetheless, specific interactions 
between Lola and the Notch pathway have been reported in the literature recently.  Lola 
was first characterized as a transcription factor that regulates axon growth in Drosophila 
(Giniger et al., 1994; Madden et al., 1999).  Support for Lola-mediated chromatin 
modification was presented in studies of Drosophila embryonic development and 
oogenesis, in which Lola was found to genetically interact with the chromosomal kinase 
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JIL-1 and to be required for chromatin condensation during programmed cell death 
(Zhang et al., 2003; Bass et al., 2007).  Finally, a recent study has shown that Lola is an 
antagonist of Notch-dependent gene expression and its activity ensures proper 
specification of the R3/R4 and R7/cone cell fate lineages in the developing Drosophila 
eye (Zheng and Carthew, 2008). 
 
A scan of the complete list of candidate gene hits from our screen reveals additional 
genes known to play a role in PcG epigenetic regulation.  This includes single hits in 
Posterior sex combs (d09185) and Taf4 (d09711), a core PcG complex member and an 
associated factor, respectively (Shao et al., 1999; Saurin et al., 2001), as well as multiple 
hits in Trithorax-like (d00183, d01453) and Mi-2 (d01680, d06327), both of which have 
been implicated in PcG-mediated transcriptional silencing (Mulholland et al., 2003; 
Kehle et al., 2002).  The significant number of hits in our screen in PcG-related genes, in 
addition to the reports cited above of specific interactions between Pipsqueak and Lola 
and the Notch pathway, suggest a link between Notch-mediated development and PcG 
regulation of gene expression.  Clearly, as highlighted by the Ferres-Marco study (Ferres-
Marco et al., 2006), the signaling networks that link the Notch pathway and chromatin 
modification systems such as Polycomb Group are complex.  Nonetheless, further 
investigation of the mechanisms by which alterations in cellular epigenetic states impact 
Notch signaling could yield great benefits, including a deeper understanding of onset and 
progression of diseases such as retinoblastoma and other neoplasias. 
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Figure 4-1.  Transposon classes used to generate the Exelixis collection 
Four different transposons were used for insertional mutagenesis of a wild-type 
background: XP (a P element), piggyBac (PB, a piggyBac element), razorBac (RB, a 
piggyBac element), and wartHog (WH, a piggyBac element).  Transposon differences are 
noted based on their insertional biases, as well as the presence of FRT and UAS sites 
within their sequences.  P-elements have an insertional bias toward 5’ regulatory regions 
of genes, whereas piggyBac transposons are more likely to insert within coding exons.  
The XP, RB and WH elements contain FRT sites to facilitate deficiency generation, while 
the XP and WH elements can mediate overexpression or anti-sensing of genes flanking 
the UAS regulatory site.  (Figure modified from Parks et al., 2004.) 
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Figure 4-1.  Transposon classes used to generate the Exelixis collection 
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Figure 4-2.  Enhancers and suppressors of Notch loss-of-function genetic 
backgrounds were isolated from the screen 
Two genetic interaction tests were conducted with the 170 confirmed modifying insertion 
lines to identify those that interact most strongly with the Notch pathway.  
Overexpression of a dominant-negative form of Delta (DeltaΔICD) with the Drosophila 
wing vein driver 34B-Gal4 produces a wing vein thickening phenotype (34B> 
DeltaΔICD; panel B).  Overexpression of DeltaΔICD using the wing margin driver C96-
Gal4 produces a wing notching phenotype (C96>DeltaΔICD; panel E, arrow).  
Enhancers of 34B>DeltaΔICD yield wing vein thickening and wing blistering (panel C), 
whereas suppressors yield reduced vein thickening (panel D).  Enhancers of 
C96>DeltaΔICD yield more severe wing notching (panel F), while suppressors yield 
milder notching (panel G).  (Figure modified from Shalaby et al., 2009.)   
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Figure 4-2.  Enhancers and suppressors of Notch loss-of-function genetic backgrounds 
were isolated from the screen 
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Table 4-1.  Testing data and candidate gene identification for all 170 confirmed 
modifying insertion lines 
The testing results for all 170 confirmed modifiers for the primary screen and the positive 
secondary tests.  In addition, candidate genes are listed for each modifier based on the 
genomic position of the transposon insertion.  Annotation rules for candidate gene 
identification are outlined in Materials and Methods (Chapter 5).  (* indicates that the 
insertion line maps to multiple genomic regions; table modified from Shalaby et al., 
2009.)    
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  Table 4-1.  Screen statistics for 170 confirmed modifying transposons 
Stock ID Tn Type Chr 
Confirmation 
retest C96>DeltaΔICD 34B>DeltaΔICD 
c04320 PB 2R WS  ME E 
d00738 XP 2R MS WE E 
d00747 XP 2R ME NO MOD E 
d01453 XP 3L MS NO MOD E 
d01680 XP 3L MS MS E 
d01988 XP 3L WS NO MOD E 
d02119 XP 3R WS NO MOD E 
d05112 XP 3R MS NO MOD E 
d05547 XP 2L MS NO MOD E 
d05884 XP 3R WS NO MOD E 
d06199 XP X WS  E E 
d06348 XP 3R WS NO MOD E 
d07035 XP X ME NO MOD E 
d07162 XP 3L MS NO MOD E 
d07814 XP 2L MS NO MOD E 
d09065-1* XP 3R ME/S NO MOD E 
d11183 XP 3L MS WS E 
f04748 WH 2L MS S E 
d04706 XP 2R ME NO MOD E  
d09960 XP 2R MS  NO MOD E  
d07144 XP 2L SE NO MOD LETHAL 
d08266 XP 2L SE NO MOD LETHAL 
d08987 XP 2L LETHAL E LETHAL 
d09141 XP 2L SE S LETHAL 
d09356 XP X WS NO MOD LETHAL 
d09802-1* XP 2L WE NO MOD LETHAL 
d10593 XP 2L SE E LETHAL 
d10617 XP 2R MS NO PROGENY LETHAL 
d11205 XP 3R LETHAL NO MOD LETHAL 
c06428 PB 2R LETHAL LETHAL LETHAL  
d00615 XP 2L ME NO MOD LETHAL  
d00720 XP 2L SE NO MOD LETHAL  
d01932 XP X SE NO MOD LETHAL  
d02520 XP 2L SE NO MOD LETHAL  
d05916-1* XP 2L SE S LETHAL  
d07122 XP X SE NO MOD LETHAL  
c01601 PB 2L WS  NO MOD NO MOD 
c02135 PB 3R WS  NO MOD NO MOD 
c03489 PB 2L WS  ME NO MOD 
d00042 XP 3L WS NO MOD NO MOD 
d00063 XP 2L MS WE NO MOD 
d00136 XP 2R MS NO MOD NO MOD 
d00183 XP 3L ME WE NO MOD 
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Stock ID 
Tn 
Type Chr 
Confirmation 
retest C96>DeltaΔICD 34B>DeltaΔICD 
d00199 XP 2L SS NO MOD NO MOD 
d00216 XP X ME WS NO MOD 
d00278 XP 2R ME MS NO MOD 
d00284 XP 3R WS WE NO MOD 
d00332 XP 2L LETHAL NO MOD NO MOD 
d00442 XP X MS NO MOD NO MOD 
d00858 XP X WE WE NO MOD 
d00910 XP 2L WS NO MOD NO MOD 
d00935 XP 2R MS NO MOD NO MOD 
d00985 XP 2R ME NO MOD NO MOD 
d00992 XP 2R SS NO MOD NO MOD 
d01160 XP X MS NO MOD NO MOD 
d01249 XP 3R SE ME NO MOD 
d01337 XP 2R ME NO MOD NO MOD 
d01383 XP 2L SS NO MOD NO MOD 
d01539 XP 3L WE MS NO MOD 
d01690 XP 2L ME NO MOD NO MOD 
d01740 XP X ME NO MOD NO MOD 
d01821 XP X SS NO MOD NO MOD 
d01988 XP 3L ME/S WS NO MOD 
d02000 XP X SS MS NO MOD 
d02080 XP 2R MS MS NO MOD 
d02114 XP X MS NO MOD NO MOD 
d02121 XP X MS NO MOD NO MOD 
d02317 XP 2L WS WE NO MOD 
d02409 XP 3R SE NO MOD NO MOD 
d02631 XP 2L ME NO MOD NO MOD 
d02683 XP 2L WS NO MOD NO MOD 
d02798 XP 3L MS NO MOD NO MOD 
d02989 XP 2R WS NO MOD NO MOD 
d03048 XP X WE SE NO MOD 
d03212 XP 2R ME WS NO MOD 
d03295 XP X SE SE NO MOD 
d03500 XP 2L ME NO MOD NO MOD 
d03547 XP 2R MS NO MOD NO MOD 
d03672-1* XP 3R MS NO MOD NO MOD 
d03727 XP 2R SE NO MOD NO MOD 
d03762 XP 3R WE NO MOD NO MOD 
d03923 XP 3R SE/S NO MOD NO MOD 
d03982 XP 3R WS NO MOD NO MOD 
d04064 XP 2L WS WE NO MOD 
d04224 XP X ME NO MOD NO MOD 
d04230 XP 2L ME  NO MOD NO MOD 
d04250 XP 2R MS NO MOD NO MOD 
d04345 XP 2R ME NO MOD NO MOD 
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Stock ID 
Tn 
Type Chr 
Confirmation 
retest C96>DeltaΔICD 34B>DeltaΔICD 
d04563 XP 2L SE MS NO MOD 
d04817 XP X ME MS NO MOD 
d04859 XP 2L WS MS NO MOD 
d05170 XP 3L MS NO MOD NO MOD 
d05202 XP 3R WS NO MOD NO MOD 
d05297 XP 3R WS NO MOD NO MOD 
d05330 XP X WS NO MOD NO MOD 
d05397 XP 3R WS NO MOD NO MOD 
d05438 XP 2R WE NO MOD NO MOD 
d05779 XP 2R MS NO MOD NO MOD 
d05800 XP X WE S NO MOD 
d05949 XP 3L SE S NO MOD 
d05968 XP 2R MS S NO MOD 
d06079 XP 2R WE NO MOD NO MOD 
d06162 XP 3R ME NO MOD NO MOD 
d06230 XP 2L ME NO MOD NO MOD 
d06268 XP 2R WS NO MOD NO MOD 
d06312 XP 2L ME S NO MOD 
d06412 XP 3R ME/S E NO MOD 
d06501 XP 2R ME NO MOD NO MOD 
d06507 XP 3R MS NO MOD NO MOD 
d06524 XP 3R MS NO MOD NO MOD 
d06597 XP 2R SE/S NO MOD NO MOD 
d06604 XP 2R LETHAL NO MOD NO MOD 
d06616 XP X MS NO MOD NO MOD 
d06821 XP 2R MS NO MOD NO MOD 
d07488-1* XP 2L MS  S NO MOD 
d07508 XP 2L MS E NO MOD 
d07658 XP 2L ME S NO MOD 
d07785 XP 3R MS E NO MOD 
d07872-1* XP 3L SE NO MOD NO MOD 
d08033 XP 2R SS NO MOD NO MOD 
d08197 XP 2R MS WE NO MOD 
d08635 XP X WS NO MOD NO MOD 
d08710 XP 2R LETHAL NO MOD NO MOD 
d08881 XP 3R MS NO MOD NO MOD 
d09084 XP 2R SE NO MOD NO MOD 
d09185 XP 2R WS NO MOD NO MOD 
d09251 XP 2L WE E NO MOD 
d09689 XP 3L WE/S NO MOD NO MOD 
d09711 XP 3L MS NO MOD NO MOD 
d09998 XP 2L ME NO MOD NO MOD 
d10135-1* XP 3L SE SE NO MOD 
d10246-1* XP 3L ME/S NO MOD NO MOD 
d10255 XP 2R MS/E NO MOD NO MOD 
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Stock ID 
Tn 
Type Chr 
Confirmation 
retest C96>DeltaΔICD 34B>DeltaΔICD 
d10370 XP 3L WS  E NO MOD 
d10551 XP 2L WS NO MOD NO MOD 
d10582 XP 2L MS NO MOD NO MOD 
d10800 XP 3R WE S NO MOD 
d10839 XP 3R ME NO MOD NO MOD 
d10879 XP 2L MS WE NO MOD 
d11130 XP X WS E NO MOD 
d11193 XP 2L WS NO MOD NO MOD 
d11300 XP 2L WE NO MOD NO MOD 
d11403 XP 2L SS NO MOD NO MOD 
d14230 XP 2L ME S NO MOD 
e00305 RB 3R WS  NO MOD NO MOD 
e03075 RB 3R WS  E NO MOD 
e03188 RB 3R WS S NO MOD 
f00190 WH 2R MS NO MOD NO MOD 
f02453 WH 2L WS  NO MOD NO MOD 
f02919 WH X WS  E NO MOD 
f06696 WH 2R ME/S NO MOD NO MOD 
f06749 WH 3L WS E NO MOD 
d00876 XP X MS NO MOD NO MOD  
d03175 XP 3L ME SE NO MOD  
d06042 XP 3R WS NO MOD NO MOD  
d06327 XP 3L SS NO MOD NO MOD  
d06878 XP 2R ME NO MOD NO MOD  
d03852 XP 3L MS WS NO PROGENY 
c01192 PB 2L WE SE S 
c06362 PB 2L WE WE S 
d00366 XP X ME NO MOD S 
d00740 XP 3L LETHAL NO MOD S 
d01851 XP 2R ME NO MOD S 
d02599 XP X MS WE S 
d03329 XP X WS WE S 
d09082 XP 2L WS NO MOD S 
f00286 WH X WS NO MOD S 
f00392 WH 2L MS NO MOD S 
d03038 XP 2R WS NO MOD SE/S  
d00006 XP 3R ME ME SS 
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Stock ID Tn Type Chr Candidate Gene Hit 1 Candidate Gene Hit 2 Candidate Gene Hit  3 
c04320 PB 2R pipsqueak     
d00738 XP 2R Ptc-related CG30432 CG8335 
d00747 XP 2R short stop     
d01453 XP 3L CG9384 CG33260 Trithorax-like 
d01680 XP 3L Suppressor of Triplolethal Mi-2   
d01988 XP 3L Ecdysone-inducible gene L2     
d02119 XP 3R CG18522 CG18519   
d05112 XP 3R CG6173 CG6164 CG6159 
d05547 XP 2L CG17646     
d05884 XP 3R CG8036 CG8032   
d06199 XP X CG32572 CG18358   
d06348 XP 3R CG18410 Ets96B polybromo 
d07035 XP X Fasciclin 2     
d07162 XP 3L Cysteine string protein CG11523 Dead-box-1 
d07814 XP 2L Myosin heavy chain     
d09065-1* XP 3R CG33681  bubblegum   
d11183 XP 3L karst     
f04748 WH 2L kuz B4   
d04706 XP 2R no man's land     
d09960 XP 2R CG18375      
d07144 XP 2L no man's land     
d08266 XP 2L wingless     
d08987 XP 2L CG31666     
d09141 XP 2L CG33635  split ends   
d09356 XP X no man's land     
d09802-1* XP 2L trachealess     
d10593 XP 2L Hormone receptor-like in 38     
d10617 XP 2R CG8370 ATP citrate lyase   
d11205 XP 3R puckered CG7900    
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Stock ID Tn Type Chr Candidate Gene Hit 1 Candidate Gene Hit 2 Candidate Gene Hit  3 
c06428 PB 2R CG14767 CG30357   
d00615 XP 2L elbowB     
d00720 XP 2L spalt major     
d01932 XP X CG15321     
d02520 XP 2L dachshund CG4580   
d05916-1* XP 2L caudal diaphanous   
d07122 XP X Cytochrome P450-18a1     
c01601 PB 2L Pray For Elves     
c02135 PB 3R CG13650 CG34027   
c03489 PB 2L CG6509     
d00042 XP 3L formin3 CG8634   
d00063 XP 2L numb     
d00136 XP 2R SP2637     
d00183 XP 3L Trithorax-like CG33260 CG9384 
d00199 XP 2L Oatp30B CG33298 CG31883 
d00216 XP X Gga CG3004   
d00278 XP 2R deadpan peanut   
d00284 XP 3R Glutathione S Transferase D1 Glutathione S transferase D2   
d00332 XP 2L no man's land     
d00442 XP X CG41478     
d00858 XP X raspberry CG32676   
d00910 XP 2L numb CG3769 CG33723 
d00935 XP 2R no man's land     
d00985 XP 2R no man's land     
d00992 XP 2R smooth CG18367   
d01160 XP X CG32714     
d01249 XP 3R squeeze CG5558   
d01337 XP 2R CG30089     
d01383 XP 2L numb     
d01539 XP 3L CG13907 CG32479   
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Stock ID Tn Type Chr Candidate Gene Hit 1 Candidate Gene Hit 2 Candidate Gene Hit  3 
d01690 XP 2L bereft CG17745   
d01740 XP X CG4991  CG16700   
d01821 XP X CG3842     
d01988 XP 3L Ecdysone-inducible gene L2     
d02000 XP X no sequence available     
d02080 XP 2R scruin like at the midline CG30118   
d02114 XP X Fimbrin     
d02121 XP X CG32556 CG8188 CG5884 
d02317 XP 2L Cytochrome P450 reductase CG9493   
d02409 XP 3R CG6782 CG6783 CG14709 
d02631 XP 2L spire     
d02683 XP 2L Glycerol 3 phosphate dehydrogenase     
d02798 XP 3L CG11714 CG6128 CG11711 
d02989 XP 2R Phosphodiesterase 8 retained   
d03048 XP X CG32560 CG15816 CG32559 
d03212 XP 2R no man's land     
d03295 XP X CG9650     
d03500 XP 2L CG9894 Phosphoglycerate kinase   
d03547 XP 2R CG9945 Hillarin   
d03672-1* XP 3R CG5834     
d03727 XP 2R CG4612 CG30169   
d03762 XP 3R CG2525 CG1129   
d03923 XP 3R Bestrophin 1 CG12814   
d03982 XP 3R 
Zinc/iron regulated transporter-related 
protein 3 gilgamesh   
d04064 XP 2L CG33113 CG31917 CG3887 
d04224 XP X CG9921 Dorsal switch protein 1   
d04230 XP 2L RNA-binding protein 9 lilliputian   
d04250 XP 2R longitudinals lacking     
d04345 XP 2R no man's land     
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Stock ID Tn Type Chr Candidate Gene Hit 1 Candidate Gene Hit 2 Candidate Gene Hit  3 
d04563 XP 2L junctophilin     
d04817 XP X diminutive     
d04859 XP 2L CG3762     
d05170 XP 3L CG9972 Shaker cognate b   
d05202 XP 3R CG31038 CG34133   
d05297 XP 3R 
SNF4/AMP-activated protein kinase 
gamma subunit     
d05330 XP X CG5937 CG5941 roughex 
d05397 XP 3R jaguar     
d05438 XP 2R CG8229 CG33199 
Translocase of outer 
membrane 7 
d05779 XP 2R CG18375     
d05800 XP X no man's land     
d05949 XP 3L CG9007     
d05968 XP 2R Defense repressor 1 CG3927   
d06079 XP 2R dappled CG1621   
d06162 XP 3R CG11033 Mst85C 
NAD-dependent 
methylenetetrahydrofolate 
dehydrogenase 
d06230 XP 2L Hormone receptor-like in 39 CG31626 CG8677 
d06268 XP 2R peanut     
d06312 XP 2L 
Heterogeneous nuclear 
ribonucleoprotein at 27C xl6 nop5 
d06412 XP 3R Ras oncogene at 85D Rlb1   
d06501 XP 2R no man's land     
d06507 XP 3R CG11975 CG11971   
d06524 XP 3R PP2A-B' CG7217  cap binding protein 20 
d06597 XP 2R no man's land     
d06604 XP 2R no man's land     
d06616 XP X CG11138 LIM-kinase1   
d06821 XP 2R Picot CG5197   
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Stock ID Tn Type Chr Candidate Gene Hit 1 Candidate Gene Hit 2 Candidate Gene Hit  3 
d07488-1* XP 2L thread Myosin binding subunit   
d07508 XP 2L sloppy paired 1     
d07658 XP 2L taiman     
d07785 XP 3R CG4860 CG10014 CG4848 
d07872-1* XP 3L scabrous     
d08033 XP 2R nahoda CG3700 Mediator complex subunit 23 
d08197 XP 2R CG18316 cul-4   
d08635 XP X CG11473 CG17761    
d08710 XP 2R no man's land     
d08881 XP 3R CG11984  CG11985  CG11986  
d09084 XP 2R CG17390      
d09185 XP 2R Posterior sex combs     
d09251 XP 2L CG33316      
d09689 XP 3L Cysteine string protein CG11523   
d09711 XP 3L TBP-associated factor 4 Zn72D   
d09998 XP 2L CG13397  CG13398  A kinase anchor protein 200 
d10135-1* XP 3L dikar CG10107    
d10246-1* XP 3L archipelago CG1265    
d10255 XP 2R Ryanodine receptor 44F sticks and stones   
d10370 XP 3L CG6199  Angelman syndrome CG14141  
d10551 XP 2L CG10186  CG10132    
d10582 XP 2L arrest     
d10800 XP 3R headcase     
d10839 XP 3R CG2931  CG1081    
d10879 XP 2L no man's land     
d11130 XP X CG32727 CG15035    
d11193 XP 2L Phospholipase at 21C     
d11300 XP 2L CG10631  CG10628  CG10463  
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Stock ID Tn Type Chr Candidate Gene Hit 1 Candidate Gene Hit 2 Candidate Gene Hit  3 
d11403 XP 2L 
Organic Anion Transporting 
Polypeptide CG33298    
d14230 XP 2L no sequence available     
e00305 RB 3R CG11880      
e03075 RB 3R eIF3-S10     
e03188 RB 3R no man's land     
f00190 WH 2R Tbp     
f02453 WH 2L CG13131 Translocation protein 1   
f02919 WH X CG4281  CG14054    
f06696 WH 2R no man's land     
f06749 WH 3L CG17181  CG12169    
d00876 XP X CG10962 CG33224   
d03175 XP 3L tribbles     
d06042 XP 3R CG31098 CG31102 CG31097  
d06327 XP 3L Mi-2 Su(Tpl)   
d06878 XP 2R patched CG30353    
d03852 XP 3L CG32373 CG7496   
c01192 PB 2L Star     
c06362 PB 2L CG31729 CG6116   
d00366 XP X CG10777 CG10778 Ribosomal protein S14a 
d00740 XP 3L lariat debranching enzyme moleskin   
d01851 XP 2R Sox box protein-15 Ribosomal protein S23   
d02599 XP X bifocal CG2371   
d03329 XP X Amun CG1837   
d09082 XP 2L CG4455  chiffon   
f00286 WH X CG32580      
f00392 WH 2L split ends 
mitochondrial ribosomal 
protein L10 CG11617  
d03038 XP 2R ken and barbie Thiolase   
d00006 XP 3R puckered CG7900   
 246 
Stock ID Tn Type Chr Candidate Gene Hit 1 Candidate Gene Hit 2 Candidate Gene Hit  3 
d03672-2     CG6489 CG31359 CG5834 
d03672-3     CG5834 CG5834   
d03672-4     CG31449     
d05916-2     Ecdysone-inducible gene L2     
d05916-3     lethal (2) 01810     
d07488-2     CG9342 CR33318   
d07872-2     I'm not dead yet CG32027   
d09065-2     tramtrack     
d09802-2     cropped     
d10135-2     poly-glutamine tract binding protein 1     
d10246-2     alan-shepard     
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Table 4-2.  The distribution of transposon screen candidate gene hits among major 
functional classes 
The 170 confirmed modifiers were grouped into major functional classes based on 
published reports and/or FlyBase Release FB2007_3 annotations.  Refer to Table 4-1 for 
a compilation of annotations.  (Modified from Shalaby et al., 2009.) 
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Table 4-2.  The distribution of transposon screen candidate gene hits among major 
functional classes 
 
Functional Category Total 
Cell-cell communication 27 
Cell metabolism 39 
Cytoskeletal/trafficking 20 
Gene Regulation 62 
Lipid metabolism 7 
Novel/unable to assign 79 
No identified CG in region 16 
Protein metabolism 27 
Transporters 14 
Total Genes 275 
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Table 4-3.  Screen statistics for 170 confirmed modifying transposons 
Of 10,447 independent insertion lines screened, 170 were confirmed as modifiers of the 
GMR>DlWT/+ eye phenotype.  The breakdown of the transposon class with which these 
170 insertion lines were generated is summarized.  Clearly, the P (XP) transposon class is 
most highly represented among confirmed modifiers.  This is likely due to a combination 
of the presence of two UAS sites in the XP transposon, which allows for bi-directional 
overexpression or anti-sensing of flanking genes, as well as the insertional bias of P 
elements toward 5’ regulatory regions.  (Enh./Sup. – GMR>DlWT modification 
phenotype possesses characteristics of both enhancement and suppression; table modified 
from Shalaby et al., 2009.) 
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Table 4-3.  Screen statistics for 170 modifying transposons 
Transposon 
type 
Total in 
collection Total screened 
 Passed retest and 
negative 2° test a Enhancer Suppressor Lethal Enh./Sup. 
PB 3548 2421 7 2 4 1 0 
RB 3288 2228 3 0 3 0 0 
WH 5637 3632 8 0 7 0 1 
XP 3715 2166 152 60 78 6 8 
Total 16188 10447 170 62 92 7 9 
        
a 284 of 798 primary hits were 
retested       
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MATERIALS AND METHODS 
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Fly stocks and culture 
All fly stocks were maintained using standard procedures.  All crosses were performed at 
25°C, unless otherwise noted. 
 
 
I.  Chapter 2:  EMS Screen 
Drosophila strains used 
Primary EMS Screen Stocks 
GMR-Gal4 (Freeman 1996; Hay et al. 1994) 
UAS-DeltaWT (T. L. Jacobsen, Ph.D. Thesis, Indiana University);  
w;iso2;iso3 [Bloomington Drosophila Stock Center (BDSC)] 
Dr/TM6C (BDSC)  
Dl14/TM6C (California Institute of Technology, 1940) 
BDSC Deficiency Kit Stocks 
Df(2L)BSC4  Df(2L)FCK-20  Df(2R)vg-C 
Df(2L)BSC106 Df(2L)Prl   Df(2R)CX1 
Df(2L)BSC16  Df(2L)BSC30   Df(2R)BSC18 
Df(2L)ast2  Df(2L)b87e25   Df(2R)Exel7131 
Df(2L)BSC37  Df(2L)TE35BC-24  Df(2R)BSC11 
Df(2L)dpp[d14] Df(2L)r10   Df(2R)Jp1 
Df(2L)C144  Df(2L)cact-255rv64  Df(2R)Jp8 
Df(2L)JS17  Df(2L)TW137   Df(2R)BSC49 
Df(2L)BSC28  Df(2L)Exel6049  Df(2R)BSC44 
Df(2L)BSC31  Df(2L)C'   Df(2R)robl-c 
Df(2L)drm-P2  In(2R)bw[VDe2L]Cy[R] Df(2R)BSC45 
Df(2L)ed1  Df(2R)M41A4   Df(2R)14H10Y-53 
Df(2L)BSC109 Df(2R)nap9   Df(2R)14H10W-35 
Df(2L)Exel6011 Df(2R)ST1   Df(2R)PC4 
Df(2L)cl-h3  Df(2R)H3C1   Df(2R)P34 
Df(2L)BSC5  Df(2R)H3E1   Df(2R)BSC26 
Df(2L)BSC6  Df(2R)Np5   Df(2R)BSC22 
Df(2L)BSC7  Df(2R)w45-30n  Df(2R)AA21 
Df(2L)spd[j2]  Df(2R)BSC29   Df(2R)Exel7162 
Df(2L)XE-3801 Df(2R)B5   Df(2R)BSC19 
Df(2L)BSC41  Df(2R)X1   Df(2R)Egfr5 
Df(2L)TE29Aa-11 Df(2R)stan1   Df(2R)59AD 
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Df(2L)BSC53  Df(2R)en-A   Df(2R)vir130 
Df(2L)N22-14  Df(2R)en30   Df(2R)Px2 
Df(2L)BSC17  Df(2R)BSC39   Df(2R)ED4071 
Df(2L)BSC50  Df(2R)CB21   Df(2R)ES1 
Df(2L)BSC32  Df(2R)BSC40   Df(2R)Kr10 
Df(2L)BSC36  Df(2R)BSC3  
 
Modifier 11A-2 mapping stocks 
Df(2L)Exel7038 (BDSC) 
Df(2L)ED678 (BDSC) 
Df(2L)N22-3 (BDSC) 
Df(2L)Exel7039 (BDSC) 
Df(2L)ED647 (BDSC) 
Df(2L)ED632 (Szeged Drosophila Stock Center) 
raw1 (Nusslein-Volhard et al., 1984) 
 
Modifier 96B-1 mapping stocks 
Df(2L)M36F-S6 (BDSC) 
Df(2L)OD15 (BDSC) 
Df(2L)TW158 (BDSC) 
Df(2L)TW9 (BDSC) 
Df(2L)Exel7072 (BDSC) 
Df(2L)Exel7073 (BDSC) 
P(WH)CG10602f04195 (Exelixis) 
tailup1 (Nusslein-Volhard et al., 1984) 
P(WH)ssp3f04580 (Exelixis) 
 
Modifier 97-4 mapping stocks 
Df(2R)ED1791 (BDSC) 
Df(2R)BSC132 (BDSC) 
 
Modifier 159-1a mapping stocks 
Df(2R)14F06Y-28 (BDSC) 
Df(2R)02B100Y-14 (BDSC) 
Df(2R)14F06W-10 (BDSC) 
eiF3-S814F06 (Mohr and Gelbart, 2002) 
 254 
 
 
Primary screen 
w;iso2;iso3 males were starved for 6 hours and then fed a solution of 25 mM 
ethylmethane sulfonate (EMS) in 5% sucrose for 24 hours.  EMS-fed males were crossed 
en masse to GMR-Gal4 UAS-DlWT (GMR>DlWT; Freeman, 1996; Hay et al., 1994; T.L. 
Jacobsen, Ph.D. Thesis) virgin females.  F1 progeny were screened for enhancement or 
suppression of the GMR>DlWT/+ rough eye phenotype.  Individual isolated modifiers 
were subjected to transmission crosses back to the GMR>DlWT/CyO stock to confirm 
modifying phenotype and to begin defining linkage of modifying mutations.  
Transmitting second chromosome modifiers were balanced using GMR>DlWT/CyO; 
transmitting third chromosome modifiers were balanced using Dr/TM6C.  From a total of 
127,200 haploid genomes screened, 1141 candidate modifiers of GMR>DlWT/+ were 
identified.  Of these 1141 initial modifiers, 195 were confirmed as transmitting modifiers. 
 
Secondary testing    
Transmitting modifiers were subjected to negative and positive secondary tests.  For 
negative secondary tests, modifiers were crossed to flies containing the GMR-Gal4 
transgene (Freeman 1996; Hay et al. 1994) alone, and the eye phenotypes of F1 progeny 
were assessed for modification of the GMR-Gal4 rough eye phenotype.  The purpose of 
this test was to determine whether the modifier was affecting GMR-Gal4 driver 
expression, rather than specifically impacting Notch signaling.  The positive secondary 
test consisted of crossing modifiers that passed negative secondary testing to flies 
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heterozygous for the lethal Delta allele Dl14.  The purpose of this test was to prioritize the 
transmitting modifiers based on the strength of their genetic interaction with a Notch 
pathway mutant.  Dl14/+ mutant flies exhibit thickening of the L2 wing vein, as well as 
ectopic vein formation at the L4/L5 crossvein.  Modifiers were scored for the strength of 
their enhancement or suppression of the Dl14/+ wing phenotype.   
 
Inter se complementation testing 
Transmitting modifiers that passed negative secondary testing were placed into 
complementation groups via inter se complementation testing.  Each modifier was 
crossed to all others in a single polarity (i.e., Modifier A/CyO males crossed to Modifier 
B/CyO virgin females).  At least 50 progeny were scored from each cross.  Homozygous 
viability of >95% was considered to constitute complementation. 
 
Deficiency mapping 
Thirteen modifiers that displayed strong interactions with the Notch pathway based on 
the primary screen and secondary testing results were selected for low resolution 
mapping using the BDSC Chromosome 2 Deficiency Kit (BDSC Df Kit).  Each 
individual modifier was crossed to the entire BDSC Df Kit (see: Drosophila strains used) 
and complementation was analyzed.  At least 50 progeny were scored from each cross; 
viability of >95% for the Modifier A/Df genotype was considered to be complementation. 
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Of the thirteen modifiers that underwent BDSC Df Kit mapping, modifiers 11A-2, 96B-1, 
97-4, and 159-1a were selected to undergo higher resolution mapping using smaller 
deficiencies and candidate gene lethal mutations.  Complementation testing was 
conducted for each modifier using the relevant deficiency or candidate gene stocks (see: 
Drosophila strains used).  At least 50 progeny were scored from each cross; heterozygous 
viability of >95% was considered to constitute complementation. 
 
 
II. Chapter 3:  Not1 Analysis 
 
Drosophila strains used 
 
w1118; In(2LR)Gla, wgGla-1/CyO, P{w[+mC]=GAL4-twi.G}2.2, P{UAS-2xEGFP}AH2.2 
(BDSC) 
 
Stocks for generating deficiencies 
 
P{hsFLP}1, w1118; Adv/CyO (Exelixis) 
iso w1118; wgSp-1/CyO (Exelixis 
d00208 (Exelixis) 
f02183 (Exelixis) 
f04141 (Exelixis) 
 
97-4 candidate gene mapping stocks 
 
mir-14k10213 (Spradling et al., 1999) 
l(2)SH1677SH1677 (Oh et al., 2003) 
l(2)SH0497SH0497 (Oh et al., 2003) 
 
Meiotic mapping stocks 
 
cn c px sp (BDSC) 
al dp b pr Bl cn c px sp/CyO (BDSC) 
Oregon R (BDSC) 
 
97-4/Not complex genetic interaction stocks 
 
Dl14/TM6c (California Institute of Technology, 1940) 
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DlBX44/TM6c (our own laboratory stock) 
dx152 (Fuwa et al., 2006) 
P{PZ}Rga03834/TM3 (Frolov et al., 1998) 
P{SUPor-P}l(2)NC136KG10496/CyO (Myster et al., 2004) 
P{wHy}DG14804/TM3 (Huet et al., 2002) 
P{3'SUPor-P}twinKG00877/TM3 (Bellen et al., 2004) 
P{wHy}twinDG24102/TM3 (Huet et al., 2002) 
 
Driver Stocks 
 
34B-Gal4/CyO (Ingham and Fietz, 1995);  
1348-Gal4 (isolated by G. Technau, University of Mainz, Mainz, Germany)   
actin5C-Gal4/CyO (BDSC) 
C96-Gal4 (Gustafson and Boulianne, 1996) 
C179-Gal4 (de Celis et al., 1996) 
cut-Gal4 (A gift from G.L. Boulianne, The Hospital for Sick Children, Toronto, Canada) 
dpp-Gal4/TM3 (Staehling-Hampton et al., 1994) 
elav-Gal4 (Luo et al., 1994) 
eyeless-Gal4 (Bose et al., 2006) 
GMR-Gal4 (Freeman, 1996; Hay et al.; 1994) 
neur-Gal4/TM3 (Reddy et al., 1999) 
pannier-Gal4/TM3 (Heitzler et al., 1996) 
patched-Gal4 (Speicher et al., 1994) 
scabrous-Gal4 (Mlodzik et al., 1990) 
sparkling-Gal4 (A gift from M. Noll)  
vestigial-Gal4/TM6b (Simmonds et al., 1995) 
wingless-Gal4 (A gift from T. Klein, University of Cologne, Cologne, Germany) 
 
Responder Stocks 
 
P{GD4070}v12571 [Vienna Drosophila RNAi Center (VDRC)] 
P{GD4070}v13740 (VDRC) 
P{GD9640}41680 (VDRC) 
P{GD9640}41681/TM3 (VDRC) 
P{GD8619}v19096 (VDRC) 
UAS-DeltaWT (T. L. Jacobsen, Ph.D. Thesis, Indiana University) 
UAS-DeltaΔICD (Huppert et al., 1997) 
UAS-Serrate (Speicher et al., 1994)  
UAS-Nact (Rebay et al., 1993) 
UAS-E(spl)m8 (Tata and Hartley, 1995) 
 
 
Single-gene mapping of modifier 97-4 
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Small deficiency generation and mapping 
The potential molecular location of the 97-4 modifier gene was narrowed down to a 41.7 
kb interval containing 15 genes, within the interval 45F1-45F6 on the Drosophila 
cytogenetic map, using deficiency mapping.  To better define the gene affected by 
mutations on the 97-4 chromosome, two small overlapping deficiencies were generated 
using a method developed by Exelixis (Parks et al., 2004).  For Df(2R)d00208/f02183, 
Exelixis insertion line d00208 males were crossed to recombinase stock P{hsFLP}1, 
w1118;Adv/CyO (Exelixis) virgin females.  Progeny males of genotype P{hsFLP}1, 
w1118/Y;d00208 were mated to insertion line f02183 female virgins.  Females were 
allowed to egg lay for 48 hours, and the parents and progeny were heat shocked for 1 
hour at 37°C to activate the recombinase.  Parents were allowed to mate for another 24 
hours and then were removed from the vial.  Daily one-hour heat shocks at 37°C were 
continued for four additional days.  Virgin female progeny were collected and crossed to 
iso w1118;wgSp-1/CyO balancer males.  White-eyed male progeny of this cross possess the 
desired deficiency; they were mated to iso w1118; wgSp-1/CyO (Exelixis) female virgins to 
create a balanced stock.  Presence of the deficiency was confirmed by its failure to 
complement a large deficiency which uncovers this region, Df(2R)BSC29.  The identical 
procedure was used with the Exelixis insertion lines d00208 and f04141 to create the 
Df(2R)d00208/f04141 stock. 
 
Both Df(2R)d00208/f02183 and Df(2R)d00208/f04141 were subsequently used for 
complementation testing with the 97-4 complementation group members.  
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Df(2R)d00208/f02183 complemented all of the 97-4 complementation group members, 
while Df(2R)d00208/f04141 failed to complement all of the 97-4 group members. 
 
Candidate gene complementation 
Of the 15 genes within the mapped 41.7 kb region, only four had lethal stocks available 
for complementation testing with the 97-4 complementation group members:  mir-14 
(mir-14k10213; Spradling et al., 1999), Not1/CG1814 [l(2)SH1677SH1677; Oh et al., 2003], 
and RpL31 [l(2)SH0497SH0497; Oh et al., 2003)].  Of these, only l(2)SH1677SH1677 failed to 
complement 97-4 complementation group members, reducing the potential location of 
97-4 group lethality to Not1 and CG1814.  
 
To identify whether Not1 or CG1814 was the gene affected by mutations in the 97-4 
complementation group, the effects of RNAi expression of each gene on the GMR>DlWT 
rough eye phenotype were analyzed.  The VDRC Not1 RNAi expression lines 
P{GD4070}v12571, P{GD4070}v13740, P{GD9640}41680, and P{GD9640}41681/TM3) 
were crossed to GMR>DlWT.  Similarly, the CG1814 RNAi expression line 
P{GD8619}v19096 was crossed to GMR>DlWT.  Critical class progeny of all crosses 
were scored for modification of the GMR>DlWT/+ rough eye phenotype.  Adult eye 
pictures were taken using the Leica MZ16 In-focus system. 
  
Meiotic Mapping 
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Meiotic mapping was conducted using a cn c marker stock generated by recombining the 
BDSC stock cn c px sp with the wild type stock Oregon-R.  This was done to remove the 
px marker which produces vein defects similar to Dl14/+ and which would complicate 
analysis of recombinant chromosomes generated for meiotic mapping.  cn c was mated to 
the 97-4 modifier and resulting virgin female progeny were crossed to the marker stock al 
dp b pr Bl cn c px sp/CyO (BDSC).  Sets of 30 males from the recombinant classes cn + 
and + c, as well as the non-recombinant classes cn c and + +, were mated individually to 
Dl14/TM6C virgin females.  Bl+ Sb+ progeny were scored for modification of the Dl14/+ 
wing vein thickening phenotype. 
 
GFP-balancing of 97-4 complementation group stocks 
For accurate identification of critical class progeny for molecular tests, each 97-4 
complementation group member was balanced over a GFP-marked balancer.  Each 97-4 
group member, balanced over CyO, was crossed to w1118;In(2LR)Gla, wgGla-1/CyO, 
P{w[+mC]=GAL4-twi.G}2.2, P{UAS-2xEGFP}AH2.2 (BDSC).  GFP-expressing L3 
larval progeny were selected using a Zeiss Stemi SV11 fluorescent microscope and 
placed into a fresh food vial to create each balanced stock. 
 
Lethal phase testing 
Embryos from each GFP-balanced 97-4 complementation group stock were collected on 
apple juice egg lay plates.  For blind embryo selection, at least 1000 embryos were 
collected under bright light using a Zeiss dissecting microscope.  For GFP-expressing 
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embryo selection, at least 200 embryos were collected under fluorescence using a Zeiss 
Stemi SV11 fluorescent microscope.  Embyros were arranged in groups of twenty on 
fresh egg lay plates, and hatching and development of embryos was monitored.   
 
Not1 genetic interaction testing 
Analysis of Not1 genetic interactions with the Notch pathway were conducted by 
crossing all of the Not1 EMS mutations into each of the following Notch loss-of-function 
genotypes: Dl14/TM6C (California Institute of Technology, 1940), DlBX44/TM6C (our own 
laboratory stock), dx152 (Fuwa et al., 2006), 34B-Gal4 UAS-DeltaΔICD/+ (Ingham and 
Fietz, 1995; Huppert et al., 1997).  Critical class progeny were scored for enhancement or 
suppression of the wing vein thickening phenotype associated with each of these genetic 
backgrounds.  Adult wings were dehydrated in 100% ethanol and mounted on glass slides 
with a 1:1 solution of Permount and xylene.  Wing pictures were taken on a Zeiss 
Axioskop using a Zeiss Axiocam camera and Zeiss Axiocam plug-in software.  
 
CCR4-NOT complex genetic interaction testing 
Analysis of CCR4-NOT complex member genetic interactions were conducted using the 
following Drosophila CCR4-NOT homolog loss-of-function stocks:  P{PZ}Rga03834/TM3 
(Not2), P{SUPor-P}l(2)NC136KG10496/CyO (Not3/5), P{wHy}DG14804/TM3 (Caf1), 
P{3'SUPor-P}twinKG00877/TM3 (Ccr4), and P{wHy}twinDG24102/TM3 (Ccr4).  Each of 
these stocks was crossed to Dl14/TM6C; critical class progeny were scored for 
enhancement or suppression of Dl14/+ wing vein thickening.  Each stock was also 
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crossed to GMR>DlWT; critical class progeny were scored for modification of the 
GMR>DlWT/+ rough eye phenotype.   
 
Not1 RNAi phenotypic analysis 
The effects of tissue-specific NOT1 knockdown was examined using the UAS-Not1 RNAi 
transgenic line P{GD4070}v12571 (VDRC).  All of the following Gal4 drivers were 
crossed to P{GD4070}v12571:  34B-Gal4/CyO (Ingham and Fietz, 1995), 1348-Gal4 
(isolated by G. Technau, University of Mainz, Mainz, Germany), Actin5C-Gal4/CyO 
(BDSC), C96-Gal4 (Gustafson and Boulianne, 1996), C179-Gal4 (de Celis et al., 1996), 
cut-Gal4 (a gift from G.L. Boulianne, The Hospital for Sick Children, Toronto, Canada), 
dpp-Gal4/TM3 (Staehling-Hampton et al., 1994), elav-Gal4 (Luo et al., 1994), eyeless-
Gal4 (Bose et al., 2006), GMR-Gal4 (Freeman, 1996; Hay et al.; 1994), neur-Gal4/TM3 
(Reddy et al., 1999), pannier-Gal4/TM3 (Heitzler et al., 1996), patched-Gal4 (Speicher et 
al., 1994), scabrous-Gal4 (Mlodzik et al., 1990), sparkle-Gal4 (a gift from M. Noll, 
University of Zurich, Zurich, Switzerland), vestigial-Gal4/TM6b (Simmonds et al., 
1995), wingless-Gal4 (a gift from T. Klein, University of Cologne, Cologne, Germany).  
Crosses were conducted at both 18°C and 25°C.  Critical class progeny were scored for 
phenotypes.  For wing pictures of surviving critical class adults, adult wings were 
dehydrated in 100% ethanol and mounted on glass slides with a 1:1 solution of Permount 
and xylene.  For other tissues, surviving critical class adults were submerged in mineral 
oil.  Pictures were taken on a Zeiss Axiocam or a Zeiss Stemi SV11 using the Zeiss 
Axiocam camera and Zeiss Axiocam plug-in software. 
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Immunohistochemistry 
Primary antibodies used (all mouse monoclonals unless otherwise noted):  anti-Cut at 1:5 
[Developmental Studies Hybridoma Bank (DSHB), University of Iowa, Iowa City, 
Iowa]; anti-Wingless at 1:5 (DSHB); anti-Prospero at 1:5 (DSHB); anti-Achaete at 1:5 
(DSHB), anti-Hindsight at 1:5 (DSHB); anti-22C10 at 1:50 (DSHB); guinea pig anti-
Delta at 1:2000 (GP582).  Secondary antibodies used:  Alexa488-conjugated goat anti-
mouse at 1:1000 (Molecular Probes, Eugene, OR); Alexa488-conjugated goat anti-guinea 
pig at 1:1000 (Molecular Probes, Eugene, OR); Texas Red-conjugated goat anti-mouse 
Texas Red at 1:500 (Jackson Immunoresearch, West Grove, PA); horseradish peroxidase 
(HRP)-conjugated goat anti-mouse at 1:1000 (Jackson Immunoresearch, West Grove, 
PA).  Peroxidase activity was visualized using 3, 3’ – diaminobenzidine (Farr and 
Nakane, 1981).  Images were captured using the SP5 Leica confocal microscope. 
 
For all non-embryo immunohistochemical stainings, tissues were dissected in PBS and 
fixed in a solution of 4% paraformaldehyde in PBS for 20 minutes.  Fixed tissues were 
washed three times for 10 minutes per wash in a 0.1% solution of Tween-20 in PBS 
(TPBS).  Tissues were incubated in the appropriate primary antibody diluted in TPBS 
with 5% normal goat serum overnight at 4°C, followed by another series of three 10 
minute washes in TPBS at room temperature.  Tissues were stained with the appropriate 
secondary antibody diluted in TPBS with 5% normal goat serum for four hours at room 
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temperature and then washed twice for 10 minutes in TPBS and once for 10 minutes in 
PBS.  Tissues were mounted in glycerol with 2% n-propyl gallate on glass slides. 
 
For embryo stainings, staged 16-23 hour embryo collections were conducted on apple 
juice plates.  Collected embryos were dechorionated for three minutes in 50% bleach and 
then fixed in a 1:1 solution of heptane and 4% paraformaldehyde in PBS for 20 minutes.  
Embryos were dehydrated in 100% methanol and then rehydrated in sequential washes of 
methanol and PBS.  Embryos were washed three times for ten minutes in TPBS and then 
incubated in the appropriate primary antibody diluted in TPBS with 5% normal goat 
serum overnight at 4°C.  Stained embryos were washed three times for 10 minutes in 
TPBS at room temperature and then incubated for four hours at room temperature in the 
appropriate secondary antibody diluted in TPBS with 5% normal goat serum.  Embryos 
were washed twice for 10 minutes in TPBS and once for 10 minutes in PBS.  After 
completion of staining, embryos were dehydrated in ethanol and cleared overnight in 
methyl salicylate.  Embryos were mounted on glass slides in methyl salicylate. 
 
 
III. Chapter 4:  Transposon Screen 
The following description of materials and methods for this chapter are taken from the 
following paper, in review:  Shalaby, N.A., Parks, A.L., Morreale, E.J., Osswalt, M.C., 
Pfau, K.M., Pierce, E.L., Muskavitch, M.A.T.  (2009).  A screen for modifiers of Notch 
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signaling uncovers Amun, a protein with a critical role in sensory organ development.  
(submitted to Genetics). 
 
Drosophila strains used 
The following strains were used for the screen: the Exelixis Inc. collection housed in the 
laboratory of Spyros Artavanis-Tsakonas (Artavanis-Tsakonas 2004); GMR-Gal4 
(Freeman 1996; Hay et al. 1994); 34B-Gal4 (Ingham and Fietz 1995); C96-Gal4 
(Gustafson and Boulianne 1996), a gift from Barry Yedvobnick, Emory University, 
Atlanta, GA; UAS-DeltaWT (on chromosome 2, T. L. Jacobsen, Ph.D. Thesis, Indiana 
University); and UAS-DeltaΔICD (Huppert et al. 1997). 
 
Primary screen 
The screen was performed by assaying the effects of each of 10,447 transposon insertions 
from the Exelixis stock collection (Artavanis-Tsakonas 2004) on the eye phenotype of 
GMR-Gal4 UAS-DeltaWT/+ (GMR>DeltaWT/+) flies. The collection is comprised of 
four different transposon types: three piggyBac-based transposons (PB, RB, and WH) and 
one P element-based transposon (XP). Two of the four transposons contain at least one 
upstream activating sequence cassette (UAS,  Brand and Perrimon 1993). The WH 
transposon contains a single terminal UAS cassette that can activate or interfere with (via 
anti-sense transcript production) expression of neighboring genes. The XP transposon 
contains two terminal UAS cassettes that have the potential to alter expression of genes 
located adjacent to either or both ends of the inserted transposon. The PB and RB vectors 
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contain no UAS sequences, therefore their effects on genes are limited to the site of 
insertion. Our primary screen consisted of crossing males carrying autosomal or viable 
X-linked insertions to GMR>DeltaWT-bearing virgin females and scoring the F1 progeny 
for changes in the rough eye phenotype. Modifying transposons were categorized as 
enhancers or suppressors of weak, moderate, or strong intensity. Of 798 primary screen 
modifiers, 284 were retested with GMR>DeltaWT to confirm modification. A negative 
secondary test was performed by crossing confirmed modifiers to flies carrying the GMR-
Gal4 transgene alone to eliminate modifiers that affect eye development in the same 
manner as seen in the primary screen. Positive secondary analyses were performed to 
prioritize the candidate modifiers using phenotypes that result from expression of a 
dominant-negative Delta variant created by truncation of the Delta intracellular domain 
(DeltaΔICD, Huppert et al. 1997) in the developing wing vein [34B-Gal4 UAS-
DeltaΔICD/+ (34B>DeltaΔICD)] or wing margin [UAS-DeltaΔICD/+; C96-Gal4/+ 
(C96>DeltaΔICD)]. We assessed enhancement and suppression of both of these 
phenotypes. 
 
Annotation of hits 
All high priority modifiers were annotated by aligning the relevant transposon-flanking 
sequence (Thibault et al. 2004) against the Drosophila melanogaster genome 
(FB2007_03 Dmel Release 5.4)  using the FlyBase BLAST website 
(flybase.bio.indiana.edu/blast). A 10 kb genome browser snapshot was taken, and 
transposon-specific criteria were used to assess which genes were potentially affected by 
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the transposon insertion. A gene was considered potentially disrupted if the transposon is 
inserted within the transcription unit or within 2 kb of the 5’ end or 1 kb of the 3’ end of 
the transcription unit. In addition, for UAS-containing transposons (XP and WH), a gene 
was considered a potential target for UAS-directed expression if it is within 5 kb of the 
transposon insertion site (and “downstream” of the UAS), unless there is a potential RNA 
polymerase II transcription stop site between the UAS and the gene in question. Genes 
identified as possible modifiers were placed into functional categories using previously 
published data when available, and/or FlyBase (FB2007_03 Dmel Release 5.4) Gene 
Ontology (GO) terms. 
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